

Official Title: Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis who are Naive to TNF Inhibitors

NCT Number: NCT02163759

Document Date: Protocol Version 8: 15-March-2019

PROTOCOL

TITLE: PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS

PROTOCOL NUMBER: GA28948

VERSION NUMBER: 8

EUDRACT NUMBER: 2013-004279-11

IND NUMBER: 100366

TEST PRODUCT: Etrolizumab (PRO145223, RO5490261)

MEDICAL MONITOR: [REDACTED], M.D.

SPONSOR: F. Hoffmann-La Roche Ltd

DATE FINAL: Version 1: 25 January 2014

DATES AMENDED: Version 2: 8 April 2014
Version 3: 23 July 2014
Version 4: 18 September 2015
Version 5: 18 December 2016
Version 6: 30 August 2017
Version 7: 25 October 2018
Version 8: See electronic date stamp below

PROTOCOL AMENDMENT APPROVAL

Approver's Name

[REDACTED]

Title

Company Signatory

Date and Time (UTC)

15-Mar-2019 15:21:17

CONFIDENTIAL

This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche's local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered.

Etrolizumab—F. Hoffmann-La Roche Ltd
Protocol GA28948, Version 8

PROTOCOL AMENDMENT, VERSION 8: RATIONALE

Protocol GA28948 has been amended to provide further clarification. Changes to the protocol, along with a rationale for each change, are summarized below:

- Exploratory efficacy objectives have been modified as follows (Sections 2.1, 3.4.1, and 6.4.3):
 - Evaluation of response at Week 10, in subgroups by baseline expression levels of colonic tissue and/or peripheral blood biomarkers, has been added to predict patient subgroups with a greater likelihood of responding to etrolizumab.
 - Evaluation of corticosteroid-free response and remission as determined by the modified Mayo Clinic Score has been removed. This endpoint is applicable only to studies with a maintenance phase.
- Language in Section 6.4 has been updated to clarify that the efficacy analyses will be performed using a modified intent-to-treat analysis set including all patients randomized who received at least one dose of study drug, with patients grouped according to the treatment assigned at randomization.
- The partial Mayo Clinic Score (pMCS) assessment indicated in the Schedule of Assessments for the 12-Week Safety Follow-Up (Appendix 2) has been removed. This assessment was added in 2014, but a recent review concluded that the value of the data from this assessment is minimal and removing it would not impact patient safety or the analysis of any efficacy endpoints of the study. This change also accounts for the inability of patients to record data to calculate pMCS during this time period.

Additional minor changes have been made to improve clarity and consistency. Substantive new information appears in italics. This amendment represents cumulative changes to the original protocol.

TABLE OF CONTENTS

PROTOCOL AMENDMENT ACCEPTANCE FORM	10
PROTOCOL SYNOPSIS	11
1. BACKGROUND	26
1.1 Background on Ulcerative Colitis	26
1.2 Background on Etrolizumab.....	27
1.3 Study Rationale and Benefit-Risk Assessment.....	28
2. OBJECTIVES.....	31
2.1 Efficacy Objectives	31
2.2 Safety Objectives.....	34
2.3 Pharmacokinetic Objectives	34
2.4 Exploratory Pharmacodynamic, Predictive, and Prognostic Objectives	34
3. STUDY DESIGN	34
3.1 Description of Study	34
3.1.1 Overview of Study Design	34
3.1.1.1 Rescue Therapy	38
3.1.1.2 Number of Patients.....	41
3.1.2 Data Monitoring Committee	41
3.2 End of Study and Length of Study	41
3.3 Rationale for Study Design	42
3.3.1 Rationale for Test Product Dosage.....	42
3.3.2 Rationale for Patient Population	43
3.3.3 Rationale for Control Group.....	44
3.3.4 Rationale for Active Comparator.....	44
3.3.5 Rationale for Biomarker Assessments.....	44
3.4 Outcome Measures	45
3.4.1 Efficacy Outcome Measures.....	45
3.4.2 Safety Outcome Measures	46
3.4.3 Pharmacokinetic Outcome Measures.....	46
3.4.4 Exploratory Biomarker Outcome Measures.....	47

4.	MATERIALS AND METHODS	47
4.1	Patients.....	47
4.1.1	Inclusion Criteria.....	47
4.1.2	Exclusion Criteria.....	49
4.2	Method of Treatment Assignment and Blinding	53
4.3	Study Treatment.....	57
4.3.1	Formulation, Packaging, and Handling.....	58
4.3.1.1	Etrolizumab and Placebo.....	58
4.3.1.2	Adalimumab and Placebo.....	59
4.3.1.3	Concomitant Background Treatment for Ulcerative Colitis	59
4.3.2	Dosage, Administration, and Compliance.....	59
4.3.2.1	Etrolizumab and Etrolizumab Placebo	60
4.3.2.2	Adalimumab and Adalimumab Placebo	61
4.3.2.3	Concomitant Background Treatment and Rescue Therapy	62
4.3.3	Investigational Medicinal Product Accountability	64
4.3.4	Assessment of Compliance	65
4.3.5	Destruction of the Investigational Medicinal Product/Comparator	65
4.3.6	Reporting of Prefilled Syringe Complaints/Events	65
4.4	Concomitant Therapy	66
4.4.1	Permitted Therapy	66
4.4.2	Prohibited Therapy	66
4.5	Study Assessments.....	67
4.5.1	Description of Study Assessments	67
4.5.1.1	Medical History and Demographic Data	67
4.5.1.2	Physical Examinations.....	67
4.5.1.3	Vital Signs.....	67
4.5.1.4	Ulcerative Colitis Disease Activity Assessments	67
4.5.1.5	Laboratory Assessments	71
4.5.1.6	Chest X-ray.....	74
4.5.1.7	Electrocardiograms.....	74
4.5.1.8	Patient-Reported Outcomes	75

4.5.1.9	Medication Use and Compliance	76
4.5.1.10	Samples for Roche Clinical Repository.....	76
4.5.2	Timing of Study Assessments	79
4.5.2.1	Screening and Pretreatment Assessments.....	79
4.5.2.2	Assessments during Treatment.....	82
4.5.2.3	Assessments at Study Completion/Early Withdrawal from Treatment Visit.....	82
4.5.2.4	Safety Follow-Up Assessments	84
4.5.2.5	Assessments at Unscheduled Visits.....	85
4.6	Patient, Study, and Site Discontinuation.....	85
4.6.1	Patient Discontinuation	85
4.6.1.1	Discontinuation from Study Drug	86
4.6.1.2	Withdrawal from Study.....	86
4.6.2	Study and Site Discontinuation.....	86
5.	ASSESSMENT OF SAFETY.....	87
5.1	Safety Plan	87
5.1.1	Potential Risks for Etrolizumab.....	87
5.1.1.1	Serious Infections	88
5.1.1.2	Hypersensitivity Reactions.....	91
5.1.1.3	Local Injection-Site Reactions	92
5.1.1.4	Hepatic Effects	92
5.1.1.5	Malignancies.....	93
5.1.1.6	Immunogenicity	93
5.1.1.7	Decreased Effectiveness of Immunizations	94
5.1.2	Risks Associated with Adalimumab	94
5.1.3	Risks Associated with Worsening of Ulcerative Colitis.....	94
5.2	Safety Parameters and Definitions	95
5.2.1	Adverse Events	95
5.2.2	Serious Adverse Events (Immediately Reportable to the Sponsor).....	95
5.2.3	Adverse Events of Special Interest (Immediately Reportable to the Sponsor).....	96

5.3	Methods and Timing for Capturing and Assessing Safety Parameters.....	97
5.3.1	Adverse Event Reporting Period	97
5.3.2	Eliciting Adverse Event Information	97
5.3.3	Assessment of Severity of Adverse Events	98
5.3.4	Assessment of Causality of Adverse Events	98
5.3.5	Procedures for Recording Adverse Events.....	99
5.3.5.1	Diagnosis versus Signs and Symptoms.....	99
5.3.5.2	Adverse Events Occurring Secondary to Other Events.....	100
5.3.5.3	Persistent or Recurrent Adverse Events.....	100
5.3.5.4	Abnormal Laboratory Values	101
5.3.5.5	Abnormal Vital Sign Values	101
5.3.5.6	Abnormal Liver Function Tests	102
5.3.5.7	Deaths	102
5.3.5.8	Preexisting Medical Conditions.....	103
5.3.5.9	Lack of Efficacy or Worsening of Ulcerative Colitis.....	103
5.3.5.10	Hospitalization or Prolonged Hospitalization.....	103
5.3.5.11	Adverse Events Associated with an Overdose or Error in Drug Administration	104
5.3.5.12	Patient-Reported Outcome Data	104
5.4	Immediate Reporting Requirements from Investigator to Sponsor.....	104
5.4.1	Emergency Medical Contacts	105
5.4.2	Reporting Requirements for Serious Adverse Events and Adverse Events of Special Interest.....	105
5.4.3	Reporting Requirements for Pregnancies.....	106
5.4.3.1	Pregnancies in Female Patients	106
5.4.3.2	Pregnancies in Female Partners of Male Patients.....	106
5.4.3.3	Abortions	107
5.4.3.4	Congenital Anomalies/Birth Defects	107
5.4.4	Reporting Requirements for Medical Device Complaints.....	107
5.5	Follow-Up of Patients after Adverse Events	107

5.5.1	Investigator Follow-Up	107
5.5.2	Sponsor Follow-Up	107
5.6	Post-Study Adverse Events	108
5.7	Expedited Reporting to Health Authorities, Investigators, Institutional Review Boards, and Ethics Committees.....	108
6.	STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN	109
6.1	Determination of Sample Size	109
6.2	Summaries of Conduct of Study	110
6.3	Summaries of Treatment Group Comparability	110
6.4	Efficacy Analyses	110
6.4.1	Primary Efficacy Endpoint.....	111
6.4.2	Secondary Efficacy Endpoints.....	111
6.4.3	Exploratory Efficacy Endpoints	112
6.5	Safety Analyses	112
6.5.1	Adverse Events	113
6.5.2	Laboratory Tests.....	113
6.6	Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses.....	114
7.	DATA COLLECTION AND MANAGEMENT	114
7.1	Data Quality Assurance	114
7.2	Electronic Case Report Forms.....	114
7.3	Electronic Patient-Reported Outcome Data.....	115
7.4	Source Data Documentation.....	115
7.5	Use of Computerized Systems	116
7.6	Retention of Records	116
8.	ETHICAL CONSIDERATIONS.....	116
8.1	Compliance with Laws and Regulations	116
8.2	Informed Consent.....	117
8.3	Institutional Review Board or Ethics Committee	118
8.4	Confidentiality.....	118
8.5	Financial Disclosure	119

9.	STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION	119
9.1	Study Documentation	119
9.2	Protocol Deviations.....	119
9.3	Site Inspections	119
9.4	Administrative Structure.....	119
9.5	Publication of Data and Protection of Trade Secrets	120
9.6	Protocol Amendments	121
10.	REFERENCES	122

LIST OF TABLES

Table 1	Efficacy Outcomes Definitions	33
Table 2	Population Pharmacokinetic Modeling Predicted Percentage of Patients Achieving 1.7- μ g/mL Steady-State Trough Concentration under Different Dosing Scenarios	43
Table 3	Study Drug Administration Schema	56
Table 4	Treatment/Concomitant Background Treatments	57
Table 5	Adverse Event Severity Grading Scale for Events Not Specifically Listed in the NCI CTCAE	98
Table 6	Causal Attribution Guidance	99

LIST OF FIGURES

Figure 1	Study Schema.....	40
Figure 2	Effects of High and Low Baseline Expression of the α E Biomarker in Colon on the Remission Status of Ulcerative Colitis Patients Treated with Etrolizumab in EUCALYPTUS (Observed Data)	45
Figure 3	Overview of Screening Activities.....	80

LIST OF APPENDICES

Appendix 1	Schedule of Assessments.....	125
Appendix 2	12-Week Safety Follow-Up	131
Appendix 3	Childbearing Potential, Pregnancy Testing, and Contraception.....	132
Appendix 4	Mayo Clinic Score Measurement	134
Appendix 5	Worksheet for the PML Neurologic Examination.....	142
Appendix 6	Algorithm for the Evaluation of Progressive Multifocal Leukoencephalopathy.....	149
Appendix 7	Patient Daily Diary	150
Appendix 8	Clinical Criteria for Diagnosing Anaphylaxis.....	151
	152
Appendix 10	Quality of Life in Inflammatory Bowel Disease Questionnaire (IBDQ).....	161
Appendix 11	EuroQoL Five-Dimension (EQ-5D) Questionnaire	173
Appendix 12	Nancy Histological Index.....	177

PROTOCOL AMENDMENT ACCEPTANCE FORM

TITLE: PHASE III, RANDOMIZED, DOUBLE-BLIND,
DOUBLE-DUMMY, PLACEBO-CONTROLLED,
MULTICENTER STUDY TO EVALUATE
THE EFFICACY (INDUCTION OF REMISSION) AND
SAFETY OF ETROLIZUMAB COMPARED WITH
ADALIMUMAB AND PLACEBO IN PATIENTS WITH
MODERATE TO SEVERE ULCERATIVE COLITIS
WHO ARE NAIVE TO TNF INHIBITORS

PROTOCOL NUMBER: GA28948

VERSION NUMBER: 8

EUDRACT NUMBER: 2013-004279-11

IND NUMBER: 100366

TEST PRODUCT: Etrolizumab (PRO145223, RO5490261)

MEDICAL MONITOR: [REDACTED], M.D.

SPONSOR: F. Hoffmann-La Roche Ltd

I agree to conduct the study in accordance with the current protocol.

Principal Investigator's Name (print)

Principal Investigator's Signature

Date

Please return the signed original of this form to a Sponsor representative. Please retain a copy for your study files.

PROTOCOL SYNOPSIS

TITLE: PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS

PROTOCOL NUMBER: GA28948

VERSION NUMBER: 8

EUDRACT NUMBER: 2013-004279-11

IND NUMBER: 100366

TEST PRODUCT: Etrolizumab (PRO145223, RO5490261)

PHASE: III

INDICATION: Ulcerative colitis

SPONSOR: F. Hoffmann-La Roche Ltd

Objectives

Efficacy Objectives

The primary efficacy objective for this study is as follows:

- To evaluate the efficacy of etrolizumab (105 mg subcutaneous [SC] every 4 weeks [Q4W]) compared with placebo for the induction of remission in tumor necrosis factor (TNF)-naive (i.e., naive to tumor necrosis factor inhibitor) patients with ulcerative colitis (UC) as determined by the Mayo Clinic Score (MCS) at Week 10

The secondary efficacy objectives for this study are as follows:

- To evaluate the efficacy of etrolizumab compared with adalimumab for the induction of remission at Week 10
- To evaluate the efficacy of etrolizumab for the induction of clinical remission at Week 10
- To evaluate the efficacy of etrolizumab for clinical response at Week 10
- To evaluate the efficacy of etrolizumab for improvement in endoscopic appearance of the mucosa at Week 10
- To evaluate the efficacy of etrolizumab for endoscopic remission at Week 10
- To evaluate the efficacy of etrolizumab compared with placebo in achieving remission at Week 10 and maintaining it to Week 14
- To evaluate the efficacy of etrolizumab for histologic remission at Week 10
- To evaluate the efficacy of etrolizumab for onset of action, defined as change from baseline in MCS rectal bleeding subscore at Week 6
- To evaluate the efficacy of etrolizumab for onset of action, defined as change from baseline in MCS stool frequency subscore at Week 6

- To evaluate the efficacy of etrolizumab for UC bowel movement signs and symptoms at Week 10 as assessed by the Ulcerative Colitis Patient-Reported Outcome Signs and Symptoms (UC-PRO/SS) measure
- To evaluate the efficacy of etrolizumab for UC abdominal symptoms at Week 10 as assessed by the UC-PRO/SS measure
- To evaluate the efficacy of etrolizumab for patient-reported health-related QOL at Week 10 as assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ)

The exploratory efficacy objectives for this study are as follows:

- To evaluate the impact of etrolizumab on remission at Week 14 in patients who achieved clinical remission at Week 10 compared with placebo
- To evaluate the efficacy of etrolizumab compared with placebo in achieving clinical remission at Week 10 and maintaining it to Week 14
- To evaluate change in histologic disease activity from baseline to Week 10 as measured by the Nancy Histological Index
- To evaluate improvement in histologic and/or endoscopic disease activity
- To evaluate change in health utilities at Week 10, as assessed by the EuroQoL Five-Dimension Questionnaire (EQ-5D)
- To evaluate *response and* remission at Week 10 in subgroups by baseline expression levels of colonic tissue and/or peripheral blood biomarkers (including, but not limited to, α E integrin) to predict patient subgroups with a greater likelihood of responding to etrolizumab
- To evaluate response *and* remission endpoints, as determined by the modified MCS (mMCS)

Safety Objectives

The safety objectives for this study are as follows:

- To evaluate the overall safety and tolerability of etrolizumab during induction of remission of UC
- To evaluate the incidence and severity of infection-related adverse events
- To evaluate the incidence and severity of hypersensitivity reactions
- To evaluate the incidence and the clinical significance of anti-therapeutic antibodies (ATAs) to etrolizumab, or if required, adalimumab

Pharmacokinetic Objectives

The pharmacokinetic (PK) objectives for this study are as follows:

- To evaluate the etrolizumab serum concentration at the time of primary and secondary endpoints (Weeks 10 and 14) and during drug washout at the time of safety follow-up
- To evaluate the interindividual variability and potential covariate effects on etrolizumab serum exposure

Exploratory Pharmacodynamic, Predictive, and Prognostic Objectives

The exploratory pharmacodynamic (PD), predictive, and prognostic objectives for this study are as follows:

- To evaluate the expression levels of biomarkers including, but not limited to, α E integrin, in colonic tissue and/or peripheral blood *and/or serum* at baseline, during, or end of the treatment period
- To evaluate biomarkers in stool at baseline and during the treatment period through assessments that may include, but are not limited to, analyses of the microbiota and bacterial cultures

Study Design

Description of Study

This is a multicenter, Phase III, randomized, double-blind, double-dummy, placebo and active comparator controlled study to evaluate the safety, efficacy, and tolerability of etrolizumab (105 mg SC Q4W) in the induction of remission for patients naive to TNF inhibitors.

Comparisons will be made against placebo and adalimumab (160 mg SC Week 0, 80 mg SC Week 2, 40 mg SC Weeks 4, 6, and 8).

Patients enrolled in this study may be eligible to participate in an open-label extension and safety monitoring (OLE-SM) study (GA28951), which consists of two parts: Part 1 (designated OLE [open label extension]) and Part 2 (designated SM [safety monitoring]).

Disease severity will be measured using the MCS (see protocol), which is the current outcome measure accepted by regulatory authorities for drug development in UC. The study population consists of TNF-naive patients with moderately to severely active UC (defined as MCS of 6–12, endoscopy subscore of ≥ 2 , as determined by the central reading procedure described in the protocol, a rectal bleeding subscore ≥ 1 , and a stool frequency subscore ≥ 1) and involvement that extends to a minimum of 20 cm from the anal verge.

Patients must have had an inadequate response, loss of response, or intolerance to prior immunosuppressant and/or corticosteroid treatment.

Patients who are on background immunosuppressant therapy (6-MP, AZA, MTX) may be enrolled if they have received a stable dose for at least 8 weeks prior to randomization (Day 1). Such patients should continue on stable doses of their background immunosuppressant therapy during the study, unless dose reduction or discontinuation is required due to toxicity.

Generally accepted criteria for discontinuing immunosuppressants due to toxicity include, but are not limited to, acute pancreatitis, severe leukopenia, severe thrombocytopenia, or clinically significant elevations of the liver-associated enzymes from baseline, especially in the presence of an elevated total bilirubin. The ultimate decision to reduce the dose or discontinue immunosuppressants due to toxicity remains at the discretion of the investigator.

Patients on oral corticosteroid therapy (prednisone at a stable dose of ≤ 30 mg, or equivalent) may be enrolled according to the following criteria:

- If corticosteroid therapy is ongoing or has recently been initiated, the dose has to be stable for at least 4 weeks immediately prior to randomization
- If corticosteroids are being tapered, the dose has to be stable for at least 2 weeks immediately prior to randomization

Such patients should continue stable doses of their background corticosteroid until Week 10, at which point a corticosteroid taper will be initiated for clinical remitters. Initiation of corticosteroid or an increase in corticosteroid dose above the patient's entry dose (up to a maximum of 30 mg/day prednisone [or equivalent]) will not be permitted during screening. Use of budesonide will be allowed at stable doses (≤ 9 mg) provided that the dose has been stable for ≥ 4 weeks prior to randomization. Oral 5-ASA treatment and probiotics for the treatment of UC may be continued at a stable dose as long as the dose(s) had been stable for ≥ 4 weeks and ≥ 2 weeks, respectively, prior to randomization. Certain concomitant treatments are prohibited (see protocol for list of all prohibited concomitant treatments).

A total of approximately 350 patients from approximately 115 global sites will be randomized in a 2:2:1 ratio (etrolizumab:adalimumab:placebo). Patients will be stratified by concomitant treatment with corticosteroids (yes/no) at randomization, concomitant treatment with immunosuppressants (yes/no) at randomization, and disease activity measured during screening (MCS ≤ 9 /MCS ≥ 10).

The study will be divided into:

- Screening period of up to 35 days
- Double-blind treatment period of up to 14 weeks, which consists of a 10-week induction period and an additional 4-week treatment period for patients who meet the definition of clinical remission at Week 10
- Safety follow-up period of 12 weeks.

An extended safety-monitoring period of an additional 92 weeks (after 12-week safety follow-up) for progressive multifocal leukoencephalopathy (PML) will be conducted in an open-label extension and safety monitoring (OLE-SM) study under a separate protocol.

The study design is double-blind, double-dummy, placebo-controlled so all patients will receive two study treatments: active etrolizumab + adalimumab placebo, active adalimumab + etrolizumab placebo, or etrolizumab placebo + adalimumab placebo.

Study Drug Administration

Etrolizumab/etrolizumab placebo and adalimumab/adalimumab placebo will be administered SC via a prefilled syringe (PFS) in the clinic by an unblinded health care professional (HCP) because the adalimumab syringe is not visually identical to the adalimumab placebo syringe. Unblinded HCPs will not be involved in performing patient assessments and will have no further interaction with blinded site staff or patients. Study site personnel involved in performing patient assessments and the patients must remain blinded to study treatment.

Patients randomized to an active treatment arm will receive one active drug and one placebo according to the randomization code to achieve blinding. Patients randomized to the placebo arm will receive no active treatment but will receive etrolizumab placebo SC and adalimumab placebo SC. The injections are not required to be administered in any specific order. Patients will be monitored for 1 hour in the clinic following the injections.

A detailed guide to the injections required at each study visit is provided in the protocol.

Patients are to visit the clinic every 2 weeks from Day 1 to Week 10 and at Weeks 12 and 14 only for patients who achieve clinical remission at Week 10.

The last dose of adalimumab/adalimumab placebo will be given at Week 8, after which patients will begin a 4-week washout period from adalimumab. Patients who achieve clinical remission at Week 10 (without use of rescue medications) will continue in the study. Patients continuing beyond Week 10 will receive etrolizumab/etrolizumab placebo at Week 12. The patient's clinical remission status will be assessed again at Week 14 by MCS.

Patients not achieving clinical remission at Week 10 and patients who achieve clinical remission at Week 10 but required the use of rescue medications prior to Week 10 should remain in the blinded study until Week 12. They will not receive any more study medication in this study after Week 10. These patients may enroll in Part 1 (OLE) of Study GA28951 at Week 12 (Day 1 OLE), if eligible, where they will receive open-label etrolizumab. Clinical remitters at Week 10 (who did not use rescue medications prior to Week 10) should remain in the blinded study until Week 14, at which time they may enroll in the Part 1 (OLE) of Study GA28951, if eligible. The first dose of open-label etrolizumab will be given upon enrollment into Part 1 (OLE) of Study GA28951. If patients are not eligible to enroll in Part 1 (OLE) of Study GA28951, they will enter the 12-week safety follow-up period of this study and will then be requested to enroll in Part 2 (SM) of Study GA28951 for 92 weeks of extended PML monitoring.

Concomitant Drugs for Ulcerative Colitis during the Study

Throughout the treatment phase of the study, patients are to maintain their stable baseline doses of their concomitant medications (5-ASA, corticosteroids, immunosuppressants) for UC except that all patients receiving corticosteroids who achieve clinical remission and who continue in this study past Week 10 must begin a corticosteroid taper at Week 10.

Immunosuppressants during the Study

Patients should remain on their stable baseline doses of immunosuppressants (AZA, 6-MP, MTX) throughout the study unless dose reduction or discontinuation is required because of a toxicity related to the medication. Generally accepted criteria for discontinuing immunosuppressants due to toxicity include, but are not limited to, acute pancreatitis, severe leukopenia, severe thrombocytopenia, or clinically significant elevations of the liver-associated enzymes from baseline, especially in the presence of an elevated total bilirubin. The ultimate decision to reduce dose or discontinue immunosuppressants due to toxicity remains at the discretion of the investigator.

Oral Corticosteroids during the Study

During the Induction Phase, patients are to maintain their stable baseline corticosteroid dose. For patients who achieve clinical remission and remain in the study for an additional 4 weeks beyond the Week 10 Induction Phase, corticosteroids are to be tapered starting from Week 10. Patients who were receiving prednisone at a dose of > 10 mg/day (or equivalent) are to have their dose reduced at a rate of 5 mg per week until a 10 mg/day dose is achieved. Patients receiving prednisone at doses ≤ 10 mg/day (or equivalent), or once a 10 mg/day dose (or equivalent) is achieved by tapering, are to have their dose reduced at a rate of 2.5 mg/week. Patients receiving budesonide should taper their dose starting from Week 10 from 9 mg every day to 9 mg every other day for 2 weeks and then discontinue budesonide treatment.

Number of Patients

A total of approximately 350 patients are to be randomized into one of three study treatment groups in a 2:2:1 ratio as follows:

- Treatment Group A: etrolizumab SC plus adalimumab placebo SC
- Treatment Group B: adalimumab SC plus etrolizumab placebo SC
- Treatment Group C: etrolizumab placebo SC plus adalimumab placebo SC

Target Population

Patients must meet the following criteria for study entry:

- Able and willing to provide written informed consent
- 18–80 years of age, inclusive
- Diagnosis of UC established at least 3 months prior to randomization (Day 1) by clinical and endoscopic evidence. This diagnosis should be corroborated by histopathology conducted at any time prior to screening and documented by a histopathology report (Note: histopathology may be performed at screening, if no prior report is readily available).
- Moderately to severely active UC as determined by an MCS of 6–12 with an endoscopic subscore ≥ 2, as determined by the central reading procedure described in the protocol, a rectal bleeding subscore ≥ 1, and a stool frequency subscore ≥ 1 during the screening period (prior to day of randomization).. See protocol for additional information regarding the time window.
- Evidence of UC extending a minimum of 20 cm from the anal verge as determined by baseline endoscopy (flexible sigmoidoscopy or colonoscopy) performed during screening, 4–16 days prior to randomization. See protocol for additional information regarding the time window.
- Naive to treatment with TNF inhibitor therapy
- Patients must have had an inadequate response, loss of response, or intolerance to prior immunosuppressant and/or corticosteroid treatment.

Inadequate response to, loss of response to, or intolerance to prior immunosuppressant treatment is defined as one or more of the following:

Persistent signs and symptoms of active disease despite a history of at least one 12-week regimen of oral AZA (≥ 1.5 mg/kg) or 6-MP (≥ 0.75 mg/kg) and/or MTX (≥ 15 mg/week) within the previous 5 years

Persistent signs and symptoms of active disease despite a 6-TG level of ≥ 230 pmol/8 × 10⁸ RBCs during at least one 12-week regimen of oral AZA or 6-mercaptopurine (6-MP) at a stable or increasing dose within the previous 5 years.

History of intolerance to AZA, 6-MP, or MTX (including, but not limited to, nausea/vomiting, abdominal pain, pancreatitis, LFT abnormalities, lymphopenia, *TPMT* genetic mutation, infection) within the previous 5 years

Inadequate response, loss of response, or intolerance to corticosteroid treatment is defined as one or more of the following:

Steroid refractory: persistent symptoms of active disease despite treatment with at least one 4-week induction regimen that included a dose of ≥ 30 mg prednisone (oral) daily, or equivalent, for at least 2 weeks or IV for at least 1 week within the previous 5 years

Steroid dependent: two failed attempts to taper steroids below a dose equivalent to 10 mg prednisone (oral) daily

Steroid intolerant: history of intolerance to corticosteroids (including, but not limited to, Cushing's syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, infection) within the previous 5 years

- Any ongoing UC therapy must be at stable doses:
 - May be receiving oral 5-ASA compounds provided that the dose has been stable for ≥ 4 weeks immediately prior to randomization
 - May be receiving oral corticosteroid therapy (prednisone at a stable dose of ≤ 30 mg a day, or equivalent steroid)
 - If corticosteroid therapy is ongoing or has recently been initiated, the dose has to be stable for at least 4 weeks immediately prior to randomization.
 - If corticosteroids are being tapered, the dose has to be stable for at least 2 weeks immediately prior to randomization.
 - May be receiving budesonide therapy at a stable dose of up to 9 mg a day provided that the dose has been stable for ≥ 4 weeks prior to randomization
 - May be receiving probiotics (e.g., Culturelle, *Saccharomyces boulardii*), provided that the dose has been stable for the ≥ 2 weeks immediately prior to randomization
 - May be receiving AZA, 6-MP, or MTX, provided that the dose has been stable for the 8 weeks immediately prior to randomization
- For women who are not postmenopausal (at least 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use a highly effective method of contraception for the duration of the study [i.e., during the treatment period and for at least 24 weeks after the last dose of study drug]
 - The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:
 - With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 24 weeks after the last dose of study drug to avoid exposing the embryo to study drug. Men must refrain from donating sperm during this same period.
 - The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- Must have received a colonoscopy within the past year or be willing to undergo a colonoscopy in lieu of a flexible sigmoidoscopy at screening. This colonoscopy must:
 - Confirm disease extent (defined as 1) left-sided colitis [up to the splenic flexure], 2) extensive colitis [beyond the splenic flexure but not involving the entire colon], and 3) pancolitis)
 - Include removal of any adenomatous polyps
 - Document evidence of surveillance for dysplasia for all patients with left-sided colitis of > 12 years' duration and total/extensive colitis of > 8 years duration

Patients who meet any of the following criteria will be excluded from study entry:

Exclusion Criteria Related to Inflammatory Bowel Disease

- Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC
- Past or present ileostomy or colostomy
- Diagnosis of indeterminate colitis
- Suspicion of ischemic colitis, radiation colitis, or microscopic colitis
- Diagnosis of toxic megacolon within 12 months of initial screening visit
- Any diagnosis of Crohn's disease
- Past or present fistula or abdominal abscess
- A history or current evidence of colonic mucosal dysplasia
- Patients with any stricture (stenosis) of the colon
- Patients with history or evidence of adenomatous colonic polyps that have not been removed

Exclusion Criteria Related to Prior or Concomitant Therapy

- Prior treatment with TNF- α antagonists
- Any prior treatment with etrolizumab or other anti-integrin agents (including natalizumab, vedolizumab, and efalizumab)
- Any prior treatment with rituximab
- Any treatment with tofacitinib during screening
- Any prior treatment with anti-adhesion molecules (e.g., anti-MAdCAM-1)
- Use of IV steroids within 30 days prior to screening with the exception of a single administration of IV steroid
- Use of agents that deplete B or T cells (e.g., alemtuzumab or visilizumab) within 12 months prior to randomization, with the exception of AZA and 6-MP
- Use of anakinra, abatacept, cyclosporine, sirolimus, or mycophenolate mofetil (MMF) within 4 weeks prior to randomization
- Chronic nonsteroidal anti-inflammatory drug (NSAID) use (Note that occasional use of NSAIDs and acetaminophen [e.g., headache, arthritis, myalgias, or menstrual cramps] and aspirin up to 325 mg daily is permitted.)
- Patients who are currently using anticoagulants including, but not limited to, warfarin, heparin, enoxaparin, dabigatran, apixaban, rivaroxaban. (Note that antiplatelet agents such as aspirin up to 325 mg daily or clopidogrel are permitted.)
- Patients who have received treatment with corticosteroid enemas/suppositories and/or topical (rectal) 5-ASA preparations within 2 weeks prior to randomization
- Apheresis (i.e., Adacolumn apheresis) within 2 weeks prior to randomization
- Received any investigational treatment including investigational vaccines within 5 half-lives of the investigational product or 28 days after the last dose, whichever is greater, prior to randomization
- History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric, human, or humanized antibodies, fusion proteins, or murine proteins or hypersensitivity to etrolizumab (active drug substance) or any of the excipients (L-histidine, L-arginine, succinic acid, polysorbate 20)
- Patients administered tube feeding, defined formula diets, or parenteral alimentation/nutrition who have not discontinued these treatments \geq 3 weeks prior to randomization

Exclusion Criteria Related to General Safety

- Pregnant or lactating
- Lack of peripheral venous access
- Hospitalized (other than for elective reasons) during the screening period
- Inability to comply with study protocol, in the opinion of the investigator
- Significant uncontrolled comorbidity, such as cardiac (e.g., moderate to severe heart failure New York Heart Association Class III/IV), pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders
- Neurological conditions or diseases that may interfere with monitoring for PML
- History of demyelinating disease
- Clinically significant abnormalities on screening neurologic examination (PML Objective Checklist)
- Clinically significant abnormalities on the screening PML Subjective Checklist
- History of alcohol, drug, or chemical abuse ≤ 6 months prior to screening
- Conditions other than UC that could require treatment with > 10 mg/day of prednisone (or equivalent) during the course of the study
- History of cancer, including hematologic malignancy, solid tumors, and carcinoma in situ, within 5 years before screening with the following exceptions:
 - A history of chronic myelogenous leukemia, hairy cell leukemia, melanoma, renal cell carcinoma, or Kaposi sarcoma is exclusionary, irrespective of the duration of time before screening.
 - History of a cervical smear indicating the presence of adenocarcinoma in situ (AIS), high-grade squamous intraepithelial lesions (HSIL), or cervical intraepithelial neoplasia (CIN) of Grade > 1 is exclusionary, irrespective of the duration of time before screening.
 - Local basal cell or squamous cell carcinoma of the skin that has been excised and is considered cured is not exclusionary

Exclusion Criteria Related to Infection Risk

- Congenital or acquired immune deficiency
- Patients must undergo screening for HIV and test positive for preliminary and confirmatory tests
- Positive hepatitis C virus (HCV) antibody test result, unless the patient (1) has undetectable HCV RNA levels for > 6 months after completing a successful course of HCV anti-viral treatment and an undetectable HCV RNA at screening or (2) has a known history of HCV antibody positivity with a history of undetectable HCV RNA for > 6 months and undetectable HCV RNA at screening in the absence of history of HCV anti-viral treatment.
- Patients must undergo screening for hepatitis B virus (HBV). This includes testing for HBsAg (HBV surface antigen), anti-HBc total (HBV core antibody total), and HBV DNA (patients who test negative for these tests are eligible for this study):
 - Patients who test positive for surface antigen (HBsAg +) are not eligible for this study, regardless of the results of other hepatitis B tests.
 - Patients who test positive only for core antibody (anti-HBc +) must undergo further testing for hepatitis B DNA (HBV DNA test).
 - If the HBV DNA test is positive, the patient is not eligible for this study.
 - In the event the HBV DNA test cannot be performed, the patient is not eligible for this study.
 - If the HBV DNA test is negative, the patient is eligible for this study. These patients will undergo periodic monitoring for HBV DNA during the study.
- Evidence of or treatment for *Clostridium difficile* (as assessed by *C. difficile* toxin testing) within 60 days prior to randomization or other intestinal pathogens (as assessed by stool culture and ova and parasite evaluation) within 30 days prior to randomization.

- Evidence of or treatment for clinically significant cytomegalovirus (CMV) colitis (based on the investigator's judgment) within 60 days prior to randomization. Laboratory confirmation of CMV from colon biopsy sample is required during screening evaluation only if clinical suspicion is high and to determine the need for CMV treatment.
- History of active or latent TB (regardless of treatment history)
 - Patients with a history of active or latent TB (based on a positive screening assay, either purified protein derivative [PPD] skin test or QuantiFERON[®]-TB Gold test) are not eligible for this study.
 - Patients with a chest X-ray (posteroanterior [PA] and lateral) within 3 months of randomization suspicious for pulmonary TB are **not** eligible for this study.
 - Any immunosuppressed patient with a strong suspicion of TB exposure and no prior vaccination with bacille Calmette-Guérin (BCG) should be considered at risk for having latent TB infection. Patients at risk for TB exposure include:
 - Patients who have household contact with a person with active TB
 - Patients living in areas with high incidence of TB
 - Patients who frequently visit areas with high prevalence of active TB
 - Patients who meet these criteria should be evaluated per local practice to exclude latent TB.
- History of recurrent opportunistic infections and/or history of severe disseminated viral infections (e.g., herpes)
- Any serious opportunistic infection within the last 6 months prior to screening
- Any current or recent signs or symptoms (within 4 weeks before screening and during screening) of infection, except for the following:
 - Minor infections (e.g., common cold) that have, in the investigator's judgment, completely resolved prior to randomization
 - Fungal infections of the nail beds
 - Oral or vaginal candidiasis that has resolved with or without treatment prior to randomization
- Any major episode of infection requiring treatment with IV antibiotics within 8 weeks prior to screening or oral antibiotics within 4 weeks prior to screening
 - Treatment with antibiotics as adjunctive therapy for UC in the absence of documented infection is not exclusionary.
- Received a live attenuated vaccine within 4 weeks prior to randomization
- History of organ transplant

Exclusion Criteria Related to Laboratory Abnormalities (at Screening)

- Serum creatinine $> 2 \times$ upper limit of normal (ULN)
- ALT or AST $> 3 \times$ ULN or alkaline phosphatase $> 3 \times$ ULN or total bilirubin $> 2.5 \times$ ULN (unconjugated hyperbilirubinemia that is associated with known Gilbert's syndrome is not an exclusion criterion)
- Platelet count $< 100,000/\mu\text{L}$
- Hemoglobin < 8 g/dL
- Absolute neutrophil count $< 1500/\mu\text{L}$
- Absolute lymphocyte count $< 500/\mu\text{L}$

Length of Study

The maximum length of the treatment period will be 14 weeks. Patients who do not achieve clinical remission at Week 10, patients who receive defined rescue treatment, and all patients who complete the 14-week treatment period of the study will be given the option of enrolling into Part 1 (OLE) of Study GA28951 after Week 12, if eligible, where they will receive open-label etrolizumab treatment.

Patients not enrolling in Part 1 (OLE) of Study GA28951 to receive open-label etrolizumab will have a 12-week safety follow-up after the last dose of study medication in this study. These patients will then be requested to enroll into Part 2 (SM) of Study GA28951 only for an additional 92 weeks of extended PML follow-up.

The total length of the study is expected to last from the first patient screened to either the last patient last follow-up visit in this protocol or last patient enrolled into Study GA28951, whichever is later.

End of Study

The end of the study is defined as the last patient last safety follow-up visit in this protocol or last patient in this protocol enrolled into Study GA28951 (OLE–SM), whichever is later.

Efficacy Outcome Measures

The efficacy outcome measures for this study are as follows:

Primary Outcome Measure:

- Remission at Week 10

Secondary Outcome Measures:

- Clinical remission at Week 10
- Clinical response at Week 10
- Improvement in endoscopic appearance of the mucosa at Week 10
- Endoscopic remission at Week 10
- Remission at Week 10 and Week 14
- Histologic remission at Week 10
- Change from baseline in MCS rectal bleeding subscore at Week 6
- Change from baseline in MCS stool frequency subscore at Week 6
- Change from baseline to Week 10 in UC bowel movement signs and symptoms as assessed by the UC-PRO/SS
- Change from baseline to Week 10 in UC abdominal symptoms as assessed by the UC-PRO/SS
- Change from baseline to Week 10 in patient's health-related QOL as assessed by the overall score of the IBDQ

Exploratory Efficacy Outcome Measures:

- Clinical remission at Week 10 and remission at Week 14
- Clinical remission at Weeks 10 and 14
- Change from baseline to Week 10 in histologic disease activity
- Improvement in histologic and/or endoscopic disease activity from baseline
- Change in health utilities, as assessed by the EQ-5D, from baseline to Week 10
- *Response and* remission at Week 10 in patient subgroups by baseline expression levels of colonic tissue and/or peripheral blood biomarkers, including, but not limited to, α E integrin
- *Response and* remission endpoints, as determined by the mMCS

Safety Outcome Measures

The safety outcome measures for this study are as follows:

- Incidence and severity of adverse events
- Incidence of serious adverse events
- Incidence and severity of infection-related adverse events
- Incidence of serious infection-related adverse events
- Incidence and severity of injection-site reactions

- Incidence of adverse events leading to study drug discontinuation
- Incidence of laboratory abnormalities
- Incidence and severity of hypersensitivity reaction events
- Incidence of ATAs to etrolizumab, or if required, adalimumab

Pharmacokinetic Outcome Measures

The PK outcome measures for this study are as follows:

- Serum concentration during drug washout (through end of safety follow-up)
- Serum concentration at primary and secondary endpoints Weeks 10 and 14

Exploratory Biomarker Outcome Measures

The exploratory biomarker outcome measures for this study are as follows:

- Relationship between baseline levels of exploratory colonic tissue and/or peripheral blood *and/or serum* biomarkers and *changes in* response to treatment or disease progression
- *Relationship between* baseline levels of stool biomarkers, which may include, but are not limited to, those in the microbiota and bacterial cultures
- *Changes from baseline in stool biomarkers in response to treatment or disease progression*

Investigational Medicinal Products

Test Product

Etrolizumab prefilled syringe (PFS): containing SC formulation, 105 mg given as 0.7 mL of a 150-mg/mL solution will be administered by SC injection Q4W.

Comparator

Placebo PFS: etrolizumab SC matching placebo given in the amount of 0.7 mL solution will be administered by SC injection Q4W

Adalimumab (Humira®) is supplied for single-use as a 1-mL glass PFS with a fixed 27-gauge ½-inch needle, providing 40 mg (0.8 mL) of adalimumab administered as an SC injection, or as a single-use, 1-mL, glass PFS with a fixed 29-gauge ½-inch needle, providing 40 mg (0.4 mL) of adalimumab.

Adalimumab placebo will be supplied by the Sponsor as a liquid formulation in PFSs and is administered as an SC injection. Each 1-mL PFS will contain 0.7 mL of a solution of 20 mM histidine, 0.2 M arginine succinate, and 0.04% polysorbate 20, pH 5.8.

Non-Investigational Medicinal Products

Patients are to continue on their baseline dose of corticosteroid (including budesonide) to the end of the Induction Phase (Week 10). Tapering of corticosteroid (including budesonide) is to be attempted from Week 10 in clinical remitters.

Patients should remain on their stable baseline doses of immunosuppressants (AZA, 6-MP, MTX) throughout the study unless dose reduction or discontinuation is required because of a toxicity related to the medication. Generally accepted criteria for discontinuing immunosuppressants due to toxicity include, but are not limited to, acute pancreatitis, severe leukopenia, severe thrombocytopenia, or clinically significant elevations of the liver-associated enzymes from baseline, especially in the presence of an elevated total bilirubin. The ultimate decision to reduce dose or discontinue immunosuppressants due to toxicity remains at the discretion of the investigator.

Probiotics and oral 5-ASA may be continued at a stable dose throughout the study.

Occasional use of NSAIDs and acetaminophen (e.g., headache, arthritis, myalgias, menstrual cramps) and aspirin up to 325 mg daily are permitted throughout the study.

Antidiarrheals (e.g., loperamide, diphenoxylate with atropine) for control of chronic diarrhea are permitted throughout the study

Statistical Methods

Primary Analysis

The primary analysis will be performed when all data through Week 14 are in the database and data have been cleaned and verified.

Whereas Sponsor personnel will be unblinded to treatment assignment to perform the primary analyses, patients and study site personnel who were blinded during the study will remain blinded to individual treatment assignment until after the study is completed (after all patients have either completed the safety follow-up period or discontinued early from the study) and the database is locked.

Detailed specifications of the statistical methods will be described in the Statistical Analysis Plan (SAP).

Determination of Sample Size

A total of approximately 350 patients will be randomized in a 2:2:1 ratio: etrolizumab (n=140), adalimumab (n=140), and placebo (n=70), respectively.

Under the assumption of a difference in remission rates between the etrolizumab and placebo arms of 25% (35% vs. 10%), the sample size of 140 patients receiving etrolizumab and 70 patients receiving placebo will provide >90% power to detect a difference with use of a χ^2 test at the two-sided 5% significance level. The assumption is based on the observed Week 10 remission results in the Phase II etrolizumab study for the TNF-naive subgroup. In addition, under the assumption of a remission rate of $\leq 20\%$ in the adalimumab arm (based on the clinical remission induction results achieved in the Phase III adalimumab ULTRA2 trial), the planned size of 140 patients/active treatment arm will provide approximately 80% power to detect a 15% absolute difference between the remission rates in the etrolizumab and adalimumab arms (35% vs. 20%), with use of a χ^2 test at the two-sided 5% significance level.

LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

Abbreviation	Definition
5-ASA	5-aminosalicylate
6-MP	6-mercaptopurine
AIS	adenocarcinoma in situ
ATA	anti-therapeutic antibody
AZA	azathioprine
BCG	bacille Calmette-Guérin
CD	Crohn's disease
CHO	Chinese hamster ovary
CIN	cervical intraepithelial neoplasia
CMV	cytomegalovirus
CRO	contract research organization
CRP	C-reactive protein
CSF	cerebrospinal fluid
EC	Ethics Committee
ECG	electrocardiogram
eCRF	electronic Case Report Form
EDC	electronic data capture
ePRO	electronic patient-reported outcomes
EQ-5D	EuroQoL Five-Dimension Questionnaire
FDA	U.S. Food and Drug Administration
GI	gastrointestinal
HBcAb	hepatitis B core antibody
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCP	health care professional
HCV	hepatitis C virus
HIPAA	Health Insurance Portability and Accountability Act
HSIL	high-grade squamous intraepithelial lesions
IBD	inflammatory bowel disease
IBDQ	Inflammatory Bowel Disease Questionnaire
ICH	International Council for Harmonisation
iDMC	independent Data Monitoring Committee
IHC	immunohistochemistry
IMP	investigational medicinal product
IND	Investigational New Drug

Abbreviation	Definition
IRB	Institutional Review Board
IV	intravenous
IxRS	interactive voice/Web-based response system
JAK	Janus kinase
JCV	John Cunningham virus
LD	loading dose
LFT	liver function test
MAb	monoclonal antibody
MAdCAM-Fc	mucosal addressin cell adhesion molecule-fragment crystallizable region
MCS	Mayo Clinic Score
mMCS	modified Mayo Clinic Score
MMF	mycophenolate mofetil
MP	mercaptopurine
MRI	magnetic resonance imaging
MTX	methotrexate
NCI CTCAE	National Cancer Institute Common Terminology Criteria for Adverse Events
NSAID	nonsteroidal anti-inflammatory drug
OLE	open-label extension
OLE-SM	open-label extension–safety monitoring
PA	posteroanterior
PCR	polymerase chain reaction
PD	pharmacodynamic
PEG	polyethylene glycol
PFS	prefilled syringe
PGA	physician’s global assessment
PK	pharmacokinetic
pMCS	partial Mayo Clinic Score
PML	progressive multifocal leukoencephalopathy
PPD	purified protein derivative
PRO	patient-reported outcome
Q4W	every 4 weeks
QOL	quality of life
qPCR	quantitative polymerase chain reaction
RCR	Roche Clinical Repository
SAP	Statistical Analysis Plan

Abbreviation	Definition
SC	subcutaneous
SM	safety monitoring
SmPC	Summary of Product Characteristics
SUSAR	Suspected Unexpected Serious Adverse Reaction
TB	tuberculosis
TNF	tumor necrosis factor
TNF- α	tumor necrosis factor–alpha
TNF-IR	inadequate response to anti-tumor necrosis factor
TNF-naive	naive to tumor necrosis factor inhibitor
UC	ulcerative colitis
UC-PRO/SS	Ulcerative Colitis Patient-Reported Outcome Signs and Symptoms
ULN	upper limit of normal

1. **BACKGROUND**

1.1 **BACKGROUND ON ULCERATIVE COLITIS**

Ulcerative colitis (UC) is an idiopathic inflammatory bowel disease (IBD) that affects the colon in a diffuse, continuous, and superficial pattern. Approximately 40%–50% of patients have disease limited to the rectum and rectosigmoid colon, 30%–40% have disease extending beyond the sigmoid but not involving the whole colon, and 20% have a total colitis. Proximal spread occurs in continuity without areas of uninvolved mucosa. When the whole colon is involved, the inflammation extends 2–3 cm into the terminal ileum in 10%–20% of patients.

UC is characterized by mucosal ulceration, rectal bleeding, diarrhea, and abdominal pain and may be complicated by severe bloody diarrhea and toxic megacolon, requiring major and sometimes urgent surgery. UC represents dysregulation of the mucosal immune system in genetically susceptible individuals in response to commensal microbiota and other environmental triggers. The overall incidence of UC ranges from 6.3 to 24.3 cases per 100,000 persons per year, and prevalence ranges from 4.9 to 505.0 cases per 100,000 persons, with the highest estimates in European and Northern American populations (Molodecky et al. 2012). Although the incidence and prevalence vary between regions of the world, both have been increasing in some regions, which may be due in part to better detection and diagnosis, as well as environmental factors such as improved hygiene and Western diet. The disease can affect any age group, but occurrence peaks between the ages of 15 and 35 years.

The goals of treatment are to induce and maintain remission, decrease corticosteroid use (as measured by steroid-free remission), induce mucosal healing, reduce hospitalization and surgery, improve health-related quality of life (QOL), and avoid disability. For mildly to moderately active UC, oral and rectal preparations of 5-aminosalicylate (5-ASA) medications are used either alone or together and result in remission in approximately 50% of patients. Patients whose UC fails to respond to 5-ASA drugs or who have moderately to severely active UC often receive conventional therapy, including corticosteroids and immunomodulator therapy (e.g., azathioprine [AZA], 6-mercaptopurine [6-MP], and methotrexate [MTX]). Remission is achieved in about 70% of patients treated with corticosteroids, but approximately 20% of patients become steroid dependent and only half maintain steroid-free remission (Faubion et al. 2001). Corticosteroids are also associated with significant side effects, such as infections, osteopenia, glucose intolerance, and adrenal suppression. Immunomodulators, such as 6-MP, AZA, and MTX, have also been used to achieve steroid-free remission, but efficacy in maintaining steroid-free remission is modest (Lobel et al. 2004; Chebli et al. 2010; Mañosa et al. 2011; Khan et al. 2013). In addition, these medications are associated with significant side effects, including hepatotoxicity, pancreatitis, and bone marrow suppression.

More recently, monoclonal antibodies (MAbs) targeting tumor necrosis factor–alpha (TNF- α), such as infliximab and adalimumab, have been used to induce and maintain remission in patients whose immunomodulatory therapy fails, are steroid dependent or refractory, and have moderately to severely active UC. These biologic agents induce remission in up to 40% of patients, but sustained remission is seen in only 10%–20% of patients over 1 year (Rutgeerts et al. 2005; Sandborn et al. 2013). Importantly, TNF inhibitor therapies are associated with serious adverse events, such as bacterial infection, including tuberculosis (TB), disseminated fungal infections, lymphoma, and demyelination (Chang and Lichtenstein 2006). In fulminant steroid-unresponsive colitis, infliximab and (less commonly) cyclosporine are utilized as bridging agents to avoid urgent colectomy. With either therapy, however, treatment failure occurs in approximately 55%–60% of patients (Laharie et al. 2012).

In short, a large proportion of patients with moderately to severely active UC do not maintain a durable response to therapy. Available therapies are associated with significant adverse events and at best achieve sustained remission in only 10%–30% of patients with IBD who have chronic disease (Hanauer et al. 2002; Sandborn et al. 2005). Patients whose disease fails to respond to medical therapy may be treated with total proctocolectomy with an ileal pouch-anal anastomosis. Although surgical intervention may be curative, complications such as chronic pouchitis, fecal incontinence, or decreased female fertility can occur (Bradley and Oliva-Hemker 2012). The current treatments are associated with significant adverse events, resulting in low rates of sustained remission, or are highly invasive.

Consequently, there continues to be a high unmet medical need in moderately to severely active UC. Targeted therapy with an improved safety profile and ability to sustain remission and prevent long-term complications would provide a valuable therapeutic option for these patients.

1.2 BACKGROUND ON ETROLIZUMAB

A new class of molecules targeting the integrin receptors that regulate leukocyte trafficking to specific tissues in the body has been developed for treatment of IBD. Clinical studies have shown evidence of efficacy for these agents, including natalizumab (anti- α 4) for Crohn's disease (CD) (Sandborn et al. 2005) and vedolizumab (anti- α 4 β 7) for UC and CD (Feagan et al. 2005, 2008); both agents have been approved for their respective indications. Natalizumab and vedolizumab require IV administration, but only vedolizumab is gut-selective. Natalizumab is not gut-selective and is associated with the risk of progressive multifocal leukoencephalopathy (PML). Etrolizumab distinguishes itself from these molecules by specifically binding the integrin β 7 subunit, found in both α 4 β 7 (Holzmann et al. 1989; Hu et al. 1992) and α E β 7 (Cepek et al. 1993), which regulate trafficking and retention of leukocyte/lymphocyte subsets, respectively, in the intestinal mucosa.

It is important to note that etrolizumab does not bind to $\alpha4\beta1$ (target for natalizumab), which regulates trafficking to both mucosal and non-mucosal tissues, including the CNS. Etrolizumab, therefore, represents a novel gut mucosal-selective anti-trafficking agent whose selectivity may enhance efficacy in UC and eliminate generalized immunosuppression by preferentially targeting trafficking to the gut rather than to other organs and tissues. Data from multiple nonclinical toxicology studies of up to 6 months' duration in adult animals demonstrated no adverse effects in any organ system (including the CNS and hematologic and cardiovascular systems). No adverse events were observed in the embryo-fetal developmental toxicity studies.

Etrolizumab is a humanized MAb based on the human IgG1 subgroup-III V_H, κ subgroup-1 V_L consensus sequences and was constructed using standard recombinant DNA techniques. This recombinant antibody consists of two heavy chains (446 residues) and two light chains (214 residues) and is produced in Chinese hamster ovary (CHO) cells that have been genetically engineered to synthesize the antibody. The protein is manufactured in bioreactors and purified using a series of harvest, purification, and formulation steps. The potency of etrolizumab is determined by an in vitro assay that measures the inhibition of adhesion of $\alpha4\beta7$ -expressing cells to mucosal addressin cell adhesion molecule-fragment crystallizable region (MAdCAM-Fc).

Safety assessments for etrolizumab have been completed in the adult Phase I, Phase II, and Phase II open-label extension (OLE) studies without significant safety concerns.

The following is a summary of the etrolizumab safety experience to date:

- There were no observed significant adverse effects in multiple nonclinical toxicity studies of up to 6 months' duration in adult animals or in embryo-fetal developmental toxicity studies. No adverse effects were seen in any organ system (including the CNS and hematologic and cardiovascular systems), no effects were seen in embryo-fetal development, and there was no evidence of increased rates of infection.
- No significant adverse safety signal, including any evidence of increased rates of serious or opportunistic infections, was associated with etrolizumab treatment in the Phase I or Phase II trials in adult patients with moderately to severely active UC who received either single or multiple doses of intravenous (IV) or subcutaneous (SC) etrolizumab.
- No events of PML have been reported in etrolizumab-treated patients.

See the most recent Etrolizumab Investigator's Brochure for details on nonclinical and clinical studies.

1.3 STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT

Although effective therapeutic options, including TNF inhibitors, are available to help patients with moderate to severe UC to reduce the acute symptomatic flares in disease activity, no currently available therapy, including approved anti-integrins (natalizumab for

CD and vedolizumab for UC and CD), achieves sustained remission in more than 10%–30% of patients with IBD (Hanauer et al. 2002; Sandborn et al. 2005; Feagan et al. 2013). Furthermore, TNF inhibitors are associated with elevated rates of serious bacterial infection, including TB, and (more rarely) lymphoma and demyelination (Chang and Lichtenstein 2006). Adalimumab has been very commonly associated with respiratory tract infections, neutropenia, injection-site reactions, rash, musculoskeletal pain, headache, elevated liver enzymes, abdominal pain, and nausea. Adalimumab has been commonly associated with intestinal, skin, soft tissue, genitourinary tract, and systemic infections (including sepsis); skin cancers (excluding melanoma); hypersensitivity; mood alterations; tachycardia; and vascular disorders (Humira[®] Summary of Product Characteristics [SmPC]). Consequently, patients and investigators carefully weigh these benefit-risk tradeoffs both before embarking and while managing long-term treatment with TNF inhibitors.

The recent availability of the gut-selective anti-integrin class of monoclonal antibody treatments may provide potential treatment alternatives to TNF inhibitors and may exhibit a more tolerable safety profile.

Etolizumab distinguishes itself from other anti-integrins on the basis of gut selectivity combined with a dual mechanism of action. It binds $\alpha E\beta 7$ in addition to $\alpha 4\beta 7$ and so regulates retention as well as trafficking of leukocytes/lymphocytes in the intestinal mucosa.

No clinically significant safety signals have been detected on administration of etolizumab to patients with moderate to severe UC across a dose range of 0.3–10.0 mg/kg IV/SC in the single-ascending-dose stage and of 0.5–3.0 mg/kg SC and 4 mg/kg IV monthly for three doses in the multidose stage of the Phase I study.

A global Phase II multicenter study (Study ABS4986g; EUCALYPTUS) designed to determine the exposure-response relationship and to further characterize the safety and tolerability of etolizumab in treatment of adult patients with moderately to severely active UC has been completed. Patients whose treatment with standard therapy and/or TNF inhibitors has failed were randomized in a 1:1:1 ratio to receive 100 mg etolizumab SC (0.7 mL of 150 mg/mL solution via vial and syringe, with an intended nominal dose of 100 mg) at Weeks 0, 4, and 8 or 420 mg SC at Week 0 (loading dose [LD]) followed by 300 mg SC (three injections of 0.7 mL of 150 mg/mL solution via vial and syringe, with an intended nominal dose of 300 mg) at Weeks 2, 4, and 8 (40 patients per dose arm) versus matching placebo SC (40 patients per arm). The primary objective of the study was to obtain evidence of clinical efficacy of etolizumab as measured by induction of clinical remission (Mayo Clinic Score [MCS] ≤ 2 and no individual subscore > 1) at Week 10 (2 weeks after the final dose).

Compared with patients assigned to receive placebo, patients who received etrolizumab showed clinically meaningful efficacy for both doses: the proportion of patients in clinical remission at Week 10 was 20.5% in the 100-mg dose group and 10.3% in the 300-mg+LD group versus 0% in the placebo group ($p=0.004$ and $p=0.048$, respectively). In the TNF-naïve subgroup, clinical remission at Week 10 was observed in 43.8% versus 0% of patients in the 100-mg etrolizumab versus placebo group and in 25% of 300-mg+LD group. No new safety signals were observed and etrolizumab was well tolerated in the Phase II EUCALYPTUS study and in the OLE study (SPRUCE), and no events of PML have been reported to date.

Given the efficacy and safety profile demonstrated in the Phase II studies, further investigation is warranted to compare sustained clinical remission with etrolizumab against adalimumab in a previously TNF-naïve population.

The present double-blinded, placebo-controlled and active-comparator study employs a robust design that uses independent and centrally read endoscopy to confirm patient eligibility and endpoint determination. The study is powered to detect a clinically meaningful difference of 25% in the proportion of patients achieving induction of remission at Week 10 between etrolizumab-treated patients and placebo-treated patients. The study is also powered to detect a clinically meaningful difference of 15% in the proportion of patients achieving induction of remission between etrolizumab-treated patients and placebo-treated patients with the TNF inhibitor adalimumab 10 weeks after initiation of treatment. All patients will be allowed to receive rescue therapy at any time. Non-remitters at Week 10, patients requiring use of rescue medications who complete the Week 10 assessment, and all patients at Week 14 will be allowed to enroll in an OLE study beginning at Week 12 to receive open-label etrolizumab therapy, if eligible.

There is no known safety risk identified for etrolizumab at this time, but as an investigational medicinal product with limited Phase II data, the full safety profile for etrolizumab will be further characterized as Phase III clinical development progresses. A safety plan is provided in Section 5.1 that describes potential risks for etrolizumab and the risk-mitigation strategies to minimize risks for the patients in this trial.

Refer to the most recent Etrolizumab Investigator's Brochure for additional details on clinical and nonclinical studies and additional safety information.

2. OBJECTIVES

The study will assess the efficacy of etrolizumab compared with placebo for induction of remission and will also carry out a comparative assessment of etrolizumab and adalimumab in inducing remission.

2.1 EFFICACY OBJECTIVES

The primary efficacy objective for this study is as follows:

- To evaluate the efficacy of etrolizumab (105 mg SC every 4 weeks [Q4W]) compared with placebo for the induction of remission in TNF-naive patients with UC as determined by the MCS at Week 10

The secondary efficacy objectives for this study are as follows:

- To evaluate the efficacy of etrolizumab compared with adalimumab for the induction of remission at Week 10
- To evaluate the efficacy of etrolizumab for the induction of clinical remission at Week 10
- To evaluate the efficacy of etrolizumab for clinical response at Week 10
- To evaluate the efficacy of etrolizumab for improvement in endoscopic appearance of the mucosa at Week 10
- To evaluate the efficacy of etrolizumab for endoscopic remission at Week 10
- To evaluate the efficacy of etrolizumab compared with placebo in achieving remission at Week 10 and maintaining it to Week 14
- To evaluate the efficacy of etrolizumab for histologic remission at Week 10
- To evaluate the efficacy of etrolizumab for onset of action, defined as change from baseline in MCS rectal bleeding subscore at Week 6
- To evaluate the efficacy of etrolizumab for onset of action, defined as change from baseline in MCS stool frequency subscore at Week 6
- To evaluate the efficacy of etrolizumab for UC bowel movement signs and symptoms at Week 10 as assessed by the Ulcerative Colitis Patient-Reported Outcome Signs and Symptoms (UC-PRO/SS) measure
- To evaluate the efficacy of etrolizumab for UC abdominal symptoms at Week 10 as assessed by the UC-PRO/SS measure
- To evaluate the efficacy of etrolizumab for patient-reported health-related QOL at Week 10 as assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ)

The exploratory efficacy objectives for this study are as follows:

- To evaluate the impact of etrolizumab on remission at Week 14 in patients who achieved clinical remission at Week 10 compared with placebo
- To evaluate the efficacy of etrolizumab compared with placebo in achieving clinical remission at Week 10 and maintaining it to Week 14

- To evaluate change in histologic disease activity from baseline to Week 10 as measured by the Nancy Histological Index
- To evaluate improvement in histologic and/or endoscopic disease activity
- To evaluate change in health utilities at Week 10, as assessed by the EuroQoL Five-Dimension Questionnaire (EQ-5D)
- To evaluate *response and* remission at Week 10 in subgroups by baseline expression levels of colonic tissue and/or peripheral blood biomarkers (including, but not limited to, α E integrin) to predict patient subgroups with a greater likelihood of responding to etrolizumab
- To evaluate response *and* remission endpoints, as determined by the modified MCS (mMCS)

The efficacy outcomes definitions are given in [Table 1](#).

Table 1 Efficacy Outcomes Definitions

Outcome Measure	Outcome Measure Definition
Mayo Clinic Score	MCS is a composite of 4 assessments, each rated from 0–3: stool frequency, rectal bleeding, endoscopy, and physician’s global assessment
Partial Mayo Clinic Score	pMCS is a composite of 3 assessments, each rated from 0–3: stool frequency, rectal bleeding, and physician’s global assessment
Modified MCS	mMCS is a composite of 3 assessments of the MCS, each rated from 0–3: stool frequency, rectal bleeding, and endoscopy
Remission	MCS \leq 2 with individual subscores \leq 1 and a rectal bleeding subscore of 0
Clinical remission	MCS \leq 2 with individual subscores \leq 1
Clinical response	MCS with \geq 3-point decrease and 30% reduction from baseline as well as \geq 1-point decrease in rectal bleeding subscore or an absolute rectal bleeding score of 0 or 1
Improvement in endoscopic appearance of the mucosa	Endoscopic subscore \leq 1
Endoscopic remission	Endoscopic subscore = 0
Histologic remission	NHI \leq 1 ^a

MCS = Mayo Clinic Score; mMCS = modified Mayo Clinic Score; pMCS = partial Mayo Clinic Score; NHI = Nancy histological index.

^a See [Appendix 12](#)

2.2 SAFETY OBJECTIVES

The safety objectives for this study are as follows:

- To evaluate the overall safety and tolerability of etrolizumab during induction of remission of UC
- To evaluate the incidence and severity of infection-related adverse events
- To evaluate the incidence and severity of hypersensitivity reactions
- To evaluate the incidence and the clinical significance of anti-therapeutic antibodies (ATAs) to etrolizumab, or if required, adalimumab

2.3 PHARMACOKINETIC OBJECTIVES

The pharmacokinetic (PK) objectives for this study are as follows:

- To evaluate the etrolizumab serum concentration at the time of primary and secondary endpoints (Weeks 10 and 14) and during drug washout at the time of safety follow-up.
- To evaluate the interindividual variability and potential covariate effects on etrolizumab serum exposure

2.4 EXPLORATORY PHARMACODYNAMIC, PREDICTIVE, AND PROGNOSTIC OBJECTIVES

The exploratory pharmacodynamic (PD), predictive, and prognostic objectives for this study are as follows:

- To evaluate the expression levels of biomarkers including, but not limited to, α E integrin, in colonic tissue and/or peripheral blood *and/or serum* at baseline, during, or end of the treatment period
- To evaluate biomarkers in stool at baseline and during the treatment period through assessments that may include, but are not limited to, analyses of the microbiota and bacterial cultures

3. STUDY DESIGN

3.1 DESCRIPTION OF STUDY

3.1.1 Overview of Study Design

This is a multicenter, Phase III, randomized, double-blind, double-dummy, placebo and active comparator controlled study to evaluate the safety, efficacy, and tolerability of etrolizumab (105 mg SC Q4W) in the induction of remission for patients naive to TNF inhibitors. Comparisons will be made against placebo and adalimumab (160 mg SC Week 0, 80 mg SC Week 2, 40 mg SC Weeks 4, 6, and 8).

Patients enrolled in this study may be eligible to participate in an open-label extension and safety monitoring (OLE-SM) study (GA28951), which consists of two parts: Part 1 (designated OLE [open label extension]) and Part 2 (designated SM [safety monitoring]).

Disease severity will be measured using the MCS (see [Appendix 4](#)), which is the current outcome measure accepted by regulatory authorities for drug development in UC. The study population consists of TNF-naïve patients with moderately to severely active UC (defined as MCS of 6–12, endoscopy subscore of ≥ 2 , as determined by the central reading procedure described in Section [4.5.1.4](#), a rectal bleeding subscore ≥ 1 , and a stool frequency subscore ≥ 1) and involvement that extends to a minimum of 20 cm from the anal verge.

Patients must have had an inadequate response, loss of response, or intolerance to prior immunosuppressant and/or corticosteroid treatment.

Patients who are on background immunosuppressant therapy (6-MP, AZA, MTX) may be enrolled if they have received a stable dose for at least 8 weeks prior to randomization (Day 1). Such patients should continue on stable doses of their background immunosuppressant therapy during the study, unless dose reduction or discontinuation is required due to toxicity.

Generally accepted criteria for discontinuing immunosuppressants due to toxicity include, but are not limited to, acute pancreatitis, severe leukopenia, severe thrombocytopenia, or clinically significant elevations of the liver-associated enzymes from baseline, especially in the presence of an elevated total bilirubin. The ultimate decision to reduce the dose or discontinue immunosuppressants due to toxicity remains at the discretion of the investigator.

Patients on oral corticosteroid therapy (prednisone at a stable dose of ≤ 30 mg, or equivalent) may be enrolled according to the following criteria:

- If corticosteroid therapy is ongoing or has recently been initiated, the dose has to be stable for at least 4 weeks immediately prior to randomization
- If corticosteroids are being tapered, the dose has to be stable for at least 2 weeks immediately prior to randomization

Such patients should continue stable doses of their background corticosteroid until Week 10, at which point a corticosteroid taper will be initiated for clinical remitters.

Initiation of corticosteroid or an increase in corticosteroid dose above the patient's entry dose (up to a maximum of 30 mg/day prednisone [or equivalent]) will not be permitted during screening. Use of budesonide will be allowed at stable doses (≤ 9 mg) provided that the dose has been stable for ≥ 4 weeks prior to randomization. Oral 5-ASA treatment and probiotics for the treatment of UC may be continued at a stable dose as long as the dose(s) had been stable for ≥ 4 weeks and ≥ 2 weeks, respectively, prior to randomization. Certain concomitant treatments are prohibited (see Section [4.1.2](#) for list of all prohibited concomitant treatments).

A total of approximately 350 patients (see [Figure 1](#)) from approximately 115 global sites will be randomized in a 2:2:1 ratio (etrolizumab:adalimumab:placebo). Patients will be stratified by concomitant treatment with corticosteroids (yes/no) at randomization, concomitant treatment with immunosuppressants (yes/no) at randomization, and disease activity measured during screening ($MCS \leq 9/MCS \geq 10$).

The study will be divided into:

- Screening period of up to 35 days (for details see [Section 4.5.2.1](#))
- Double-blind treatment period of up to 14 weeks, which consists of a 10-week induction period and an additional 4-week treatment period for patients who meet the definition of clinical remission at Week 10
- Safety follow-up period of 12 weeks

An extended safety-monitoring period of an additional 92 weeks (after 12-week safety follow-up) for PML will be conducted in an OLE and safety monitoring (OLE-SM) study (GA28951) under a separate protocol.

The study design is double-blind, double-dummy, placebo-controlled so all patients will receive two study treatments: active etrolizumab + adalimumab placebo, active adalimumab + etrolizumab placebo, or etrolizumab placebo + adalimumab placebo.

Study Drug Administration

Etrolizumab/etrolizumab placebo and adalimumab/adalimumab placebo will be administered SC via a prefilled syringe (PFS) in the clinic by an unblinded health care professional (HCP) because the adalimumab syringe is not visually identical to the adalimumab placebo syringe. Unblinded HCPs will not be involved in performing patient assessments and will have no further interaction with blinded site staff or patients. Study site personnel involved in performing patient assessments and the patients must remain blinded to study treatment.

Patients randomized to an active treatment arm will receive one active drug and one placebo according to the randomization code to achieve blinding. Patients randomized to the placebo arm will receive no active treatment but will receive etrolizumab placebo SC and adalimumab placebo SC. The injections are not required to be administered in any specific order. Patients will be monitored for 1 hour in the clinic following the injections.

A detailed guide to the injections required at each study visit is provided in [Section 4.2](#) and [Table 3](#).

Patients are to visit the clinic every 2 weeks from Day 1 to Week 10 and at Weeks 12 and 14 only for patients who achieve clinical remission at Week 10.

The last dose of adalimumab/adalimumab placebo will be given at Week 8, after which patients will begin a 4-week washout period from adalimumab. Patients who achieve clinical remission at Week 10 (without use of rescue medications) will continue in the study. Patients continuing beyond Week 10 will receive etrolizumab/etrolizumab placebo at Week 12. The patient's clinical remission status will be assessed again at Week 14 by MCS.

Patients not achieving clinical remission at Week 10 and patients who achieve clinical remission at Week 10 but required the use of rescue medications prior to Week 10 should remain in the blinded study until Week 12. They will not receive any more study medication in this study after Week 10. These patients may enroll in Part 1 (OLE) of Study GA28951 at Week 12 (Day 1 OLE), if eligible, where they will receive open-label etrolizumab (see Section 4.5.2.3). Clinical remitters at Week 10 (who did not use rescue medications prior to Week 10) should remain in the blinded study until Week 14, at which time they may enroll in the Part 1 (OLE) of Study GA28951, if eligible. The first dose of open-label etrolizumab will be given upon enrollment into Part 1 (OLE) of Study GA28951. If patients are not eligible to enroll in Part 1 (OLE) of Study GA28951, they will enter the 12-week safety follow-up period of this study and will then be requested to enroll in Part 2 (SM) of Study GA28951 for 92 weeks of extended PML monitoring.

Concomitant Drugs for Ulcerative Colitis during the Study

Throughout the treatment phase of the study, patients are to maintain their stable baseline doses of their concomitant medications (5-ASA, corticosteroids, immunosuppressants) for UC except that all patients receiving corticosteroids who achieve clinical remission and who continue in this study past Week 10 must begin a corticosteroid taper at Week 10.

Immunosuppressants during the Study

Patients should remain on their stable baseline doses of immunosuppressants (AZA, 6-MP, MTX) throughout the study unless dose reduction or discontinuation is required because of a toxicity related to the medication. Generally accepted criteria for discontinuing immunosuppressants due to toxicity include, but are not limited to, acute pancreatitis, severe leukopenia, severe thrombocytopenia, or clinically significant elevations of the liver-associated enzymes from baseline, especially in the presence of an elevated total bilirubin. The ultimate decision to reduce dose or discontinue immunosuppressants due to toxicity remains at the discretion of the investigator.

Oral Corticosteroids during the Study

During the Induction Phase, patients are to maintain their stable baseline corticosteroid dose. For patients who achieve clinical remission and remain in the study for an additional 4 weeks beyond the Week 10 Induction Phase, corticosteroids are to be tapered starting from Week 10. Patients who were receiving prednisone at a dose of > 10 mg/day (or equivalent) are to have their dose reduced at a rate of 5 mg per week until a 10 mg/day dose is achieved. Patients receiving prednisone at doses ≤ 10 mg/day (or equivalent), or once a 10 mg/day dose (or equivalent) is achieved by tapering, are to have their dose reduced at a rate of 2.5 mg/week. Patients receiving budesonide should taper their dose starting from Week 10 from 9 mg every day to 9 mg every other day for 2 weeks and then discontinue budesonide treatment.

3.1.1.1 Rescue Therapy Rescue Therapy That Can Be Given with Study Medication for the Treatment of Ulcerative Colitis

Prior to Week 10, any patient who requires initiation of an immunosuppressant (AZA, 6-MP, or MTX), corticosteroid, or oral or topical 5-ASA, or who requires an increase in dose over baseline levels for treatment of worsening disease symptoms should stay in the study until Week 12 after performing the Week 10 assessment. Patients not achieving clinical remission at the Week 10 assessment and patients who achieve clinical remission at Week 10 but required the use of rescue medications prior to Week 10 can enroll in Part 1 (OLE) of Study GA28951 to receive open-label etrolizumab, if eligible, at Week 12 (a 2-week delay to allow for adalimumab washout). Alternatively, they can enter the 12-week safety follow-up and then enroll in Part 2 (SM) of Study GA28951 for extended PML monitoring.

After Week 10, any patient who requires initiation of an immunosuppressant, corticosteroid, or oral or topical 5-ASA or increase in dose over baseline levels for treatment of worsening disease symptoms should remain in the study to perform the Week 14 assessment and can then enroll in Part 1 (OLE) of Study GA28951 to receive open-label etrolizumab, if eligible, or enter the 12-week safety follow-up and then enroll in Part 2 (SM) of Study GA28951 for extended PML monitoring.


Endoscopy to document disease activity for patients exiting the treatment period early for any reason may be performed at the discretion of the investigator.

Rescue Therapy That Cannot Be Given with Study Medication for the Treatment of Ulcerative Colitis

At ANY time during the conduct of the study, use of other immunosuppressive agents including, but not limited to, anakinra, abatacept, anti-integrins, T- or B-cell depleters (except AZA and 6-MP), TNF inhibitors (including TNF inhibitor biosimilars), cyclosporine, tacrolimus, anti-adhesion molecules, Janus kinase (JAK) inhibitors, or investigational agents are prohibited. Patients who receive such therapies are not to receive further study treatment or open-label treatment and will be required to enter the 12-week safety follow-up period of this study. These patients will also be requested to enroll in Part 2 (SM) of Study GA28951 for 92 weeks of extended PML monitoring.

A complete list of study visits and assessments can be found in the Schedule of Assessments (see [Appendix 1](#) and [Appendix 2](#)).

Figure 1 Study Schema



6-MP=6-mercaptopurine; AZA=azathioprine; CS=corticosteroid; d=day; EP=endpoint; MCS=Mayo Clinic Score; OLE=open-label extension; OLE-SM=open-label extension-safety monitoring study; MTX=methotrexate; Q2W=every 2 weeks; Q4W=every 4 weeks; QD=once a day; QOD=every other day; Rx=study treatment; SC=subcutaneous; SM=safety monitoring; TNF-naive=naive to tumor necrosis factor inhibitor; UC=ulcerative colitis; wk=week.

3.1.1.2 Number of Patients

A total of approximately 350 patients are to be randomized into one of three study treatment groups in a 2:2:1 ratio as follows:

- Treatment Group A: etrolizumab SC plus adalimumab placebo SC
- Treatment Group B: adalimumab SC plus etrolizumab placebo SC
- Treatment Group C: etrolizumab placebo SC plus adalimumab placebo SC

3.1.2 Data Monitoring Committee

An independent Data Monitoring Committee (iDMC) will monitor safety and study conduct on an ongoing basis. Members of the iDMC will be external to the Sponsor and will follow a charter that outlines the iDMC roles and responsibilities. The iDMC will meet approximately every 6 months (frequency adjustable as required) to review unblinded safety and study conduct data prepared by an independent data coordinating center. If the iDMC deems a benefit-risk assessment necessary, the iDMC may also review unblinded efficacy data. The iDMC may recommend stopping the study early for safety reasons. However, the iDMC may not recommend stopping the trial early for positive efficacy or solely for futility.

3.2 END OF STUDY AND LENGTH OF STUDY

Length of Study

The maximum length of the treatment period will be 14 weeks. Patients who do not achieve clinical remission at Week 10, patients who receive defined rescue treatment (see Section 3.1.1.1), and all patients who complete the 14-week treatment period of the study will be given the option of enrolling into Part 1 (OLE) of Study GA28951 after Week 12, if eligible, where they will receive open-label etrolizumab treatment.

Patients not enrolling in Part 1 (OLE) of Study GA28951 to receive open-label etrolizumab will have a 12-week safety follow-up after the last dose of study medication in this study. These patients will then be requested to enroll into Part 2 (SM) of Study GA28951 only for an additional 92 weeks of extended PML follow-up.

The total length of the study is expected to last from the first patient screened to either the last patient last follow-up visit in this protocol or last patient enrolled into Study GA28951, whichever is later.

End of Study

The end of the study is defined as the last patient last safety follow-up visit in this protocol or last patient in this protocol enrolled into Study GA28951 (OLE-SM), whichever is later.

3.3 RATIONALE FOR STUDY DESIGN

3.3.1 Rationale for Test Product Dosage

Data from Phase I (Study ABS4262g) and Phase II (Study ABS4986g; EUCALYPTUS) indicated that the 100-mg Q4W regimen is sufficient to maintain β 7 receptor occupancy both in blood and in colonic tissue, is well tolerated, and results in meaningful clinical efficacy, and therefore, will be evaluated further in this Phase III study. The rationale for proposing a 105-mg Q4W SC regimen is discussed below.

- The Phase II nominal 100-mg SC Q4W dose (0.7 mL of 150 mg/mL solution via vial and syringe, with an actual dose of 105 mg) showed clinically meaningful efficacy without clinically meaningful safety imbalances (see Section 1.2). The Phase III formulation is a PFS containing 0.7 mL of 150 mg/mL etrolizumab solution, corresponding to delivering a dose of 105 mg etrolizumab per injection.

In the Phase II EUCALYPTUS study, the 100-mg SC Q4W dose resulted in an increased clinical remission rate in TNF-naïve patients (43.8%; $p=0.007$), as well as in the combined TNF-naïve and inadequate response to anti-tumor necrosis factor (TNF-IR) group (20.5%; $p=0.004$) at Week 10 as compared with the clinical remission rate in placebo patients (0%). These data suggest that the 100-mg SC Q4W dose regimen is efficacious in patients with moderately and severely active UC.

- Up to a 4–5-fold higher exposure did not result in a greater PD effect or an increase in clinical benefit.

A higher dose (420 mg SC at Week 0 followed by 300 mg at Weeks 2, 4, and 8) was also tested in the EUCALYPTUS study without any major safety concerns. However, there was no clear distinction in observed pharmacological effects (including clinical efficacy outcome and PD response, such as β 7 receptor occupancy) between high-dose and the 100-mg dose cohorts. Although the study was not powered to enable a formal comparison of the two active arms, the data suggest that the observed clinical remission rate at Week 10 in the low-dose cohort was not further improved in the high-dose cohort.

Preliminary concentration quartile-response analysis was conducted for the data pooled from both low- and high-dose cohorts to see whether patients in the higher concentration quartiles had better remission rate. The results did not show any exposure response relationship.

- Exposure lower than 100 mg Q4W is likely not sufficient to maintain β 7 integrin receptor occupancy.

In the Phase I study (Study ABS4262g), the etrolizumab PK profile appears nonlinear at a dose level of < 1 mg/kg IV. The duration of β 7 receptor occupancy is dose dependent. A single dose of 0.3 mg/kg IV maintained β 7 receptor occupancy for only approximately 2 weeks, which is likely insufficient to ensure maximal β 7 receptor occupancy at all times within a Q4W dosing interval.

On the basis of data from the Phase II EUCALYPTUS study, it is assumed that maximal/near maximal occupancy of $\beta 7$ receptors both in the blood and in colonic tissue is minimally necessary for etrolizumab's clinical activity. Per this assumption, population PK simulations were performed and results showed that a 100-mg SC Q4W regimen can provide steady-state serum trough concentration ($C_{\text{trough,ss}}$) of at least 1.7 $\mu\text{g/mL}$ (the minimum serum concentration observed that maintained colonic tissue $\beta 7$ occupancy) in $\geq 84\%$ of patients, whereas a dose lower than the 100-mg SC Q4W regimen (e.g., 50 mg Q4W SC) is likely not sufficient for maintaining $\beta 7$ receptor occupancy at all times during the Q4W dosing interval, since only 56% of patients were predicted to reach a 1.7 $\mu\text{g/mL}$ level in their $C_{\text{trough,ss}}$ (see Table 2).

Lower doses are also anticipated to result in etrolizumab serum level falling into the nonlinear PK concentration range and hence are likely to increase variability in exposure.

Table 2 Population Pharmacokinetic Modeling Predicted Percentage of Patients Achieving 1.7- $\mu\text{g/mL}$ Steady-State Trough Concentration under Different Dosing Scenarios

	Q4W SC Dosing		
	300 mg	100 mg	50 mg
Percentage of patients expected to have $C_{\text{trough,ss}} > 1.7\mu\text{g/mL}$	98	84	56

$C_{\text{trough,ss}}$ = steady-state trough concentrations; Q4W = every 4 weeks; SC = subcutaneous.

Note: 1.7 $\mu\text{g/mL}$ is the minimum serum concentration observed in the Phase II study that maintained $\beta 7$ occupancy in the colonic tissue.

In conclusion, on the basis of available etrolizumab efficacy, PK, PD, and safety data (see Section 1.2), a PFS delivering a dose of 105 mg Q4W is considered the most appropriate dosing regimen for this Phase III study.

3.3.2 Rationale for Patient Population

There is a high unmet medical need for patients with moderately to severely active UC who have failed to achieve sufficient benefit from immunosuppressants. Current therapies (TNF inhibitors) achieve clinical remission at induction in only approximately 15%–40% of patients (Reinisch et al. 2011; Rutgeerts et al. 2005) and can be associated with significant adverse events.

The Phase II EUCALYPTUS study provided evidence of efficacy, including induction of remission at Week 10, in patients with moderately to severely active UC refractory to or intolerant of conventional and/or TNF inhibitor therapies. Results from this study showed that at Week 10, the proportions of patients in clinical remission (defined as $\text{MCS} \leq 2$ and all subscores ≤ 1) in the overall population were 20.5% in the 100-mg arm

compared with 0% in the placebo arm. In the TNF-naive subgroup, clinical remission at Week 10 was observed in 43.8% versus 0% of patients in the 100-mg etrolizumab versus placebo group, suggesting substantial efficacy in the TNF-naive population at Week 10.

In summary, because of the limitations of the currently available therapies for the treatment of moderately to severely active UC and the favorable benefit-risk observed in the TNF-naive population in EUCALYPTUS, this Phase III study is designed to test the efficacy and safety of etrolizumab in this patient population.

3.3.3 Rationale for Control Group

Patients in the placebo-treated control group will enter the study while on their stable background UC treatment.

A placebo-treated control group will be used in this study to assess the differences in efficacy, safety, and tolerability in patients who receive etrolizumab plus their stable background UC therapy compared with patients who receive placebo plus their stable background UC therapy. The use of a control group is necessary given the inherent variability in disease flares and the use of subjective assessments, such as the patient-reported outcomes (PROs). Patients in the control group will undergo the same study assessments as the etrolizumab-treated patients.

3.3.4 Rationale for Active Comparator


Adalimumab is a biologic licensed for the induction of clinical remission in UC. Adalimumab was successful at achieving induction of clinical remission at Week 8 in approximately 16.5%–18.5% (Reinisch et al. 2011) of patients with moderately to severely active UC, indicating that a substantial proportion of treated patients were unable to achieve induction of clinical remission.

The active-treated control group will be used in this study to assess the differences in efficacy, safety, and tolerability in patients who receive etrolizumab plus their stable background UC therapy compared with patients who receive adalimumab plus their stable background UC therapy.

3.3.5 Rationale for Biomarker Assessments

A biomarker that may predict an increased chance of response to therapy would be valuable to patients and treating physicians to aid in guiding treatment decisions. Etrolizumab binds to the $\beta 7$ integrin and blocks $\alpha 4\beta 7$:MAdCAM and $\alpha E\beta 7$:E-cadherin binding. In exploratory analyses from the Phase II EUCALYPTUS study (described in Section 1.3), TNF-naive patients with higher baseline biopsy αE gene expression by quantitative polymerase chain reaction (qPCR) and $\alpha E+$ cell counts by immunohistochemistry (IHC) have a higher rate of remission at Week 10 (see Figure 2). The baseline levels of αE and other biomarkers will be evaluated in the Phase III study to determine whether they may function as predictive response biomarkers.

Figure 2 Effects of High and Low Baseline Expression of the α E Biomarker in Colon on the Remission Status of Ulcerative Colitis Patients Treated with Etrolizumab in EUCALYPTUS (Observed Data)



LD=loading dose; SC=subcutaneous.

All patients enrolled in the current study will have mandatory colonic mucosal sampling at the screening visit to analyze the relationship of α E levels (and other biomarkers) with response to treatment. In addition, samples will be collected at Week 10 for potential exploratory PD biomarker analyses.

Additional biomarkers, including, but not limited to, protein biomarkers or mRNA gene expression will be assessed at baseline and after treatment to increase the knowledge and understanding of disease biology, patient populations, etrolizumab mechanism of action and relationships to exposure, and inform biomarkers predictive of response to treatment.

3.4 OUTCOME MEASURES

3.4.1 Efficacy Outcome Measures

The efficacy outcome measures for this study are as follows:

Primary Outcome Measure:

- Remission at Week 10

Secondary Outcome Measures:

- Clinical remission at Week 10
- Clinical response at Week 10
- Improvement in endoscopic appearance of the mucosa at Week 10
- Endoscopic remission at Week 10
- Remission at Week 10 and Week 14
- Histologic remission at Week 10
- Change from baseline in MCS rectal bleeding subscore at Week 6

- Change from baseline in MCS stool frequency subscore at Week 6
- Change from baseline to Week 10 in UC bowel movement signs and symptoms as assessed by the UC-PRO/SS
- Change from baseline to Week 10 in UC abdominal symptoms as assessed by the UC-PRO/SS
- Change from baseline to Week 10 in patient's health-related QOL as assessed by the overall score of the IBDQ

Exploratory Efficacy Outcome Measures:

- Clinical remission at Week 10 and remission at Week 14
- Clinical remission at Weeks 10 and 14
- Change from baseline to Week 10 in histologic disease activity
- Improvement in histologic and/or endoscopic disease activity from baseline
- Change in health utilities, as assessed by the EQ-5D, from baseline to Week 10
- *Response and* remission at Week 10 in patient subgroups by baseline expression levels of colonic tissue and/or peripheral blood biomarkers, including, but not limited to, α E integrin
- *Response and* remission endpoints, as determined by the mMCS

3.4.2 Safety Outcome Measures

The safety outcome measures for this study are as follows:

- Incidence and severity of adverse events
- Incidence of serious adverse events
- Incidence and severity of infection-related adverse events
- Incidence of serious infection-related adverse events
- Incidence and severity of injection-site reactions
- Incidence of adverse events leading to study drug discontinuation
- Incidence of laboratory abnormalities
- Incidence and severity of hypersensitivity reaction events
- Incidence of anti-therapeutic antibodies (ATAs) to etrolizumab, or if required, adalimumab

3.4.3 Pharmacokinetic Outcome Measures

The PK outcome measures for this study are as follows:

- Serum concentration during drug washout (through end of safety follow-up)
- Serum concentration at primary and secondary endpoints Weeks 10 and 14

3.4.4 Exploratory Biomarker Outcome Measures

The exploratory biomarker outcome measures for this study are as follows:

- Relationship between baseline levels of exploratory colonic tissue and/or peripheral blood *and/or serum* biomarkers and *changes in* response to treatment or disease progression
- *Relationship between* baseline levels of stool biomarkers, which may include, but are not limited to, those in the microbiota and bacterial cultures
- *Changes from baseline in stool biomarkers in response to treatment or disease progression*

4. MATERIALS AND METHODS

4.1 PATIENTS

The target population is patients with moderately to severely active UC (defined as MCS of 6–12, endoscopy subscore of ≥ 2 , as determined by the central reading procedure described in Section 4.5.1.4, a rectal bleeding subscore ≥ 1 , and a stool frequency subscore ≥ 1) and colonic involvement extending a minimum of 20 cm from the anal verge who have had inadequate response or intolerance to conventional therapy and are naive to TNF inhibitor therapy.

4.1.1 Inclusion Criteria

Patients must meet the following criteria for study entry:

- Able and willing to provide written informed consent
- 18–80 years of age, inclusive
- Diagnosis of UC established at least 3 months prior to randomization (Day 1) by clinical and endoscopic evidence. This diagnosis should be corroborated by histopathology conducted at any time prior to screening and documented by a histopathology report (Note: histopathology may be performed at screening, if no prior report is readily available).
- Moderately to severely active UC as determined by an MCS of 6–12 with an endoscopic subscore ≥ 2 , as determined by the central reading procedure described in Section 4.5.1.4, a rectal bleeding subscore ≥ 1 , and a stool frequency subscore ≥ 1 during the screening period (prior to day of randomization). See also Section 4.5.2.1 for additional information regarding the time window.
- Evidence of UC extending a minimum of 20 cm from the anal verge as determined by baseline endoscopy (flexible sigmoidoscopy or colonoscopy) performed during screening, 4–16 days prior to randomization. See also Section 4.5.2.1 for additional information regarding the time window.
- Naive to treatment with TNF inhibitor therapy

- Patients must have had an inadequate response, loss of response, or intolerance to prior immunosuppressant and/or corticosteroid treatment.

Inadequate response to, loss of response to, or intolerance to prior immunosuppressant treatment is defined as one or more of the following:

Persistent signs and symptoms of active disease despite a history of at least one 12-week regimen of oral AZA (≥ 1.5 mg/kg) or 6-mercaptopurin (6-MP; ≥ 0.75 mg/kg) and/or MTX (≥ 15 mg/week) within the previous 5 years

Persistent signs and symptoms of active disease despite a 6-TG level of ≥ 230 pmol/ 8×10^8 RBCs during at least one 12-week regimen of oral AZA or 6-mercaptopurine (6-MP) at a stable or increasing dose within the previous 5 years.

History of intolerance to AZA, 6-MP, or MTX (including, but not limited to, nausea/vomiting, abdominal pain, pancreatitis, LFT abnormalities, lymphopenia, *TPMT* genetic mutation, infection) within the previous 5 years

Inadequate response, loss of response, or intolerance to corticosteroid treatment is defined as one or more of the following:

Steroid refractory: persistent symptoms of active disease despite treatment with at least one 4-week induction regimen that included a dose of ≥ 30 mg prednisone (oral) daily, or equivalent, for at least 2 weeks or IV for at least 1 week within the previous 5 years

Steroid dependent: two failed attempts to taper steroids below a dose equivalent to 10 mg prednisone (oral) daily

Steroid intolerant: history of intolerance to corticosteroids (including, but not limited to, Cushing's syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, infection) within the previous 5 years

- Any ongoing UC therapy must be at stable doses:

May be receiving oral 5-ASA compounds provided that the dose has been stable for ≥ 4 weeks immediately prior to randomization

May be receiving oral corticosteroid therapy (prednisone at a stable dose of ≤ 30 mg a day, or equivalent steroid)

If corticosteroid therapy is ongoing or has recently been initiated, the dose has to be stable for at least 4 weeks immediately prior to randomization.

If corticosteroids are being tapered, the dose has to be stable for at least 2 weeks immediately prior to randomization.

May be receiving budesonide therapy at a stable dose of up to 9 mg a day provided that the dose has been stable for ≥ 4 weeks prior to randomization

May be receiving probiotics (e.g., Culturelle, *Saccharomyces boulardii*), provided that the dose has been stable for ≥ 2 weeks immediately prior to randomization

May be receiving AZA, 6-MP, or MTX, provided that the dose has been stable for the 8 weeks immediately prior to randomization

- For women who are not postmenopausal (at least 12 months of non–therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use a highly effective method of contraception for the duration of the study [i.e., during the treatment period and for at least 24 weeks after the last dose of study drug (see [Appendix 3](#))].

The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:

With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 24 weeks after the last dose of study drug to avoid exposing the embryo to study drug. Men must refrain from donating sperm during this same period.

The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

- Must have received a colonoscopy within the past year or be willing to undergo a colonoscopy in lieu of a flexible sigmoidoscopy at screening. This colonoscopy must:

Confirm disease extent (defined as 1) left-sided colitis [up to the splenic flexure], 2) extensive colitis [beyond the splenic flexure but not involving the entire colon], and 3) pancolitis; see Section [4.5.1.4](#))

Include removal of any adenomatous polyps

Document evidence of surveillance for dysplasia for all patients with left-sided colitis of > 12 years' duration and total/extensive colitis of > 8 years duration

4.1.2 Exclusion Criteria

Patients who meet any of the following criteria will be excluded from study entry:

Exclusion Criteria Related to Inflammatory Bowel Disease

- Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC
- Past or present ileostomy or colostomy
- Diagnosis of indeterminate colitis
- Suspicion of ischemic colitis, radiation colitis, or microscopic colitis
- Diagnosis of toxic megacolon within 12 months of initial screening visit

- Any diagnosis of Crohn's disease
- Past or present fistula or abdominal abscess
- A history or current evidence of colonic mucosal dysplasia
- Patients with any stricture (stenosis) of the colon
- Patients with history or evidence of adenomatous colonic polyps that have not been removed

Exclusion Criteria Related to Prior or Concomitant Therapy

- Prior treatment with TNF- α antagonists
- Any prior treatment with etrolizumab or other anti-integrin agents (including natalizumab, vedolizumab, and efalizumab)
- Any prior treatment with rituximab
- Any treatment with tofacitinib during screening
- Any prior treatment with anti-adhesion molecules (e.g., anti-MAdCAM-1)
- Use of IV steroids within 30 days prior to screening with the exception of a single administration of IV steroid
- Use of agents that deplete B or T cells (e.g., alemtuzumab or visilizumab) within 12 months prior to randomization, with the exception of AZA and 6-MP
- Use of anakinra, abatacept, cyclosporine, sirolimus, or mycophenolate mofetil (MMF) within 4 weeks prior to randomization
- Chronic nonsteroidal anti-inflammatory drug (NSAID) use (Note that occasional use of NSAIDs and acetaminophen [e.g., headache, arthritis, myalgias, or menstrual cramps] and aspirin up to 325 mg daily is permitted.)
- Patients who are currently using anticoagulants including, but not limited to, warfarin, heparin, enoxaparin, dabigatran, apixaban, rivaroxaban (Note that antiplatelet agents such as aspirin up to 325 mg daily or clopidogrel are permitted.)
- Patients who have received treatment with corticosteroid enemas/suppositories and/or topical (rectal) 5-ASA preparations within 2 weeks prior to randomization
- Apheresis (i.e., Adacolumn apheresis) within 2 weeks prior to randomization
- Received any investigational treatment including investigational vaccines within 5 half-lives of the investigational product or 28 days after the last dose, whichever is greater, prior to randomization
- History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric, human, or humanized antibodies, fusion proteins, or murine proteins or hypersensitivity to etrolizumab (active drug substance) or any of the excipients (L-histidine, L-arginine, succinic acid, polysorbate 20)
- Patients administered tube feeding, defined formula diets, or parenteral alimentation/nutrition who have not discontinued these treatments \geq 3 weeks prior to randomization

Exclusion Criteria Related to General Safety

- Pregnant or lactating
- Lack of peripheral venous access
- Hospitalized (other than for elective reasons) during the screening period
- Inability to comply with study protocol, in the opinion of the investigator
- Significant uncontrolled comorbidity, such as cardiac (e.g., moderate to severe heart failure New York Heart Association Class III/IV), pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders
- Neurological conditions or diseases that may interfere with monitoring for PML
- History of demyelinating disease
- Clinically significant abnormalities on screening neurologic examination (PML Objective Checklist)
- Clinically significant abnormalities on the screening PML Subjective Checklist
- History of alcohol, drug, or chemical abuse ≤ 6 months prior to screening
- Conditions other than UC that could require treatment with > 10 mg/day of prednisone (or equivalent) during the course of the study
- History of cancer, including hematologic malignancy, solid tumors, and carcinoma in situ, within 5 years before screening with the following exceptions:
 - A history of chronic myelogenous leukemia, hairy cell leukemia, melanoma, renal cell carcinoma, or Kaposi sarcoma is exclusionary, irrespective of the duration of time before screening.
 - History of a cervical smear indicating the presence of adenocarcinoma in situ (AIS), high-grade squamous intraepithelial lesions (HSIL), or cervical intraepithelial neoplasia (CIN) of Grade > 1 is exclusionary, irrespective of the duration of time before screening.
 - Local basal cell or squamous cell carcinoma of the skin that has been excised and is considered cured is **not** exclusionary

Exclusion Criteria Related to Infection Risk

- Congenital or acquired immune deficiency
- Patients must undergo screening for HIV and test positive for preliminary and confirmatory tests
- Positive hepatitis C virus (HCV) antibody test result, unless the patient (1) has undetectable HCV RNA levels for > 6 months after completing a successful course of HCV anti-viral treatment and an undetectable HCV RNA at screening or (2) has a known history of HCV antibody positivity with a history of undetectable HCV RNA for > 6 months and undetectable HCV RNA at screening in the absence of history of HCV anti-viral treatment.

- Patients must undergo screening for hepatitis B virus (HBV). This includes testing for HBsAg (HBV surface antigen), anti-HBc total (HBV core antibody total), and HBV DNA (patients who test negative for these tests are eligible for this study):

Patients who test positive for surface antigen (HBsAg +) are not eligible for this study, regardless of the results of other hepatitis B tests.

Patients who test positive only for core antibody (anti-HBc +) must undergo further testing for hepatitis B DNA (HBV DNA test).

If the HBV DNA test is positive, the patient is not eligible for this study.

In the event the HBV DNA test cannot be performed, the patient is not eligible for this study.

If the HBV DNA test is negative, the patient is eligible for this study. These patients will undergo periodic monitoring for HBV DNA during the study.
- Evidence of or treatment for *Clostridium difficile* (as assessed by *C. difficile* toxin testing) within 60 days prior to randomization or other intestinal pathogens (as assessed by stool culture and ova and parasite evaluation) within 30 days prior to randomization
- Evidence of or treatment for clinically significant cytomegalovirus (CMV) colitis (based on the investigator's judgment) within 60 days prior to randomization. Laboratory confirmation of CMV from colon biopsy sample is required during screening evaluation only if clinical suspicion is high and to determine the need for CMV treatment.
- History of active or latent TB (regardless of treatment history; see Section 4.5.1.5)

Patients with a history of active or latent TB (based on a positive screening assay, either purified protein derivative [PPD] skin test or QuantiFERON®-TB Gold test, see Section 4.5.1.5) are not eligible for this study.

Patients with a chest X-ray (posteroanterior [PA] and lateral) within 3 months of randomization suspicious for pulmonary TB are **not** eligible for this study.

Any immunosuppressed patient with a strong suspicion of TB exposure and no prior vaccination with bacille Calmette-Guérin (BCG) should be considered at risk for having latent TB infection. Patients at risk for TB exposure include:

 - Patients who have household contact with a person with active TB
 - Patients living in areas with high incidence of TB
 - Patients who frequently visit areas with high prevalence of active TB

Patients who meet these criteria should be evaluated per local practice to exclude latent TB.
- History of recurrent opportunistic infections and/or history of severe disseminated viral infections (e.g., herpes)
- Any serious opportunistic infection within the last 6 months prior to screening

- Any current or recent signs or symptoms (within 4 weeks before screening and during screening) of infection, except for the following:
 - Minor infections (e.g., common cold) that have, in the investigator's judgment, completely resolved prior to randomization
 - Fungal infections of the nail beds
 - Oral or vaginal candidiasis that has resolved with or without treatment prior to randomization
- Any major episode of infection requiring treatment with IV antibiotics within 8 weeks prior to screening or oral antibiotics within 4 weeks prior to screening
 - Treatment with antibiotics as adjunctive therapy for UC in the absence of documented infection is not exclusionary.
- Received a live attenuated vaccine within 4 weeks prior to randomization
- History of organ transplant

Exclusion Criteria Related to Laboratory Abnormalities (at Screening)

- Serum creatinine $>2 \times$ upper limit of normal (ULN)
- ALT or AST $>3 \times$ ULN or alkaline phosphatase $>3 \times$ ULN or total bilirubin $>2.5 \times$ ULN (unconjugated hyperbilirubinemia that is associated with known Gilbert's syndrome is not an exclusion criterion)
- Platelet count $<100,000/\mu\text{L}$
- Hemoglobin <8 g/dL
- Absolute neutrophil count $<1500/\mu\text{L}$
- Absolute lymphocyte count $<500/\mu\text{L}$

4.2 METHOD OF TREATMENT ASSIGNMENT AND BLINDING

After written informed consent has been obtained, all patients will receive a screening number, which will be assigned by an interactive voice/Web-based response system (IxRS). Following completion of the screening period and after all patient eligibility requirements are confirmed, patients will be assigned a patient number (a different number from the screening number) on Day 1 and will undergo randomization in a 2:2:1 ratio stratified by concomitant treatment with corticosteroids at randomization (yes/no), concomitant treatment with immunosuppressants at randomization (yes/no), and disease activity measured during screening ($\text{MCS} \leq 9/\text{MCS} \geq 10$). All patients will receive two study treatments of active etrolizumab + adalimumab placebo, active adalimumab + etrolizumab placebo, or etrolizumab placebo + adalimumab placebo. A permuted blocks randomization method will be used to obtain an approximate 2:2:1 ratio between the two treatments and placebo arm within each stratum.

During the 14-week double-blind treatment period, the IxRS will make active etrolizumab/etrolizumab placebo study treatment kit assignments at Week 0 (Day 1) and Weeks 4 and 8 for all patients and Week 12 for clinical remitters. Each kit will consist of one 1-mL PFS (0.7 mL nominal volume). At each monthly dosing visit (every 4 weeks) during the blinded treatment period, one study drug kit will be assigned for administration to each patient.

The placebo for etrolizumab will be matched SC placebo in PFS. The placebo and active kits are filled and packaged to look identical.

The IxRS will also make active adalimumab/adalimumab placebo study treatment kit assignments at Week 0 (Day 1) and Weeks 2, 4, 6, and 8. Adalimumab will be supplied for use as a single-use 1-mL glass PFS with a fixed 27-gauge ½-inch needle, providing 40 mg (0.8 mL) of adalimumab, or as a single-use, 1-mL, glass PFS with a fixed 29-gauge ½-inch needle, providing 40 mg (0.4 mL) of adalimumab.

The placebo for adalimumab will be an SC placebo. This will not be visually identical to the adalimumab PFS. Each adalimumab placebo kit will consist of one 1-mL PFS (0.7 mL nominal volume).

Despite the fact that the volume of the placebo (0.7 mL) differs from the active adalimumab (either 0.8 mL or 0.4 mL), this difference is considered acceptable, based on the observation that a patient's sensorial perception of such a small volume of liquid is minimal.

A detailed dosing schema for the study is provided in [Table 3](#).

Patients, all study site personnel, and the Sponsor and its agents (with the exception of the IxRS service provider and the unblinded HCPs involved in adalimumab administration) will be blinded to treatment assignment throughout the 14-week double-blind treatment period. Personnel responsible for performing PK assays (in order to identify appropriate dilutions of PK samples to be analyzed) will be unblinded to patients' randomized treatment assignments.

As described in [Section 6](#), in order to analyze the data, treatment assignment will be unblinded to the Sponsor personnel performing the analysis when all data through Week 14 are in the database and the data have been cleaned and verified. However, patients and all study site personnel will remain blinded to individual treatment assignment until after the study is completed (after all patients have either completed the treatment and safety follow-up period or discontinued early from the study) and the database is locked.

Given that preparation of an identical adalimumab placebo is not possible, all study drugs will be administered by an unblinded HCP. The unblinded HCP will not be involved in safety and efficacy assessments, they will have no further study-related interactions with blinded site staff or patients, and will not be involved with or have access to patient data. [REDACTED]

[REDACTED] For further details on drug administration see Section [4.3.2](#).

If unblinding is necessary for patient management (e.g., in the case of a serious adverse event), the investigator will be able to break the treatment code by contacting the IxRS. Treatment codes should not be broken except in emergency situations. If the investigator wishes to know the identity of the study drug for any other reason, he or she should contact the Medical Monitor. The investigator should document and provide an explanation for any premature unblinding (e.g., accidental unblinding, unblinding due to a serious adverse event as per health authority reporting requirements). The Sponsor Safety Reporting Department (independent from the study team) will break the treatment code for all unexpected serious adverse events (see Section [5.2.2](#)) that are considered by the investigator to be related to study drug for the purpose of regulatory reporting. The study team will remain blinded to study treatment.

Table 3 Study Drug Administration Schema

Study Treatment Group	Week 0 (Day 1)	Week 2	Week 4	Week 6	Week 8	Week 12 ^a
Active etrolizumab and placebo adalimumab	1 injection with active etrolizumab 4 injections with adalimumab placebo	2 injections with adalimumab placebo	1 injection with active etrolizumab 1 injection with adalimumab placebo	1 injection with adalimumab placebo	1 injection with active etrolizumab 1 injection with adalimumab placebo	1 injection with active etrolizumab
Active adalimumab and placebo etrolizumab	4 injections with active adalimumab 1 injection with etrolizumab placebo	2 injections with active adalimumab	1 injection with active adalimumab 1 injection with etrolizumab placebo	1 injection with active adalimumab	1 injection with active adalimumab 1 injection with etrolizumab placebo	1 injection with etrolizumab placebo
Placebo etrolizumab and placebo adalimumab	1 injection with etrolizumab placebo 4 injections with adalimumab placebo	2 injections with adalimumab placebo	1 injection with etrolizumab placebo 1 injection with adalimumab placebo	1 injection with adalimumab placebo	1 injection with etrolizumab placebo 1 injection with adalimumab placebo	1 injection with etrolizumab placebo

^a Only for patients who were determined to be clinical remitters at Week 10.

4.3 STUDY TREATMENT

Table 4 Treatment/Concomitant Background Treatments

Treatment/Concomitant Background Treatment	
Investigational medicinal product	Etrolizumab, 105 mg SC Q4W (Weeks 0 [Day 1], 4, 8 [all patients], and 12 [clinical remitters only])
Comparators	Adalimumab (160 mg Week 0 [Day 1], 80 mg SC Week 2, 40 mg SC Weeks 4, 6, and 8) Placebo etrolizumab SC Q4W (Weeks 0 [Day 1], 4, 8 [all patients], and 12 [clinical remitters only]) Placebo adalimumab SC (Weeks 0 [Day 1], 2, 4, 6, and 8)
Non-investigational medicinal products	
Induction Phase	Continuation of stable baseline doses of the following: oral 5-ASA; AZA; 6-MP; MTX Corticosteroids up to 30 mg/day of prednisone (or equivalent) Budesonide up to 9 mg/day
Week 10 to Week 14	Patients who achieve clinical remission at Week 10 should continue immunosuppressants (AZA, 6-MP, MTX) at a stable dose unless dose reduction or discontinuation is required due to immunosuppressant-related toxicity. Generally accepted criteria for discontinuing immunosuppressants due to toxicity include, but are not limited to, acute pancreatitis, severe leukopenia, severe thrombocytopenia, or clinically significant elevations of the liver-associated enzymes from baseline, especially in the presence of an elevated total bilirubin. The ultimate decision to reduce the dose or discontinue immunosuppressants due to toxicity remains at the discretion of the investigator. During the Induction Phase, patients are to maintain a stable corticosteroid dose. For patients staying in the study, corticosteroids are to be tapered starting from Week 10 in patients who achieve clinical remission. Patients receiving prednisone at a dose of > 10 mg/day (or equivalent) are to have their dose reduced at a rate of 5 mg per week until a 10 mg/day dose is achieved. Patients receiving prednisone at doses ≤ 10 mg/day (or equivalent), or once a 10 mg/day dose (or equivalent) is achieved by tapering, are to have their dose reduced at a rate of 2.5 mg/week. Patients receiving budesonide at study entry who achieve clinical remission at Week 10 should taper their dose starting from Week 10 from 9 mg every day to 9 mg every other day for 2 weeks and then discontinue budesonide treatment.
Throughout Study	Probiotics and oral 5-ASA may be continued at a stable dose throughout. Occasional use of NSAIDs and acetaminophen (e.g., headache, arthritis, myalgias, menstrual cramps) and aspirin up to 325 mg daily are permitted throughout the study. Antidiarrheals (e.g., loperamide, diphenoxylate with atropine) for control of chronic diarrhea are permitted.

5-ASA = 5-aminosalicylic acid; 6-MP = 6-mercaptopurine; AZA = azathioprine; MTX = methotrexate; Q4W = every 4 weeks; NSAID = nonsteroidal anti-inflammatory drug; SC = subcutaneous.

4.3.1 Formulation, Packaging, and Handling

4.3.1.1 Etrolizumab and Placebo

Etrolizumab will be supplied by the Sponsor as a liquid formulation in PFSs and is administered as an SC injection. Each 1-mL PFS will contain 150 mg/mL of etrolizumab (0.7 mL nominal volume). Etrolizumab is formulated as 150 mg/mL in 20 mM histidine, 0.2 M arginine succinate, and 0.04% polysorbate 20, pH 5.8. Each syringe is for single-dose parenteral administration and contains no preservatives.

Etrolizumab placebo will be supplied by the Sponsor as a liquid formulation in PFSs (0.7 mL nominal volume) and is administered as an SC injection. Drug product composition for the placebo is exactly the same as that of active drug product without the presence of etrolizumab.

Study drug packaging will be overseen by the Sponsor's Clinical Trial Supplies Department and will be labeled with the identification required by local law, the protocol number, drug identification, and dosage. The packaging and labeling of the study medication will be in accordance with Sponsor's standards and local regulations.

Upon arrival of investigational products at the site, the pharmacist or medication nurse should check them for damage and verify proper identity, quantity, integrity of seals, and temperature conditions and report any deviations or product complaints to the monitor upon discovery.

The study drug must be stored according to the details on the product label. The drug label indicates the storage temperature. [REDACTED]

Used PFSs with study drug will be stored at room temperature in designated sharps containers and returned to the site for disposal per local schedule.

Under no circumstances is the investigator to allow study medication to be used other than as directed by the protocol.

Details about the packaging and labeling of the study drug will be provided in the protocol-supporting documents.

For further details, see the current Etrolizumab Investigator's Brochure.

4.3.1.2 Adalimumab and Placebo

Adalimumab (Humira®) is supplied by the Sponsor for use as a single-use 1-mL glass PFS with a fixed 27-gauge ½-inch needle, providing 40 mg (0.8 mL) of adalimumab, or a single-use, 1-mL, glass PFS with a fixed 29-gauge ½-inch needle, providing 40 mg (0.4 mL) of adalimumab. Adalimumab is supplied as a preservative-free, sterile solution for SC administration.

Adalimumab placebo will be supplied by the Sponsor as a liquid formulation in PFSs and is administered as an SC injection. Each 1-mL PFS will contain 0.7 mL of a solution of 20 mM histidine, 0.2 M arginine succinate, and 0.04% polysorbate 20, pH 5.8. Each syringe is for single dose SC administration and contains no preservatives.

Study drug packaging will be overseen by the Sponsor's Clinical Trial Supplies Department and bear a label with the identification required by local law, the protocol number, drug identification, and dosage. The packaging and labeling of the study medication will be in accordance with the Sponsor's standards and local regulations.

Upon arrival of investigational products at the site, the unblinded HCP should check for damage and verify proper identity, quantity, integrity of seals, and temperature conditions and report any deviations or product complaints to the monitor upon discovery.

The study drug must be stored according to the details on the product label. The drug label indicates the storage temperature. PFSs of study medication should be refrigerated at 2°C–8°C and protected from excessive light and heat. PFSs should not be frozen, shaken, or stored at room temperature.

For further details, see the adalimumab SmPC or United States Package Insert (USPI).


4.3.1.3 Concomitant Background Treatment for Ulcerative Colitis

For concomitant background treatment for UC see [Table 4](#).

For further details, please refer to respective SmPCs or product label, local prescribing dosage, administration, and compliance information for the formulation, packaging, and handling details of agents prescribed as concomitant background treatment for UC.

4.3.2 Dosage, Administration, and Compliance

For detailed guidance to drug administration at each visit see the Study Drug Administration Schema ([Table 3](#) in Section 4.2).

In this study, the adalimumab and adalimumab placebo are not visually identical. To maintain the adalimumab blind, all study drug administration, including etrolizumab/etrolizumab placebo, will be administered by the unblinded HCP 

All adverse events of systemic hypersensitivity reactions or anaphylactoid or anaphylaxis reactions must be reported within 24 hours to the Sponsor and the Medical Monitor must be informed as soon as is practical (see the Study Manual for contact information).

Injections should never be given into areas where the skin is not intact or is tender, bruised, red, or hard. The injection sites will be inspected by the site personnel at each clinic visit. Any injection-site reactions (see Section 5.1.1.3) should be documented on the appropriate adverse event page(s).

If the HCP cannot administer study medication on the scheduled dosing day, study medication is to be administered within a window of +3 days from the scheduled dosing date. If the patient experiences a minor illness (e.g., minor infection), at the discretion of the investigator, study medication may be delayed for a maximum period of 2 weeks. Following the delay, study medication dosing is to be resumed in accordance with the original dosing schedule. Any potential deviation from this window is to be discussed with the Medical Monitor for the study.

Guidelines for treatment interruption or discontinuation are provided in Sections 4.6 and 5.1.

4.3.2.2 Adalimumab and Adalimumab Placebo

During this study, adalimumab is intended for use under the guidance and supervision of a physician. Adalimumab will be administered by the unblinded HCP using the commercially available Humira PFS (40 mg/0.8 mL or 40 mg/0.4 mL). Prior to use, the solution in the Humira PFS must be carefully inspected for particulate matter and discoloration. If particulates and discolorations are noted, the product should not be used.

Adalimumab is to be administered at a dose of 160 mg at Week 0 (Day 1; 4 injections), 80 mg at Week 2 (2 injections), and 40 mg (1 injection) at Weeks 4, 6, and 8.

When using the Humira PFS (40 mg/0.8 mL or 40 mg/0.4 mL), the full amount in the Humira PFS must be injected in order to provide 40 mg of adalimumab. Rotate injection sites and do not give injections into areas where the skin is tender, bruised, red, or hard.

The adalimumab placebo is described in Section 4.3.1.2. Details of the number of injections to administer at each visit with adalimumab or adalimumab placebo are provided in Table 3. The adalimumab placebo will also be administered by the unblinded HCP.

As noted previously, to maintain the adalimumab blind, all study drug administration will be administered by the unblinded HCP [REDACTED]

4.3.2.3 Concomitant Background Treatment and Rescue Therapy

Patients must have had an inadequate response, loss of response, or intolerance to prior immunosuppressant and/or corticosteroid treatment, as described in Section 4.1.1 and as described below.

Inadequate response to, loss of response to, or intolerance to prior immunosuppressant treatment is defined as one or more of the following:

- Persistent signs and symptoms of active disease despite a history of at least one 12-week regimen of oral AZA (≥ 1.5 mg/kg) or 6-MP (≥ 0.75 mg/kg) and/or MTX (≥ 15 mg/week) within the previous 5 years
- Persistent signs and symptoms of active disease despite a 6-TG level of ≥ 230 pmol/ 8×10^8 RBCs during at least one 12-week regimen of oral AZA or 6-MP at a stable or increasing dose within the previous 5 years
- History of intolerance to AZA, 6-MP, or MTX (including, but not limited to, nausea/vomiting, abdominal pain, pancreatitis, LFT abnormalities, lymphopenia, TPMT genetic mutation, infection) within the previous 5 years

Inadequate response, loss of response, or intolerance to corticosteroid treatment is defined as one or more of the following:

- Steroid refractory: persistent symptoms of active disease despite treatment with at least one 4-week induction regimen that included a dose of ≥ 30 mg prednisone (oral) daily, or equivalent, for at least 2 weeks or IV for at least 1 week within the previous 5 years
- Steroid dependent: two failed attempts to taper steroids below a dose equivalent to 10 mg prednisone (oral) daily
- Steroid intolerant: history of intolerance to corticosteroids (including, but not limited to, Cushing's syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, infection) within the previous 5 years

Patients are to be defined as refractory, dependent, or intolerant in the electronic Case Report Form (eCRF), if appropriate, irrespective of whether corticosteroid inadequate response forms part of the eligibility criteria.

Management of Concomitant Medications during the Study

Throughout the treatment phase of the study, patients are required to maintain stable doses of their concomitant medications (5-ASA, corticosteroids, immunosuppressants) for UC except that all Week 10 clinical remitters receiving corticosteroids must begin a taper at Week 10.

Immunosuppressants

Patients should remain on their stable baseline doses of immunosuppressants (AZA, 6-MP, MTX) throughout the study unless dose reduction or discontinuation is required due to a toxicity related to the medication (see Section 3.1.1 for symptoms of toxicity to AZA, 6-MP, or MTX).

Corticosteroids

During the Induction Phase, patients are to maintain a stable corticosteroid dose. For patients achieving clinical remission and who will remain in the study after the Week 10 induction timepoint, corticosteroids are to be tapered starting from Week 10. Patients receiving prednisone at a dose of > 10 mg/day (or equivalent) are to have their dose reduced at a rate of 5 mg per week until a 10 mg/day dose is achieved. Patients receiving prednisone at doses ≤ 10 mg/day (or equivalent), or once a 10 mg/day dose (or equivalent) is achieved by tapering, are to have their dose reduced at a rate of 2.5 mg/week. Patients receiving budesonide should taper their dose starting from Week 10 from 9 mg every day to 9 mg every other day for 2 weeks and then discontinue budesonide treatment.

Rescue Therapy That Can Be Given with Study Medication for the Treatment of Ulcerative Colitis

Prior to Week 10, any patient who requires initiation of an immunosuppressant (AZA, 6-MP, or MTX), corticosteroid, or oral or topical 5-ASA, or who requires an increase in dose over baseline levels for treatment of worsening disease symptoms should stay in the study until Week 12 after performing the Week 10 assessment. Patients not achieving clinical remission at the Week 10 assessment and patients who achieve clinical remission at Week 10 but required the use of rescue medications prior to Week 10 can enroll in Part 1 (OLE) of Study GA28951 to receive open-label etrolizumab, if eligible, at Week 12 (a 2-week delay to allow for adalimumab washout). Alternatively, they can enter the 12-week safety follow-up and then enroll in Part 2 (SM) of Study GA28951 for extended PML monitoring.

After Week 10, any patient who achieved clinical remission at Week 10 (without the use of rescue medications) who requires initiation of an immunosuppressant, corticosteroid, or oral or topical 5-ASA or an increase in dose over baseline levels for treatment of worsening disease symptoms should remain in the study to perform Week 14 assessment and can then enroll in Part 1 (OLE) of Study GA28951 to receive open-label etrolizumab, if eligible, or enter the 12-week safety follow-up and then enroll in Part 2 (SM) of Study GA28951 for extended PML monitoring.

Endoscopy to document disease activity for patients exiting the treatment period early for any reason may be performed at the discretion of the investigator.

Rescue Therapy That Cannot Be Given with Study Medication for the Treatment of UC

At ANY time during the conduct of the study, use of other immunosuppressive agents including, but not limited to, anakinra, abatacept, anti-integrins, T- or B-cell depleters (except AZA and 6-MP), TNF inhibitors (including TNF inhibitor biosimilars), cyclosporine, tacrolimus, anti-adhesion molecules, JAK inhibitors, or investigational agents are prohibited. Patients who receive such therapies are not to receive further study treatment or open-label treatment, and will be required to enter 12 weeks of safety follow-up in this study (see [Appendix 2](#)). After completion of the 12-week safety follow-up, these patients will be requested to enroll in Part 2 (SM) of Study GA28951 for 92 weeks of extended PML monitoring.

4.3.3 Investigational Medicinal Product Accountability

All investigational medicinal products (IMPs) required for completion of this study; namely, etrolizumab, etrolizumab placebo, adalimumab, and adalimumab placebo, will be provided by the Sponsor. The investigator is responsible for the control of the drugs under investigation. The investigational site will acknowledge receipt of IMP (e.g., drug receipt record) and disposition (e.g., drug dispensing log). Accountability will be assessed by maintaining adequate drug dispensing and return records. IxRS will be used to confirm the shipment condition and content. Any damaged shipments will be replaced.

Accurate records must be kept for all study drug provided by the Sponsor. Note that adalimumab accountability and storage will be conducted by an unblinded study staff member. Adalimumab study drug will not be available to blinded study staff.

These records must contain the following:

- Documentation of drug shipments received from the Sponsor (date received and quantity)
- Disposition of unused study drug not dispensed to patients
- Drug Dispensing Log must be kept current and should contain the following information:
 - Identification of the patient to whom the study medication was dispensed
 - Date(s) and quantity of the study medication dispensed to the patient
 - Date(s) and quantity of the unused study medication returned

All records and drug supplies must be available for inspection by the study monitor.

4.3.4 Assessment of Compliance

Patient compliance will be assessed by maintaining adequate drug dispensing logs and return records.

A Drug Dispensing Log must be kept as described in Section 4.3.3. The investigator is responsible for ensuring that dosing is administered in compliance with the protocol. Delegation of this task must be clearly documented and approved by the investigator. When the study is completed, the investigator will return all completed Drug Dispensing Logs to the Monitors.

Any unused study drug and Drug Return Records should be returned to the Monitor, unless alternate destruction has been authorized by Roche or required by local or institutional regulations (Section 4.3.3). The investigator's copy of the Drug Return Record(s) must accurately document the return of all study drug supplies to Sponsor.

4.3.5 Destruction of the Investigational Medicinal Product/Comparator

Any used PFS (etrolizumab, etrolizumab placebo, adalimumab, or adalimumab placebo) will be placed into sharps containers immediately after SC injections. The sharps containers should be discarded at the study site by the site staff per local schedule. Written documentation of destruction of unused study drug must contain the following:

- Identity (batch numbers or patient numbers) of IMP(s) destroyed
- Quantity of IMP(s) destroyed
- Date of destruction
- Method of destruction
- Name and signature of responsible person who destroyed investigational product(s).

In case of device failure or if there are any issues with the drug, the PFS should not be destroyed, and instead should be returned to the appropriate Roche Clinical Trial Supplies Department for further assessment (see Section 4.3.6).

4.3.6 Reporting of Prefilled Syringe Complaints/Events

The investigator should report all medical device complaints to the Sponsor. The investigator must document as much information as possible on the PD103 IMP Deviation Form, including product batch number and expiration date, and forward the complaint form to the Sponsor within 24 hours of the investigator becoming aware of the event. PD103 IMP Deviation Form, together with pictures of the defective PFS, should be sent to kaiseraugst.global_impcomplaint_management@roche.com.

Where possible, the investigator will retrieve the PFS unit(s) involved in the complaint and attempt to return it to the Sponsor for further assessment, if necessary.

If the medical device complaint results in an adverse event, an Adverse Event eCRF must be completed and submitted through the electronic data capture (EDC) system immediately (i.e., no more than 24 hours after learning of the event). If the event is serious, the Adverse Event eCRF must be completed and submitted through the EDC immediately (i.e., no more than 24 hours after learning of the event), as outlined in Section 5.4.2. If the medical device complaint results in an adverse event to an individual other than the study patient (e.g., nurse at the site), the device complaint must be reported on the PD103 IMP Deviation Form. The adverse event must be reported to the Sponsor as a spontaneous adverse event (see Section 5.3.5).

4.4 CONCOMITANT THERAPY

4.4.1 Permitted Therapy

Concomitant therapy includes any medication (e.g., prescription drugs, over-the-counter drugs, herbal/homeopathic remedies, preventative vaccines, vitamins, nutritional supplements) used by a patient from 8 weeks prior to randomization to the patient's last visit. All concomitant medications should be reported to the investigator and recorded on the Concomitant Medications eCRF.

Patients who use oral contraceptives or maintenance therapy for comorbidities should continue their use.

For concomitant therapy for UC and rescue treatment see Section 4.3.2.3.

4.4.2 Prohibited Therapy

Use of the following therapies is prohibited during the study:

- Any investigational treatment including investigational vaccines
- Use of lymphocyte-depleting agents (e.g., alemtuzumab or visilizumab), except for AZA and 6-MP
- Use of cyclosporine, tacrolimus, sirolimus, or MMF
- Use of natalizumab, vedolizumab, or rituximab
- Use of TNF inhibitors (including TNF inhibitor biosimilars)
- Use of anakinra or abatacept and/or other biological therapeutics
- Use of anti-adhesion molecules
- Use of JAK inhibitors

Patients who receive these specified rescue therapies are not to receive further study treatment or open-label treatment and are to be discontinued from study drug and moved to safety follow-up within this study.

4.5 STUDY ASSESSMENTS

4.5.1 Description of Study Assessments

4.5.1.1 Medical History and Demographic Data

Medical history includes clinically significant diseases and procedures. All medication taken in the last 8 weeks prior to randomization (including prescription, over-the-counter, and herbal/homeopathic remedies and therapies) are to be recorded. A detailed history of medication used for UC is required for the past 5 years.

Demographic data, including age, sex, whether the patient is a fraternal or identical twin, and self-reported race/ethnicity will be collected during screening.

4.5.1.2 Physical Examinations

A complete physical examination should include the evaluation of head, eye, ear, nose, and throat and cardiovascular, dermatological, musculoskeletal, respiratory, gastrointestinal (GI), and neurological systems, including administration of the PML Subjective Checklist and the PML Objective Checklist by the investigator (see [Appendix 5](#) for PML assessment details and [Appendix 6](#) for PML algorithm). New or worsened abnormalities from screening should be recorded as adverse events if appropriate. In addition, a symptom-driven examination should be conducted as indicated in the Schedule of Assessments.

4.5.1.3 Vital Signs

Vital signs will include measurement of heart rate and systolic and diastolic blood pressure, after the patient has been in a seated position for 5 minutes, and are to be recorded at the indicated timepoints in Schedule of Assessments (see [Appendix 1](#)), before study drug administration.

4.5.1.4 Ulcerative Colitis Disease Activity Assessments

Extent and duration of patient's disease is to be recorded on the eCRF from the patient medical records and should include therapies from the past 5 years. Extent of disease should be defined as follows: 1) left-sided colitis (up to the splenic flexure), 2) extensive colitis (beyond the splenic flexure but not involving the entire colon), and 3) pancolitis.

All measurable disease must be documented at screening and re-assessed at each subsequent evaluation. Responses will be assessed by the investigator or designee with use of the MCS and partial Mayo Clinic Score (pMCS). The MCS has a range of 0–12, whereas pMCS has a range of 0–9, with higher scores indicating more severe disease. MCS is a composite of four assessments, each rated from 0–3: stool frequency, rectal bleeding, endoscopy, and physician's global assessment (PGA). pMCS is a composite of three assessments, each rated from 0–3: stool frequency, rectal bleeding, and PGA.

During screening, patients will be instructed on how to appropriately complete an e-diary. The patient's normal number of stools is to be recorded. This is defined as the number

of stools passed when a patient is in remission, not in flare. This is to be taken from the most recent available data in the patient's medical notes or taken during patient interview at screening.

One of the components of the MCS is the endoscopic subscore. The time window for performing endoscopy during the screening is 4–16 days prior to randomization (Day 1) (i.e., Day – 16 to Day – 4). Medical Monitor approval is not required for endoscopies conducted within this window. Under no circumstances will an endoscopy be accepted more than 16 days or less than 4 days prior to randomization. Note that the total screening period is up to 35 days (see Section [4.5.2.1](#)).

The symptoms of UC must be recorded throughout the study, including the screening period. The e-diary entries will be reviewed by site personnel during screening (prior to dosing, if applicable) and during study visits including the early withdrawal from treatment visit and any unscheduled visits due to disease exacerbation. Because the colonoscopy/flexible sigmoidoscopy and bowel cleansing preparations can interfere with the assessment of patient-reported symptoms, e-diary entries used to calculate the complete MCS should not correspond to days of bowel preparation or endoscopy or the day following the endoscopy. Further details and examples of stool frequency and rectal bleeding subscore derivation are provided in [Appendix 4](#).

Colonoscopy/Flexible Sigmoidoscopy with Colonic Biopsies

Patients are to prepare their bowel prior to the colonoscopy/flexible sigmoidoscopy procedures. Medications used for bowel preparation should be recorded on concomitant medications pages of eCRF.

Stool samples for analysis of fecal calprotectin and other exploratory biomarkers (such as analyses of the microbiota and bacterial cultures) are to be collected prior to bowel preparation (polyethylene glycol [PEG]-based preparation or enema).

Full colonoscopy within a year of screening is required to ensure against enrollment of patients with colonic carcinoma and dysplasia. If full colonoscopy has not been performed within the year before screening, it should be conducted in place of the flexible sigmoidoscopy at screening. For patients not requiring a colonoscopy, a flexible sigmoidoscopy will be performed for inclusion in the study. Endoscopy will be performed during screening between 4–16 days prior to randomization.

Endoscopy will be also performed at Week 10 or at withdrawal from study (early withdrawal from treatment visit; see [Appendix 1](#)). In patients who are clinical remitters at Week 10, an additional endoscopy will be performed at Week 14.

Central reading of endoscopies will be performed throughout this study, and a detailed charter will address the standardization of endoscopic procedures, video recordings, and equipment, as well as the criteria for endoscopic assessment. For each patient, video

recording of the entire endoscopic procedure will be performed as specified in the Video Submission Guidelines. All video recordings will be edited by central read vendor to produce video clips that are representative of each segment of the colon visualized up to the splenic flexure only (rectum, sigmoid, and descending colon). The video clips will be read centrally for mucosal lesions and endoscopic severity by an independent gastroenterologist experienced in IBD who is blind to the patient's clinical activity and treatment allocation. The MCS endoscopic subscore is to be determined both locally (at the investigator site) and centrally as described above. Each segment of the colon up to the splenic flexure (rectum, sigmoid, and descending colon) will be assigned an endoscopic subscore. The score from the worst affected segment up to the splenic flexure is to be used for the MCS calculation for study conduct, except at post-baseline time points, when the sigmoid colon MCS endoscopic subscore will be used if the baseline sigmoid colon MCS endoscopic subscore is 2–3.

In the event that there is a discrepancy between the endoscopic subscore obtained by the local versus the central reader, a third read (second central reader) is to be conducted. From these three endoscopic MCS subscores, the score with which two readers agree will be reported as the final overall MCS endoscopic subscore. If no two readers agree on an MCS endoscopic subscore, the median score of the three completed reads (i.e., local read, central read #1, and central read #2) will be chosen as the final reported overall MCS endoscopic subscore.

In all cases the video recordings are to be taken prior to biopsy.

Each patient entered into the study will have colonic biopsy samples obtained during flexible sigmoidoscopy/full colonoscopy as follows:

At Screening

A total of five to six paired biopsy samples (10-12 samples) will be taken at screening.

- Four paired biopsy samples (8 samples) from the most inflamed area of the colon within 20–40 cm from the anal verge (sigmoid colon). Two pairs (4 samples) will go into formalin and two pairs (4 samples) will be placed in stabilization buffer (such as RNAlater or a similar buffer) and be shipped to a central laboratory for storage at –80°C.
- One paired biopsy sample (2 samples) from the most inflamed area of the worst affected segment (descending, sigmoid, or rectum). This biopsy pair (2 samples) will go into formalin.
- ONLY if there is suspicion for clinically significant CMV colitis, one biopsy sample from this pair should be taken from the base of an ulcer to evaluate for histological presence of CMV; otherwise, it is not necessary for inclusion in the study. Analysis should be performed locally if possible, or can be sent to a central laboratory, if necessary.

- ONLY if histopathologic confirmation of UC is needed to meet study eligibility, an additional biopsy sample can be used for histopathologic confirmation of UC, if necessary (analysis should be performed locally if possible, or can be sent to a central laboratory, if necessary).
- If neither CMV testing or histopathologic confirmation of UC is needed, these additional 2 biopsy samples should not be obtained.

**At Week 10, Week 14, and/or at early withdrawal from treatment visit
(see [Appendix 1](#))**

A total of four paired biopsy samples will be taken at each of these timepoints as specified in [Appendix 1](#).

- Two paired biopsy samples (4 samples) to be taken from the most inflamed area of the colon within 20–40 cm from the anal verge (sigmoid colon, at the same endoscopic depth of the original screening endoscopy). If there is no clearly inflamed area, a blind biopsy sample should be taken. One pair (2 samples) will go into formalin, and one pair (2 samples) will be placed in stabilization buffer (such as RNAlater or a similar buffer) and shipped to a central laboratory for storage at –80 C.
- One paired biopsy sample (2 samples) to be taken from the most inflamed area of the rectum. If there is no clearly inflamed area, a blind biopsy sample should be taken. This paired biopsy sample will go into formalin.
- One paired biopsy sample (2 samples) to be taken from the most inflamed area of the descending colonic segment. If there is no clearly inflamed area, a blind biopsy sample should be taken. This paired biopsy sample will go into formalin.

Necrotic areas of ulcerated mucosa should be avoided during biopsy. Original location (colonic segment and endoscopic depth) of biopsy specimen should be clearly indicated. Samples will all initially be sent to the laboratory vendor (unless analysis is to be performed locally, as indicated).

Progressive Multifocal Leukoencephalopathy Assessment

Study site personnel and patient will be educated regarding the signs and symptoms of PML. Close monitoring during the course of the study for any new symptoms or signs suggestive of PML will be performed with regular neurologic examinations (including evaluation of cranial nerves, motor and sensory function, coordination, and mental status) as per the Schedule of Assessments (see [Appendix 1](#)). The PML Subjective Checklist (symptom assessment) and the PML Objective Checklist (neurologic evaluation) will be administered by a qualified HCP and will be performed at screening and as indicated on the Schedule of Assessments.

During the in-clinic visits, patients will undergo PML monitoring assessments.

If a patient has a positive finding on the PML Subjective Checklist that is accompanied by a positive finding on the PML Objective Checklist or if there is strong clinical suspicion

for PML, the event should be expeditiously reported as an adverse event of special interest within 24 hours (see Section 5.1.1 and Appendix 6 for the Algorithm for Evaluation of Progressive Multifocal Leukoencephalopathy). If PML is suspected, dosing with study treatment for that patient will be suspended and the patient should be promptly referred to a neurologist. Following formal evaluation by a neurologist, if PML cannot be ruled out, the case will be referred to an expert PML adjudication committee for further work-up, which may include brain magnetic resonance imaging (MRI) performed with and without contrast. If there remains any suspicion for PML, the PML adjudication committee may recommend performing a lumbar puncture with cerebrospinal fluid (CSF) analysis for John Cunningham virus (JCV) by PCR. If JCV is detected, the patient should be treated as a PML case, permanently discontinue study drug, and transfer to safety follow-up.

Dosing with study treatments can only be resumed in patients where PML has been ruled out. See Appendix 6 for the Algorithm for Evaluation of Progressive Multifocal Leukoencephalopathy.

After completing the treatment phase of this study, patients not enrolling in Part 1 (OLE) of Study GA28951 to receive treatment with open-label etrolizumab will enter the 12-week safety follow-up phase in this study (see Appendix 2). The PML examination is to be performed at Week 12 of this safety follow-up.

Following 12-week safety follow-up, all patients will be requested to continue to be monitored for PML for an additional 92 weeks by enrolling in the Part 2 (SM) of Study GA28951; thus, providing a total of 2 years PML follow-up after the last dose of study medication. During Part 2 (SM) of Study GA28951, patients will not be administered study drug.

The PML extended follow-up period in Study GA28951 will consist of the PML assessment interview conducted by telephone at 6-month intervals (see Appendix 5).

4.5.1.5 Laboratory Assessments

Laboratory assessments will be performed as indicated on the Schedule of Assessments; see the Study Flowchart in Appendix 1. All laboratory assessments will be sent to one or more central laboratories for analysis with the exception of CMV. If there is suspicion for clinically significant CMV colitis, a colonic biopsy sample should be sent for CMV evaluation, which may be conducted locally depending on local requirements for the timing of the test result. Urine pregnancy testing will be conducted locally. If a full colonoscopy is required at screening, laboratory samples should be drawn prior to the initiation of bowel preparation.

On days of study drug administration, laboratory samples should be drawn before the administration of study drug. Laboratory assessments will include the following:

- Hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count, absolute differential count [neutrophils, eosinophils, lymphocytes, monocytes, basophils, other cells], mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and RBC distribution width)
- Serum chemistries, including liver function tests (sodium, potassium, chloride, bicarbonate, glucose, blood urea nitrogen, creatinine, calcium, phosphorus, magnesium, total and direct bilirubin, total protein, albumin, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase, creatine phosphokinase, and uric acid)
- Urinalysis
- Tuberculosis

The PPD skin test and QuantiFERON-TB Gold are acceptable screening assays for latent *Mycobacterium* TB infection.

A positive PPD tuberculin skin test reaction is considered ≥ 5 mm.

Patients with a history of bacille Calmette Guérin (BCG) vaccination should be screened using the QuantiFERON-TB Gold test only.

An indeterminate QuantiFERON-TB Gold test should be repeated. The follow up test can be either a repeat of the previous test or a PPD tuberculin skin test in patients who are eligible to have a PPD tuberculin skin test performed.

The patient is considered to have a positive diagnostic test for TB if at least one of the following circumstances applies:

- A positive QuantiFERON–TB Gold test
- Two successive indeterminate QuantiFERON–TB Gold tests
- A positive PPD tuberculin skin test

The patient is considered to have a **negative** diagnostic test for TB if at least one of the following circumstances applies:

- A negative QuantiFERON–TB Gold test
- A negative PPD tuberculin skin test

If a negative TB screening test has been documented within 3 months of screening, no new test is needed.

- JCV antibodies

A blood sample to test for antibodies to JCV will be taken and stored for possible later assessment of how widespread the JCV infection is in the study population. Sample testing for the presence of JCV antibodies is not helpful in predicting risk for PML or for evaluating neurologic symptoms. The sample may be tested if there is a strong belief that this information will be helpful in managing a patient's condition.

- C-reactive protein (CRP)

- *C. difficile* toxin assay in stool, stool culture and sensitivity testing, stool ova and parasites analysis
- Pregnancy test: All women of childbearing potential (including those who have had a tubal ligation) will have a serum pregnancy test at screening.
 - Urine pregnancy tests will be performed at specified subsequent visits. If a urine pregnancy test result is positive, it must be confirmed by a serum pregnancy test.
- Viral serology and detection
 - HBV (HBsAg, total HB core antibody [anti-HBc] and HBV DNA)
 - HCV antibody
 - HCV RNA: Measurement of HCV RNA with use of the Amplicor assay is required when the patient has a known history of HCV antibody positivity with past documentation of undetectable HCV RNA, either with or without history of anti-viral treatment. Patients with newly diagnosed HCV antibody positivity are not eligible for this study and, therefore, do not require measurement of HCV RNA.
 - HIV
- ATA assays
 - Serum samples will be collected for detection and characterization of antibodies against etrolizumab, or if required, adalimumab. Samples will be analyzed using a validated assay. For ATA samples without matched PK determinations, etrolizumab concentrations may be measured for the purpose of helping interpret ATA data. ATA samples may also be utilized for exploratory PD biomarkers.
- PK assays
 - Serum samples will be collected for determination of etrolizumab, or if required, adalimumab, concentrations in all patients. Samples will be analyzed using a validated assay.
- CMV testing of colonic biopsy sample, if there is suspicion for clinically significant CMV colitis
 - Baseline colon biopsy sample (to be obtained at the base of the ulcer) will be analyzed for histologic presence of CMV.
- Fecal calprotectin testing
- Exploratory predictive and prognostic biomarker assays
 - Peripheral blood, serum, and colon biopsy samples will be assessed using qualified methods (including, but not limited to, ELISA, IHC, and/or qPCR, RNA sequencing) for exploratory predictive and prognostic biomarker analysis.

- Exploratory PD biomarker assays

Peripheral blood, serum, stool, and colon biopsy samples will be collected and qualified methods (including, but not limited to, ELISA, IHC, bacterial culture, RNA sequencing, and/or qPCR) will be utilized for exploratory PD biomarker analysis for samples that are assessed. Biopsy tissue may also be used for exploratory determination of drug concentration. Stool samples may be used for assessments that include, but are not limited to, analyses of the microbiota and bacterial cultures.
- Histology

Colon biopsy samples will be collected and evaluated for histologic changes. Histologic activity on colon biopsies will be categorized using the Nancy histological index.

Unless the patient gives specific consent for his or her leftover samples to be stored for optional exploratory research (see Section 4.5.1.10), biological samples will be destroyed when the final Clinical Study Report has been completed, with the following exceptions:

- Serum samples collected for PK or immunogenicity analysis may be needed for additional immunogenicity characterization and for PK or immunogenicity assay development and validation; therefore, these samples will be destroyed no later than 5 years after the final Clinical Study Report has been completed.
- Blood or blood-derived samples (RNA Paxgene, serum for exploratory PD) and stool samples collected for biomarker research will be destroyed no later than 5 years after the final Clinical Study Report has been completed.
- Colon biopsy samples (formalin and RNA later) will be destroyed no later than 5 years after the final Clinical Study Report has been completed.

4.5.1.6 Chest X-ray

A chest X-ray will be performed at screening. If a chest X-ray has been documented within the previous 3 months and has shown no clinically significant abnormalities, no additional chest X-ray is required.

4.5.1.7 Electrocardiograms

Electrocardiograms (ECGs) for each patient should be obtained from the same machine whenever possible. To minimize variability, it is important that patients be in a resting position for ≥ 10 minutes prior to each ECG evaluation. Body position should be consistently maintained for each ECG evaluation to prevent changes in heart rate. Environmental distractions (e.g., television, radio, conversation) should be avoided during the pre-ECG resting period and during ECG recording. ECGs should be performed prior to meals and any scheduled vital sign measurements and blood draws.

For safety monitoring purposes, the investigator or designee must review, sign, and date all ECG tracings. Paper copies will be kept as part of the patient's permanent study file at the site. ECG outputs will be stored at site.

4.5.1.8 Patient-Reported Outcomes

Patient-reported outcomes (IBDQ, UC-PRO/SS, EQ-5D, and the stool frequency and rectal bleeding components of the MCS and pMCS) and physician-reported outcomes (PGA component of the MCS and pMCS) and the endoscopic component of MCS data will be collected to help characterize the clinical profile of etrolizumab. The instruments will be translated as required in the local language.

In order to ensure instrument validity and that data standards meet health authority requirements, the PROs completed at the sites (IBDQ, EQ-5D, and the stool frequency and rectal bleeding components of the MCS and pMCS) should be administered at the investigational site prior to the completion of non-PRO assessments and before the patient receives any disease-status information or study drug during that visit. At Week 0 (Day 1), however, IBDQ and EQ-5D do not have to be performed prior to non-PRO assessments. Patients will complete the UC-PRO/SS measure for at least 9–12 consecutive days around the time of each scheduled visit as programmed in the e-diary.

PRO data will be collected electronically using electronic patient-reported outcome (ePRO) devices (i.e., e-diary or tablet). The format of the questionnaires may change when they are converted to electronic format. Electronic data captured by the patient since the previous study visit should be reviewed with the patient at each clinic visit. ePRO data will be collected and assessed at visits according to the Schedule of Assessments in [Appendix 1](#).

Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS) Measure

The UC-PRO/SS measure will be used to assess patient-reported UC signs and symptoms. The 14-item questionnaire contains three domains: bowel movement signs and symptoms, abdominal symptoms, and systemic symptoms. The UC-PRO/SS assesses the presence of UC symptoms and in some cases the severity or frequency of the symptoms. The UC-PRO/SS has a recall specification of 24 hours. A copy of the UC PRO/SS measure is provided in [Appendix 9](#).

Inflammatory Bowel Disease Questionnaire (IBDQ)

The IBDQ will be used to assess patients' health-related QOL (Guyatt et al. 1989; Irvine 1999). The 32-item questionnaire contains four domains: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function (5 items). The items are scored on a 7-point Likert scale with a higher score indicating better health-related QOL. The IBDQ has a recall specification of 2 weeks. A copy of the IBDQ is provided in [Appendix 10](#).

Mayo Clinic Score (MCS) and Partial Mayo Clinic Score (pMCS)

The MCS is a composite of four assessments, each rated from 0–3: stool frequency, rectal bleeding, endoscopy, and PGA (Schroeder et al. 1987). The endoscopy subscore of the MCS is derived from an evaluation of findings on endoscopy and as determined by the central reading procedure described in Section 4.5.1.4. The pMCS is a composite of three assessments, each rated from 0–3: stool frequency, rectal bleeding, and PGA. The MCS has a range of 0–12 and the pMCS has a range of 0–9. Higher scores indicate more severe disease. Copies of the MCS and pMCS are provided in [Appendix 4](#).

EuroQoL Five-Dimension Questionnaire (EQ-5D)

The EQ-5D is a generic preference-based health-related QOL questionnaire that provides a single index value for health status (Rabin and deCharro 2001). This tool includes questions about mobility, self-care, usual activities, pain/discomfort, and anxiety/depression that are used to build a composite of the patient's health status. The EQ-5D questionnaire will be utilized in this study for economic modeling. A copy of the assessment is provided in [Appendix 11](#).

4.5.1.9 Medication Use and Compliance

The details of the study medication administration are to be entered directly into the eCRF following clinic administrations.

4.5.1.10 Samples for Roche Clinical Repository Overview of the Roche Clinical Repository

The Roche Clinical Repository (RCR) is a centrally administered group of facilities for the long-term storage of human biologic specimens, including body fluids, solid tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides). The collection and analysis of RCR specimens will facilitate the rational design of new pharmaceutical agents and the development of diagnostic tests, which may allow for individualized drug therapy for patients in the future.

Specimens for the RCR will be collected from patients who give specific consent to participate in this optional research. In addition, any residual colonic biopsy and blood samples for biomarkers left over at the end of the study and analyses will be transferred to the RCR in consenting patients. RCR specimens will be used to achieve the following objectives:

- To study the association of biomarkers with efficacy, adverse events, or disease progression
- To increase knowledge and understanding of disease biology
- To study drug response, including drug effects and the processes of drug absorption and disposition
- To develop biomarker or diagnostic assays and establish the performance characteristics of these assays

Approval by the Institutional Review Board or Ethics Committee

Sampling for the RCR is contingent upon the review and approval of the exploratory research and the RCR portion of the Informed Consent Form by each site's Institutional Review Board or Ethics Committee (IRB/EC) and, if applicable, an appropriate regulatory body. If a site has not been granted approval for RCR sampling, this section of the protocol will not be applicable at that site.

Sample Collection

Whole blood (DNA) will be collected for genetic analysis from consenting patients (RCR Informed Consent Form).

Samples that are obtained for exploratory analysis of biomarkers (listed below) but were not utilized or were not entirely consumed will be transferred to the RCR.

Specimen types include the following:

- Blood collected in RNA Paxgene tubes (for exploratory PD; see [Appendix 1](#) for specific collection timepoints)
- Serum for exploratory PD (see [Appendix 1](#) for specific collection timepoints)
- Stool samples may be used for exploratory biomarker analyses (see [Appendix 1](#) for specific collection timepoints)
- Colon biopsy samples (formalin and stabilization buffer [such as RNAlater or a similar buffer]; see [Appendix 1](#) for specific collection timepoints)

Potential applications of RCR samples include these samples being assayed for mRNA expression, genetic variation, and other biomarker(s) that predict response or toxicity to etrolizumab.

For all samples, dates of consent and specimen collection should be recorded on the associated RCR page of the eCRF. For sampling procedures, storage conditions, and shipment instructions, see the Reference Manual or Laboratory Manual.

RCR specimens will be destroyed no later than 15 years after the date of final closure of the associated clinical database. The RCR storage period will be in accordance with the IRB/EC-approved Informed Consent Form and applicable laws (e.g., health authority requirements).

The dynamic biomarker specimens will be subject to the confidentiality standards described in Section 8.4. The genetic biomarker specimens will undergo additional processes to ensure confidentiality, as described below.

Confidentiality

Given the sensitive nature of genetic data, Roche has implemented additional processes to ensure patient confidentiality for RCR specimens and associated data. Upon receipt by the RCR, each specimen is "double-coded" by replacing the patient identification number with a new independent number. Data generated from the use of these specimens and all clinical data transferred from the clinical database and considered relevant are also labeled with this same independent number. A "linking key" between the patient identification number and this new independent number is stored in a secure database system. Access to the linking key is restricted to authorized individuals and is monitored by audit trail. Legitimate operational reasons for accessing the linking key are documented in a standard operating procedure. Access to the linking key for any other reason requires written approval from the Pharma Repository Governance Committee and Roche's Legal Department, as applicable.

Data generated from RCR specimens must be available for inspection upon request by representatives of national and local health authorities, and Roche monitors, representatives, and collaborators, as appropriate.

Patient medical information associated with RCR specimens is confidential and may only be disclosed to third parties as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Data derived from RCR specimen analysis on individual patients will generally not be provided to study investigators unless a request for research use is granted. The aggregate results of any research conducted using RCR specimens will be available in accordance with the effective Roche policy on study data publication.

Any inventions and resulting patents, improvements, and/or know-how originating from the use of the RCR data will become and remain the exclusive and unburdened property of Roche, except where agreed otherwise.

Consent to Participate in the Roche Clinical Repository

The Informed Consent Form will contain a separate section that addresses participation in the RCR. The investigator or authorized designee will explain to each patient the objectives, methods, and potential hazards of participation in the RCR. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason during the storage period. A separate, specific signature will be required to document a patient's agreement to provide optional RCR specimens. Patients who decline to participate will not provide a separate signature.

The investigator should document whether or not the patient has given consent to participate by completing the RCR Research Sample Informed Consent eCRF.

In the event of an RCR participant's death or loss of competence, the participant's specimens and data will continue to be used as part of the RCR research.

Withdrawal from the Roche Clinical Repository

Patients who give consent to provide RCR specimens have the right to withdraw their specimens from the RCR at any time for any reason. If a patient wishes to withdraw consent to the testing of his or her specimens, the investigator must inform the Medical Monitor in writing of the patient's wishes using the RCR Subject Withdrawal Form and, if the trial is ongoing, must enter the date of withdrawal on the RCR Research Sample Withdrawal of Informed Consent eCRF. The patient will be provided with instructions on how to withdraw consent after the trial is closed. A patient's withdrawal from Study GA28948 does not, by itself, constitute withdrawal of specimens from the RCR. Likewise, a patient's withdrawal from the RCR does not constitute withdrawal from Study GA28948.

Monitoring and Oversight

RCR specimens will be tracked in a manner consistent with Good Clinical Practice by a quality-controlled, auditable, and appropriately validated laboratory information management system to ensure compliance with data confidentiality as well as adherence to authorized use of specimens as specified in this protocol and in the Informed Consent Form. Roche monitors and auditors will have direct access to appropriate parts of records relating to patient participation in the RCR for the purposes of verifying the data provided to Roche. The site will permit monitoring, audits, IRB/EC review, and health authority inspections by providing direct access to source data and documents related to the RCR samples.

4.5.2 Timing of Study Assessments

4.5.2.1 Screening and Pretreatment Assessments

Written informed consent for participation in the study must be obtained before performing any study-specific screening tests or evaluations. Informed Consent Forms for enrolled patients and for patients who are not subsequently enrolled will be maintained at the study site.

All screening tests and evaluations will be performed within 35 days prior to randomization (Day 1), except for flexible sigmoidoscopy/colonoscopy, which should be performed 4–16 days prior to randomization (see [Figure 3](#)). The screening period will not exceed 35 calendar days.

Laboratory samples should be collected from the patient early in the screening period to allow time for the laboratory results to be available for review by the site for eligibility (see Section [4.5.1.4](#)). However, the ECG and chest X-ray can be obtained any time before randomization to study medication (see Section [4.5.1.6](#) and Section [4.5.1.8](#) for additional details on the chest X-ray and ECG). Colon biopsy specimen collection is detailed in Section [4.5.1.4](#).


A blood sample to test for antibodies to JCV will be taken and stored for possible later assessment of how widespread the JCV infection is in the study population. Sample testing for the presence of JCV antibodies is not helpful in predicting risk for PML or for evaluating neurologic symptoms. The sample may be tested if there is a strong belief that this information will be helpful in managing a patient's condition.

The screening endoscopy for MCS should be performed 4–16 days prior to Day 1 (randomization) (i.e., Day –16 to Day –4). The endoscopy score from the worst affected segment up to the splenic flexure (rectum, sigmoid, and descending colon) is to be used for the MCS calculation (see Section 4.5.1.4).

The symptoms of UC must be recorded during the screening period. The e-diary entries will be reviewed by site personnel during screening. Because the colonoscopy/flexible sigmoidoscopy and bowel cleansing preparations can interfere with the assessment of patient-reported symptoms, e-diary entries used to calculate the complete MCS should not correspond to days of bowel preparation or endoscopy or the day following the endoscopy. Further details and examples of stool frequency and rectal bleeding subscore derivation are provided in Appendix 4.

The endoscopy and the stool frequency and rectal bleeding subscores will be considered, along with other PGA components, when determining the PGA for the MCS calculation at Day 1 (i.e., prior to initiation of study drug), as described in detail in Appendix 4.

Figure 3 Overview of Screening Activities



Note: Endoscopy should be performed 4–16 days prior to randomization (Day 1).

All screening evaluations must be completed and reviewed to confirm that patients meet all eligibility criteria before randomization. The investigator will maintain a screening log to record details of all patients screened and to confirm eligibility or record reasons for screening failure, as applicable.

4.5.2.1.1 Re-Testing for Laboratory Inclusion and Exclusion Criteria

Two re-tests are permitted for laboratory inclusion and exclusion criteria. If a patient does not meet laboratory criteria for a third time, he or she will be considered a screen failure.

Laboratory testing that is repeated because of administrative or technical issues (e.g., breakage of a sample vial during transit to the central laboratory or degradation of a sample during transportation) is not considered to be re-screening.

4.5.2.1.2 Re-Screening

Re-screening is required if a patient has not met all the eligibility criteria within 35 days of the original screening visit. Patients who are found to be ineligible for entry into the study may be re-screened once only (except for the laboratory tests mentioned above)—for example, if the patient develops additional manifestations of UC, a worsening of existing manifestations at a later time, if patient's clinical status has changed such that the abnormal laboratory value may be directly affected (e.g., transfusion). Each patient must be re-consented before re-screening occurs.

Re-screening is not required for the HIV preliminary and confirmatory tests, HCV antibody test, and hepatitis B assessment (i.e., HBsAg, HbcAb, and, if required, HBV DNA), provided that the following criteria are met:

- Test results are available from the initial screening
- Eligibility criteria for the assessments are satisfied
- Date of the initial screening assessment was ≤ 6 weeks prior to the re-screening Day 1 visit (day of randomization for second screening)
- In the investigator's judgment, the patient is not deemed to have been at risk for HIV, hepatitis C, or hepatitis B infection (based on medical history, or geographical or social circumstance)

As described in Section [4.5.1.5](#), if a negative TB screening test result has been documented within 3 months before screening, or re-screen, no repeat test is required.

The screening endoscopy and colonic biopsies do not need to be repeated during re-screening provided that all of the following criteria are met:

- All endoscopy-related inclusion criteria have been met
- The initial endoscopy has been performed within 28 days prior to the day of randomization for second screening
- Colon biopsies as specified by the protocol have been obtained

If the initial screening endoscopy does not meet the conditions outlined above, the endoscopy and protocol-specified colon biopsies should be repeated 4–16 days prior to randomization (Day 1).

Re-screening in the event of screen failure due to *C. difficile* or CMV infection

Patients who are classified as screen failures due to the presence of *C. difficile* or CMV infection may be re-screened 60 days after successful treatment. For patients who screen failed due to CMV infection, laboratory analysis of CMV from colon biopsy samples is required during re-screening evaluation to rule out CMV infection.

See [Appendix 1](#) for the schedule of screening and pretreatment assessments.

4.5.2.2 Assessments during Treatment

All assessments will be performed on the day of the specified visit, except where a time window is specified. Assessments scheduled on the day of study drug administration should be performed prior to dosing, unless otherwise noted (see Schedule of Assessments; [Appendix 1](#)).

For the Week 10 and Week 14 visits that are associated with an MCS requiring endoscopy, every effort should be made to schedule the endoscopy on the same day as the clinic visit. If this is not possible, endoscopy should be performed as close to the clinic visit as possible, with a maximal window of 3 days prior to and 5 days after the visit. The endoscopy score should be considered when determining the PGA (as applicable), a component of the MCS (see [Appendix 4](#)). All patients will be queried and closely monitored for any adverse event at all study assessment timepoints (every 2 weeks) during both clinic visits and study assessments made over the telephone.

An unscheduled visit is to be conducted as required (see Section [4.5.2.5](#)).

All patients will receive hands-on training in use of the e-diary and tablet. Patients will also be instructed to contact the site promptly if they have any questions about the use of the e-diary during screening or at any time during the study.

See [Appendix 1](#) for the schedule of assessments performed during the treatment period.

4.5.2.3 Assessments at Study Completion/Early Withdrawal from Treatment Visit

Clinical remitters who proceed beyond Week 10 and who complete the treatment phase until Week 14 will be asked to visit the clinic for Week 14 assessments. These patients will be given the option of enrolling in Part 1 (OLE) of Study GA28951, if eligible, at Week 14. If patients choose not to enroll into Part 1 (OLE) of the study, they should perform the safety follow-up assessments (one telephone call at 6 weeks and one clinic visit at 12 weeks after the Week 14 visit; see [Appendix 2](#)).

Patients who complete the 10-week treatment phase but do not continue into the additional 4-week treatment phase (i.e., patients who are not clinical remitters at Week 10) will be given the option of enrolling in Part 1 (OLE) of Study GA28951, if eligible, at Week 12. If the patient does not enroll in Part 1 (OLE) of the study, he or she will undergo two safety follow-up assessments (see [Appendix 2](#)).

Patients not eligible for or who choose not to enroll in Part 1 (OLE) of Study GA28951 are to enroll in Part 2 (SM) of the study for extended PML monitoring after completion of the 12-week safety follow-up in this study.

If a patient leaves the study prior to Week 10 or if a clinical remitter (who proceeds beyond Week 10) leaves the study prior to Week 14, an early withdrawal from treatment visit is to be conducted, including for those patients who will enroll in Study GA28951. Otherwise, the Week 10 visit is the last visit in the study for patients who are not eligible to be dosed at Week 12 and enroll in Part 1 (OLE) of Study GA28951 at Week 12. Assessments are specified in the Schedule of Assessments in [Appendix 1](#).

Patients who were treated with prohibited medication are to have their early withdrawal from treatment visit at their next scheduled visit followed by the 12-week safety follow-up phase of this study (telephone call at Week 6 and clinic visit at Week 12; see [Appendix 2](#)). Patients are to then enroll in Part 2 (SM) of Study GA28951 for extended PML monitoring.

4.5.2.3.1 Eligibility for Entry to Open-Label Extension-Safety Monitoring Study

Study GA28951 will be conducted under a separate protocol and eligible patients as described below will need to be willing and able to provide separate informed consent to enter this study.

Patients not achieving clinical remission at Week 10 who are eligible for and choose to enroll in Part 1 (OLE) of Study GA28951 should not receive their first dose of open-label etrolizumab until Week 12 (e.g., 2 weeks after the Week 10 timepoint to allow the active comparator washout period of 4 weeks to be completed). Patients who achieve clinical remission at Week 10 should complete the study to Week 14, at which time they may enroll in Part 1 (OLE) of Study GA28951, if eligible, and receive their first dose of open-label etrolizumab at Week 14.

Note: Patients who do not wish to receive open-label etrolizumab (Part 1 [OLE] of Study GA28951) will be requested to enroll in the 92-week extended PML monitoring (Part 2 [SM] of the study) after completing the 12-week safety follow-up in this study.

The following patients may be eligible to enroll in the open-label treatment portion (Part 1) of the OLE–SM study at Week 12 (for nonclinical remitters at Week 10) or Week 14 (for clinical remitters at Week 10):

- In the Induction Phase, any patient who requires initiation of an immunosuppressant (ASA, 6-MP, MTX), corticosteroid, or oral or topical 5-ASA, or increase in dose of these medications over baseline levels for treatment of worsening disease symptoms may enroll in Part 1(OLE) of Study GA28951 after the Week 10 assessment, if eligible.
- Patients who do not achieve clinical remission at Week 10
- All remaining patients who complete the Week 14 assessment

The following patients are NOT eligible to enroll in Part 1 (OLE) of Study GA28951 and should complete the 12-week safety follow-up in this protocol:

- Patients who discontinue study treatment prior to Week 10
- Patients who require rescue medications that are prohibited in conjunction with etrolizumab (see Section 4.3.2.3)
- Patients with severe hypersensitivity reactions (see Section 4.6.1.1), malignancies, specific de novo or reactivated serious viral infections, PML, or other life-threatening infections during the study (see Sections 4.6.1.1, 5.1.1.1, and 5.1.1.2)

4.5.2.4 Safety Follow-Up Assessments

Safety follow-up will be conducted in this study for a period of 12 weeks for patients not enrolling in Part 1(OLE) of the OLE-SM study (see Section 4.5.2.3 for patients who should enter the 12-week safety follow-up phase within this protocol). Patients will be assessed at 6-week intervals during this period, one assessment by telephone and one in-person clinic visit (see Appendix 2). The visits should be scheduled based on the date of the last dose of study drug (e.g., the Week 6 telephone visit should take place 6 weeks after the last dose of study drug). Patients enrolling into Part 1 (OLE) of Study GA28951 will not enter the safety follow-up period in this study. Adverse events should be followed as outlined in Section 5.2.1.

Following the 12-week safety-monitoring period, patients should enroll in Part 2 (SM) of Study GA28951 where they will be monitored for PML for an additional 92 weeks. Patients in Part 2 (SM) of the study for the extended PML monitoring will NOT receive treatment with open-label etrolizumab. During Part 2 (SM) of Study GA28951, patients will have telephone assessments every 6 months to assess emergence of symptoms and signs of PML. In total, follow-up for the development of any signs or symptoms of PML will be conducted for a period of 2 years after last dose of study drug.

Patients who discontinue from the study prior to completion of the 12-week safety follow-up will be asked to return to the clinic within 30 days (± 7 days) after the last dose of study drug or last scheduled visit for an early withdrawal from treatment visit (see Appendix 2).

See [Appendix 1](#) for the schedule of assessments performed at the study completion/early withdrawal from treatment visit.

After the study completion/early termination visit, adverse events should be followed as outlined in Sections [5.5](#) and [5.6](#).

See [Appendix 2](#) for the schedule of 12-week safety follow-up assessments.

4.5.2.5 Assessments at Unscheduled Visits

An unscheduled visit may occur at any time during the study, (i.e., due to relapse of disease or an adverse event). Patients who are seen by the investigator or site staff at a timepoint not required by the protocol because of assessment of potential relapse will undergo the following:

- Symptom-directed physical examination
- Review of e-diary data
- Recording of concomitant medications and procedures
- Collection of adverse events and serious adverse events
- Clinical chemistry, hematology, and CRP, if indicated
- Stool sample collection, if indicated
- Partial or complete MCS, if indicated
- Flexible sigmoidoscopy, if indicated
- Colonic biopsy to evaluate for CMV, if clinically indicated
- Collection of PK and ATA sample, if indicated

See [Appendix 1](#) for assessments that may be performed in case of an unscheduled visit.

4.6 PATIENT, STUDY, AND SITE DISCONTINUATION

4.6.1 Patient Discontinuation

The investigator has the right to discontinue a patient from study drug or withdraw a patient from the study at any time. In addition, patients have the right to voluntarily discontinue study drug or withdraw from the study at any time for any reason. Reasons for discontinuation of study drug or withdrawal from the study may include, but are not limited to, the following:

- Patient withdrawal of consent at any time
- Any medical condition that the investigator or Sponsor determines may jeopardize the patient's safety if he or she continues in the study
- Investigator or Sponsor determines it is in the best interest of the patient
- Patient non-compliance, specifically defined as missing scheduled visits or non-adherence with background medications

4.6.1.1 Discontinuation from Study Drug

Patients must discontinue study drug if they experience any of the following:

- Pregnancy
- Anaphylaxis or other severe hypersensitivity reaction
- Develop colonic mucosal dysplasia
- Malignancy (with the exception of local and resected basal or squamous cell carcinoma of the skin) or cervical Pap test with AIS, HSIL, or CIN of Grade > 1
- Specific serious infection (see Section 5.1.1.1 for details on serious infection):
 - Any patient who experiences a specific de novo or reactivated serious viral infection, such as HBV, HCV, HIV, should discontinue study medication.
 - Any patient who develops life-threatening infections during the study should discontinue study medication.
- Any medication for rescue outside defined limits of the protocol (see Section 4.4.2)

Patients who discontinue study drug prematurely for the reasons listed above will be asked to return to the clinic for an early withdrawal from treatment visit (see Section 4.5.2.3) followed by 12 weeks of safety follow-up within this study. Patients should then enroll in Part 2 (SM) of Study GA28951 for 92 weeks of monitoring for PML (see Section 4.5.2.4). Patients not eligible to receive study drug at Week 12 (i.e., patients who did not achieve clinical remission at Week 10) should be considered to have discontinued study drug early. The primary reason for premature study drug discontinuation (e.g., lack of efficacy) must be documented on the appropriate eCRF. Patients who discontinue study drug prematurely will not be replaced.

4.6.1.2 Withdrawal from Study

Every effort should be made to obtain information on patients who withdraw from the study. The primary reason for withdrawal from the study must be documented on the appropriate eCRF. Patients will not be followed for any reason after consent has been withdrawn. Patients who withdraw from the study will not be replaced.

4.6.2 Study and Site Discontinuation

The Sponsor has the right to terminate this study at any time. Reasons for terminating the study may include, but are not limited to, the following:

- The incidence or severity of adverse events in this or other studies indicates a potential health hazard to patients.
- Patient enrollment is unsatisfactory.

The Sponsor will notify the investigator if the study is placed on hold, or if the Sponsor decides to discontinue the study or development program.

The Sponsor has the right to replace a site at any time. Reasons for replacing a site may include, but are not limited to, the following:

- Excessively slow recruitment
- Poor protocol adherence
- Inaccurate or incomplete data recording
- Non-compliance with the International Council for Harmonisation (ICH) guideline for Good Clinical Practice

5. ASSESSMENT OF SAFETY

5.1 SAFETY PLAN

The safety plan for this study is designed to ensure patient safety and mitigate potential risks. The principles of the safety plan include education of investigators and patients regarding all identified and potential safety risks, specific eligibility criteria to screen out at-risk patients, monitoring to ensure timely identification and management of a safety event, and management strategy such as guidelines for treating an event and for withholding or discontinuing study treatment, as appropriate. These principles are to be applied for all safety risks in the clinical program.

5.1.1 Potential Risks for Etrolizumab

Etrolizumab is an investigational drug that demonstrated a safety profile similar to placebo in the Phase II study, EUCALYPTUS. Given the relatively limited size of Phase II studies, the full safety profile is not known at this time and will be further characterized during the Etrolizumab Phase III program.

The potential and/or hypothetical risks for etrolizumab are based on its mechanism of action, available nonclinical and clinical data, data from other anti-integrin drugs, and general risks associated with biologic agents.

Investigators should always refer to the Etrolizumab Investigator's Brochure (Section 6) for a complete summary of safety information.

Important potential risks for etrolizumab include the following:

- Infections, in particular, serious or life-threatening infections, such as:
 - PML
 - Other serious infections (e.g., gastrointestinal, opportunistic)
- Hypersensitivity reactions, in particular:
 - Anaphylactic, anaphylactoid reactions
 - Other systemic hypersensitivity reactions
- Local injection-site reactions

- Hepatic effects
- Malignancies
- Immunogenicity
- Decreased effectiveness of immunization

5.1.1.1 Serious Infections

5.1.1.1.1 Progressive Multifocal Leukoencephalopathy

Background

PML is a potentially fatal neurological condition linked to reactivation of a polyomavirus (JCV) and active viral replication in the brain. Cases of PML have been reported in patients with CD and multiple sclerosis who received concomitant treatment with the anti- α 4 integrin natalizumab and immunosuppressives. Integrin α 4 β 1, which is inhibited by natalizumab, is a pleiotropic integrin that is believed to facilitate T cell migration into the CNS. Inhibition of integrin α 4 β 1 is thought to reduce (CNS) immune surveillance and facilitate development of PML.

PML has not been attributed to vedolizumab, which selectively impedes lymphocyte trafficking into gut tissue by specifically blocking only the α 4 β 7 integrin and not the α 4 β 1 integrin, despite extensive treatment exposure (Dotan 2017).

Etolizumab targets cells expressing the β 7 integrin (α 4 β 7 and α E β 7 cells) and not α 4 β 1 cells. Despite the lack of theoretical or experimental evidence for a specific role of β 7 integrins in leukocyte homing to the CNS and given the observation of PML risk with natalizumab, the Sponsor will continue to conduct extensive risk-monitoring procedures during the Phase III trials. There have been no cases of PML in patients treated with etrolizumab to date.

Screening, Patient Selection, and PML Education

No known interventions can reliably prevent PML or adequately treat PML if it occurs; therefore, it is important to exclude patients with a perceived higher baseline risk for PML, such as patients who have received natalizumab, efalizumab, or rituximab and patients with a history of demyelinating disease or PML. Patients with neurologic disease conditions that may interfere with monitoring for PML, such as clinically significant abnormalities noted at the screening neurologic examination (subjective or objective checklists), should be excluded.

A blood sample to test for antibodies to JCV will be taken and stored for possible later assessment of how widespread the JCV infection is in the study population. Sample testing for the presence of JCV antibodies is not helpful in predicting risk for PML or for evaluating neurologic symptoms. The sample may be tested if there is a strong belief that this information will be helpful in managing a patient's condition.

Study site personnel and patient participants should be educated regarding the signs and symptoms of PML. Patients and partners/caregivers should be issued with alert cards to remind them of these and to advise them to contact the investigator right away if they notice any new or worsening neurological abnormalities.

See [Appendix 1](#) for details of assessments regarding PML.

PML Monitoring

During the study, patients should be closely monitored for any signs and symptoms of PML via regular (approximately once every 12 weeks) subjective and objective tests employing the use of checklists to assess the patient's mental and neurological status. These will comprise regular neurologic examinations (including evaluation of cranial nerves, motor and sensory function, coordination, and mental status) as per the Schedule of Assessments (see [Appendix 1](#)). The PML Subjective Checklist (symptom assessment) and the PML Objective Checklist (neurologic evaluation) will be administered (see [Appendix 5](#); Worksheet for PML Neurologic Examination) by a qualified HCP and will be performed at screening and as indicated on the Schedule of Assessments (see [Appendix 1](#)).

During the in-clinic visits, patients will undergo PML monitoring assessments.

If a patient has a positive finding on the PML Subjective Checklist that is accompanied by a positive finding on the PML Objective Checklist or if there is strong clinical suspicion for PML, the event should be expeditiously reported as an adverse event of special interest within 24 hours (see Section [5.1.1](#) and [Appendix 6](#) for the Algorithm for Evaluation of Progressive Multifocal Leukoencephalopathy).

If PML is suspected, dosing with study treatment for that patient will be suspended and the patient should be promptly referred to a neurologist. Following formal evaluation by a neurologist, if PML cannot be ruled out, the case will be referred to an expert PML adjudication committee for further work-up, which may include brain magnetic resonance imaging (MRI) performed with and without contrast. If there remains any suspicion for PML, the PML adjudication committee may recommend performing a lumbar puncture with cerebrospinal fluid (CSF) analysis for JCV DNA by PCR. If JCV DNA is detected, the patient should be treated as a PML case, permanently discontinue study drug, and transfer to safety follow-up.

Dosing with study treatments can only be resumed in patients where PML has been ruled out. Refer to [Appendix 6](#) for the Algorithm for Evaluation of Progressive Multifocal Leukoencephalopathy.

PML Treatment

There is no known effective treatment for PML. Plasmapheresis has been employed in some patients where the event has been thought to be due to administration of a drug (Tan et al. 2011). If an event of PML occurs, subsequent management of PML will be at the direction of the consulting neurologist.

Additional information for the management of this potential risk is provided in [Appendix 5](#) (Worksheet for the PML Neurologic Examination) and [Appendix 6](#) (Algorithm for the Evaluation of Progressive Multifocal Leukoencephalopathy).

5.1.1.1.2 Other Serious Infections

Background

Clinical data to date have not shown an increased risk of serious infections with etrolizumab. In the Phase II EUCALYPTUS study, serious infections were reported in 2.3% of placebo-treated patients versus none in the etrolizumab-treated patients. Nonetheless, serious infections are a potential risk due to the mechanism of action of etrolizumab, which blocks trafficking of gut-selective lymphocytes.

Patient Selection

Patients with congenital or acquired immune deficiency are excluded from the study. Patients with specific and/or recent infections, such as CMV colitis, *C. difficile*, and other intestinal pathogens, are excluded from the study (see Section [4.1.2](#) for Exclusion Criteria Related to Infection Risk). Patients with a history of recurrent opportunistic infections and/or severe disseminated viral infections or any serious opportunistic infection within the past 6 months are excluded from the study.

Patients with hepatitis B infection who test positive only for core antibody (anti-HBc+) and test negative for HBV DNA test are eligible for the study; however, these patients must undergo periodic monitoring for HBV DNA during the study.

Patients with a history of active or latent treated TB, regardless of treatment history, are excluded from the study. Investigators are reminded of the risk of false-negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.

Patients at risk for TB exposure are noted below. Patients who meet these criteria should be evaluated per local practice to exclude latent TB infection.

- Patients who have household contact with a person with active TB
- Patients living in areas with high incidence of TB
- Patients who frequently visit areas with high prevalence of active TB, etc.

Apart from their colitis, patients must be in reasonably good health with no significant uncontrolled comorbidity or clinically significant laboratory results (see Section 4.1.2 for Exclusion Criteria Related to General Safety and Exclusion Criteria Related to Laboratory Values [at Screening]).

Education, Monitoring, and Management

Patients should be monitored closely for other serious infections during the study. Patients and study staff should be informed of the possibility of increased susceptibility to infectious pathogens. Investigators will be encouraged to promptly evaluate and aggressively treat any signs and symptoms consistent with an infection.

Patients who experience a serious infection event should not receive further study drug until the event has completely resolved and treatment with anti-infective medications has been completed. All effort should be made to identify the infectious agent. For those patients who recover from a serious infection, study medication may be restarted following consultation with the Medical Monitor.

Patients who develop life-threatening infections including specific de novo or reactivated serious viral infections, such as HBV, HCV, and HIV, during the study should discontinue study drug. Any patient who develops CMV colitis should not receive further study drug until the event has resolved and treatment with appropriate anti-viral medication has been completed. Re-initiation of therapy requires consultation with the Medical Monitor.

5.1.1.2 Hypersensitivity Reactions

Background

In completed Phase I/II clinical trials of etrolizumab, one serious adverse event of hypersensitivity (Grade 2) has been reported. No anaphylactic, anaphylactoid, or severe hypersensitivity reactions were observed; however, anaphylaxis and hypersensitivity reactions will be closely monitored during the study.

Patient Selection

Patients with a history of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric, human, or humanized antibodies; fusion proteins or murine proteins; or hypersensitivity to etrolizumab or any of the excipients (L-histidine, L-arginine, succinic acid, polysorbate 20) are excluded from study participation.

Education, Monitoring, and Management

All injections in this study need to be administered in the clinic. Following all injections, the patient must be monitored for 60 minutes. Epinephrine must be readily available for immediate use if required to treat anaphylaxis. Adjunctive medications such as parenteral diphenhydramine and inhaled bronchodilators may be used IN ADDITION TO epinephrine, if necessary. Resuscitation equipment should also be available. Site personnel must be able to detect and treat such reactions.

Patients should be instructed to recognize the symptoms of any anaphylactic, anaphylactoid, or hypersensitivity reaction and to contact an HCP or seek immediate care in case of any such symptoms. Patients are to be provided with alert cards to remind them and a caregiver or partner of the above.

If the patient develops any systemic hypersensitivity or anaphylactic or anaphylactoid reaction, the event should be expeditiously reported to the Sponsor as an adverse event of special interest or serious adverse event, as appropriate, within 24 hours.

If a patient has symptoms of anaphylaxis or severe hypersensitivity, the administration of etrolizumab must be discontinued permanently.

Refer to [Appendix 8](#) (Clinical Criteria for Diagnosis Anaphylaxis).

5.1.1.3 Local Injection-Site Reactions

Background

A local injection-site reaction is any local reaction occurring at the site of injection following study drug administration. In completed Phase I/II trials in patients with UC, injection-site reactions were reported at a rate of $\leq 10\%$, all of which were of mild intensity.

Monitoring

In the clinic setting, patients should be monitored for signs of injection-site reactions in the period immediately following injections. Patients will be given guidance on reporting injection-site reactions after patient leaves clinic.

5.1.1.4 Hepatic Effects

Background

Liver toxicity has been reported with other drugs that target $\alpha 4$ integrins (natalizumab) and $\alpha 4\beta 7$ integrins (vedolizumab). Therefore, this potential risk is being monitored in all etrolizumab studies. In nonclinical chronic toxicology studies, no abnormalities indicating liver toxicity with etrolizumab were observed. The risk in humans is currently unknown.

Patient Selection

Patients with significant liver function test abnormalities should be excluded from the etrolizumab clinical studies (see Section [4.1.2](#)).

Education, Monitoring, and Management

Patients should receive guidance on reporting liver problems if they occur. Liver function tests should continue to be monitored according to the schedule of assessments and as clinically indicated. Significant hepatic events should be evaluated promptly and managed accordingly.

5.1.1.5 Malignancies

Background

There have been no reports of malignancy nor evidence for increased incidence of malignancy in completed Phase I/II trials and nonclinical studies to date. Nonetheless, given the elevated risk of malignancy in this patient population a priori, the trial includes selection criteria and additional information to minimize any hypothetical risk.

Patient Selection

Patients with a history of cancer, including hematologic malignancy, solid tumors, and carcinoma in situ, within 5 years before screening should be excluded from the study with the exception of local basal or squamous cell carcinoma of the skin that has been excised and is considered cured (see Section 4.1.2 for Exclusion Criteria Related to General History). A history of chronic myelogenous leukemia, hairy cell leukemia, melanoma, renal cell carcinoma, Kaposi sarcoma, or AIS, HSIL, or CIN of Grade > 1 is considered exclusionary irrespective of the length of time before screening.

Monitoring and Management

Investigators should remain vigilant for signs or symptoms of cancer in scheduled study assessments, including those of potential lymphoma.

Any signs or symptoms that could be suggestive of malignancy should be promptly and aggressively evaluated and reported to the Sponsor. Incident hematologic abnormalities (e.g., new or worsening neutropenia, anemia, thrombocytopenia, macrocytosis, or atypical cells in the WBC differential) should be carefully evaluated.

Patients who develop a malignancy (with the exception of local and resected basal or squamous cell carcinoma of the skin) or who develop AIS, HSIL, or CIN of Grade > 1 on cervical Pap smear or who develop colonic dysplasia during the study should be withdrawn from study drug and must not receive additional doses of study drug.

5.1.1.6 Immunogenicity

Background

As with administration of any exogenous protein, a potential exists for the development of ATAs. Such antibodies can be neutralizing, with potential for reducing therapeutic effect of the drug and/or sensitizing, producing the potential for allergic reactions. On the basis of the clinical experience to date, approximately 5% of patients develop ATAs to etrolizumab; however, this has not been correlated with any efficacy or safety sequelae.

Monitoring

To assess for the potential development of immunogenicity, antibody samples will be obtained at baseline, at regular intervals during treatment, and during the safety follow-up period (see Appendix 1; Schedule of Assessments) and stored appropriately for further evaluation as needed.

5.1.1.7 Decreased Effectiveness of Immunizations

Background

The effect of etrolizumab upon the efficacy of vaccinations is unknown.

Patient Selection and Risk Mitigation

Patients who received a live attenuated vaccine within 4 weeks prior to randomization are excluded from the study. Patients should not receive live attenuated vaccines during the study and for approximately 5 half-lives after final study drug administration.

5.1.2 Risks Associated with Adalimumab

Investigators should be aware of the risks associated with adalimumab and their management (see Humira [40 mg/0.8 mL or 40 mg/0.4 mL] SmPC).

5.1.3 Risks Associated with Worsening of Ulcerative Colitis

The worsening of UC may result in the use of rescue medications. In severe cases, worsening of UC may lead to hospitalization and, at worst, colectomy. See Section 4.5.2.5 and [Appendix 1](#) for the schedule of assessments to be performed in the event of worsening of UC, which may lead to an unscheduled visit. At any time during the study, patients who have worsening of their UC will be permitted to have rescue therapy with steroids (IV, oral, or topical). Addition of or increases in doses of 5 ASA (oral or topical) and/or immunosuppressants (i.e., AZA, 6-MP, or MTX) will also be allowed if clinically indicated by the Principal Investigator. Rescue therapy with TNF inhibitors (including TNF inhibitor biosimilars), cyclosporine, tacrolimus, sirolimus, MMF, natalizumab, vedolizumab, rituximab, other lymphocyte depleting agents (with the exception of AZA and 6-MP), anakinra, abatacept, anti-adhesion molecules, or other biological or investigational therapeutics will not be allowed in conjunction with study drug because of the level of immunosuppression anticipated with the use of these agents. Patients who receive any of these prohibited rescue medications are not to receive further treatment with study drug or open-label treatment and are to enter into safety follow-up within this study, followed by enrollment in Part 2 (SM) of Study GA28951. All patients will be allowed to receive rescue therapy at any time. Patients who are not clinical remitters at Week 10 will be allowed to enroll in Part 1 (OLE) of Study GA28951 at Week 12 to receive open-label etrolizumab therapy, if eligible. All Week 10 clinical remitters who complete the Week 14 assessment will be allowed to enroll in Part 1 (OLE) of the Study GA28951 at Week 14, if eligible. Patients who do not enter Part 1 (OLE) of Study GA28951 will be requested to continue in safety follow-up, followed by enrollment into Part 2 (SM) of Study GA28951.

5.2 SAFETY PARAMETERS AND DEFINITIONS

Safety assessments will consist of monitoring and recording adverse events, including serious adverse events and adverse events of special interest; measurement of protocol-specified safety laboratory assessments; measurement of protocol-specified vital signs; and other protocol-specified tests that are deemed critical to the safety evaluation of the study.

Certain types of events require immediate reporting to the Sponsor, as outlined in Section [5.4](#).

5.2.1 Adverse Events

According to the ICH guideline for Good Clinical Practice, an adverse event is any untoward medical occurrence in a clinical investigation patient administered a pharmaceutical product, regardless of causal attribution. An adverse event can therefore be any of the following:

- Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
- Any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a known condition) (see Sections [5.3.5.8](#) and [5.3.5.9](#))
- Recurrence of an intermittent medical condition (e.g., headache) not present at baseline
- Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is associated with symptoms or leads to a change in study treatment, concomitant treatment, or discontinuation from study drug
- Adverse events that are related to a protocol-mandated intervention, including those that occur prior to assignment of study treatment (e.g., screening invasive procedures such as biopsy sample collections)

5.2.2 Serious Adverse Events (Immediately Reportable to the Sponsor)

All serious adverse events are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section [5.4.2](#) for reporting instructions). A serious adverse event is defined as any adverse event that meets any of the following criteria:

- Fatal (i.e., the adverse event actually causes or leads to death)
- Life threatening (i.e., the adverse event, in the view of the investigator, places the patient at immediate risk of death)

This does not include any adverse event that had it occurred in a more severe form or was allowed to continue might have caused death.

- Requires or prolongs inpatient hospitalization (see Section [5.3.5.10](#))

- Results in persistent or significant disability/incapacity (i.e., the adverse event results in substantial disruption of the patient's ability to conduct normal life functions)
- Congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug
- Significant medical event in the investigator's judgment (e.g., may jeopardize the patient or may require medical/surgical intervention to prevent one of the outcomes listed above)

The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an adverse event (e.g., rated as mild, moderate, or severe, or according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] criteria; see Section 5.3.3); the event itself may be of relatively minor medical significance (such as severe headache without any further findings).

Severity and seriousness need to be independently assessed for each adverse event recorded on the eCRF.

5.2.3 Adverse Events of Special Interest (Immediately Reportable to the Sponsor)

Adverse events of special interest are required to be reported by the investigator to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for reporting instructions). Adverse events of special interest for this study include the following:

- Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law (see Section 5.3.5.6)
- Suspected transmission of an infectious agent by the study drug as defined below:

Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is considered an infectious agent. A transmission of an infectious agent may be suspected from clinical symptoms or laboratory findings that indicate an infection in a patient exposed to a medicinal product. This term applies only when a contamination of the study drug is suspected.
- Adverse events of special interest specific to etrolizumab:

Systemic hypersensitivity reactions and anaphylactic and anaphylactoid reactions (see Section 5.1.1.2 and Sampson's Criteria in Appendix 8)

Neurological signs, symptoms, and AE that may suggest possible PML on the basis of a positive finding on the PML Subjective Checklist that is accompanied by a positive finding on the PML Objective Checklist, or if there is strong clinical suspicion for PML (see Appendix 5 and Section 5.1.1.1.1)

5.3 METHODS AND TIMING FOR CAPTURING AND ASSESSING SAFETY PARAMETERS

The investigator is responsible for ensuring that all adverse events (see Section 5.2.1 for definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in accordance with instructions provided in this section and in Sections 5.4, 5.5, and 5.6. The investigator is also responsible for reporting medical device complaints (see Section 5.4.4).

For each adverse event recorded on the Adverse Event eCRF, the investigator will make an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see Section 5.3.3), and causality (see Section 5.3.4).

5.3.1 Adverse Event Reporting Period

Investigators will seek information on adverse events at each patient contact. All adverse events, whether reported by the patient or noted by study personnel, will be recorded in the patient's medical record and on the Adverse Event eCRF.

After informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protocol-mandated intervention (e.g., invasive procedures such as biopsy sample collection, discontinuation of medications) should be reported (see Section 5.4.2 for instructions for reporting serious adverse events).

After initiation of study drug, all adverse events, regardless of relationship to study drug, will be reported until the patient completes his or her last study visit. After this period, patients who enter Study GA28951 should follow the adverse event reporting requirements of that study.

If the patient does not enter Study GA28951, the Sponsor should be notified if the investigator becomes aware of any post-study serious adverse events that are believed to be related to prior study drug treatment. In addition, the Sponsor should be notified if the investigator becomes aware of any post-study events of confirmed or suspected PML, regardless of relationship to study drug, for up to 2 years after the patient's last dose of study drug (see Section 5.6).

5.3.2 Eliciting Adverse Event Information

A consistent methodology of non-directive questioning should be adopted for eliciting adverse event information at all patient evaluation timepoints. Examples of non-directive questions include the following:

“How have you felt since your last clinic visit?”

“Have you had any new or changed health problems since you were last here?”

5.3.3 Assessment of Severity of Adverse Events

The adverse event severity grading scale for the NCI CTCAE (v4. 0) will be used for assessing adverse event severity. [Table 5](#) will be used for assessing severity for adverse events that are not specifically listed in the NCI CTCAE.

Table 5 Adverse Event Severity Grading Scale for Events Not Specifically Listed in the NCI CTCAE

Grade	Severity
1	Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated
2	Moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living ^a
3	Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living ^{b,c}
4	Life-threatening consequences or urgent intervention indicated ^d
5	Death related to adverse event ^d

NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events.

Note: Based on the most recent version of NCI CTCAE (v4.0), which can be found at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

- ^a Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.
- ^b Examples of self-care activities of daily living include bathing, dressing and undressing, feeding one's self, using the toilet, and taking medications, as performed by patients who are not bedridden.
- ^c If an event is assessed as a "significant medical event," it must be reported as a serious adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.
- ^d Grade 4 and 5 events must be reported as serious adverse events (see Section 5.4.2 for reporting instructions), per the definition of serious adverse event in Section 5.2.2.

5.3.4 Assessment of Causality of Adverse Events

Investigators should use their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an adverse event is considered to be related to the study drug, indicating "yes" or "no" accordingly. The following guidance should be taken into consideration:

- Temporal relationship of event onset to the initiation of study drug
- Course of the event, considering especially the effects of dose reduction, discontinuation of study drug, or reintroduction of study drug (where applicable)
- Known association of the event with the study drug or with similar treatments
- Known association of the event with the disease under study

- Presence of risk factors in the patient or use of concomitant medications known to increase the occurrence of the event
- Presence of non-treatment-related factors that are known to be associated with the occurrence of the event

Table 6 Causal Attribution Guidance

Is the adverse event suspected to be caused by the study drug on the basis of facts, evidence, science-based rationales, and clinical judgment?	
YES	There is a plausible temporal relationship between the onset of the adverse event and administration of the study drug, and the adverse event cannot be readily explained by the patient's clinical state, intercurrent illness, or concomitant therapies; and/or the adverse event follows a known pattern of response to the study drug; and/or the adverse event abates or resolves upon discontinuation of the study drug or dose reduction and, if applicable, reappears upon re-challenge.
NO	<u>An adverse event will be considered related, unless it fulfills the criteria as specified below.</u> Evidence exists that the adverse event has an etiology other than the study drug (e.g., preexisting medical condition, underlying disease, intercurrent illness, or concomitant medication); and/or the adverse event has no plausible temporal relationship to administration of the study drug (e.g., cancer diagnosed 2 days after first dose of study drug).

5.3.5 Procedures for Recording Adverse Events

Investigators should use correct medical terminology/concepts when recording adverse events on the Adverse Event eCRF. Avoid colloquialisms and abbreviations.

Only one adverse event term should be recorded in the event field on the Adverse Event eCRF.

5.3.5.1 Diagnosis versus Signs and Symptoms Injection-Site Reactions

Local cutaneous adverse events that occur at or around the injection site during or within 24 hours following study drug injection should be separately captured as individual signs (e.g., erythema, induration/swelling at injection site) and symptoms (e.g., pain, pruritus at injection site) rather than a diagnosis of allergic reaction or injection-site reaction.

Other Adverse Events

For adverse events other than injection-site reactions, a diagnosis (if known) should be recorded on the Adverse Event eCRF rather than individual signs and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated transaminases). However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of reporting, each individual event should be recorded on the Adverse Event eCRF. If a diagnosis is subsequently established, all previously reported adverse events based on signs and

symptoms should be nullified and replaced by one adverse event report based on the single diagnosis, with a starting date that corresponds to the starting date of the first symptom of the eventual diagnosis.

5.3.5.2 Adverse Events Occurring Secondary to Other Events

In general, adverse events occurring secondary to other events (e.g., cascade events or clinical sequelae) should be identified by their primary cause, with the exception of severe or serious secondary events. However, medically significant adverse events occurring secondary to an initiating event that are separated in time should be recorded as independent events on the Adverse Event eCRF. For example:

- If vomiting results in mild dehydration with no additional treatment in a healthy adult, only vomiting should be reported on the eCRF.
- If vomiting results in severe dehydration, both events should be reported separately on the eCRF.
- If a severe gastrointestinal hemorrhage leads to renal failure, both events should be reported separately on the eCRF.
- If dizziness leads to a fall and subsequent fracture, all three events should be reported separately on the eCRF.
- If neutropenia is accompanied by an infection, both events should be reported separately on the eCRF.

All adverse events should be recorded separately on the Adverse Event eCRF if it is unclear as to whether the events are associated.

5.3.5.3 Persistent or Recurrent Adverse Events

A persistent adverse event is one that extends continuously, without resolution, between patient evaluation timepoints. Such events should be recorded only once on the Adverse Event eCRF. The initial severity (intensity or grade) of the event should be recorded at the time the event is first reported. If a persistent adverse event becomes more severe, the most extreme severity should also be recorded on the Adverse Event eCRF. If the event becomes serious, it should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning that the event became serious; see Section 5.4.2 for reporting instructions). The Adverse Event eCRF should be updated by changing the event from “non-serious” to “serious,” providing the date that the event became serious, and completing all data fields related to serious adverse events.

A recurrent adverse event is one that resolves between patient evaluation timepoints and subsequently recurs. Each recurrence of an adverse event should be recorded separately on the Adverse Event eCRF.

5.3.5.4 Abnormal Laboratory Values

Not every laboratory abnormality qualifies as an adverse event. A laboratory test result must be reported as an adverse event if it meets any of the following criteria:

- Accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a change in concomitant therapy
- Clinically significant in the investigator's judgment

It is the investigator's responsibility to review all laboratory findings. Medical and scientific judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an adverse event.

If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., alkaline phosphatase and bilirubin $5 \times$ ULN associated with cholecystitis), only the diagnosis (i.e., cholecystitis) should be recorded on the Adverse Event eCRF.

If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, the abnormality itself should be recorded on the Adverse Event eCRF, along with a descriptor indicating if the test result is above or below the normal range (e.g., "elevated potassium," as opposed to "abnormal potassium"). If the laboratory abnormality can be characterized by a precise clinical term per standard definitions, the clinical term should be recorded as the adverse event. For example, an elevated serum potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."

Observations of the same clinically significant laboratory abnormality from visit to visit should be recorded only once on the Adverse Event eCRF, (see Section 5.3.5.3 for details on recording persistent adverse events).

5.3.5.5 Abnormal Vital Sign Values

Not every vital sign abnormality qualifies as an adverse event. A vital sign result must be reported as an adverse event if it meets any of the following criteria:

- Accompanied by clinical symptoms
- Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation)
- Results in a medical intervention or a change in concomitant therapy
- Clinically significant in the investigator's judgment

It is the investigator's responsibility to review all vital sign findings. Medical and scientific judgment should be exercised in deciding whether an isolated vital sign abnormality should be classified as an adverse event.

If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on the Adverse Event eCRF.

Observations of the same clinically significant vital sign abnormality from visit to visit should be recorded only once on the Adverse Event eCRF, (see Section 5.3.5.3 for details on recording persistent adverse events).

5.3.5.6 Abnormal Liver Function Tests

The finding of an elevated ALT or AST ($>3 \times$ ULN) in combination with either an elevated total bilirubin ($>2 \times$ ULN) or clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as defined by Hy's Law). Therefore, investigators must report as an adverse event the occurrence of either of the following:

- Treatment-emergent ALT or AST $>3 \times$ ULN, in combination with total bilirubin $>2 \times$ ULN
- Treatment-emergent ALT or AST $>3 \times$ ULN, in combination with clinical jaundice

The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.1) and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event), either as a serious adverse event or an adverse event of special interest (see Section 5.4.2).

5.3.5.7 Deaths

All deaths that occur during the protocol-specified adverse event reporting period (see Section 5.3.1), regardless of relationship to study drug, must be recorded on the Adverse Event eCRF and immediately reported to the Sponsor (see Section 5.4.2). This includes death attributed to progression of UC.

Death should be considered an outcome and not a distinct event. The event or condition that caused or contributed to the fatal outcome should be recorded as the single medical concept on the Adverse Event eCRF. Generally, only one such event should be reported. If the cause of death is unknown and cannot be ascertained at the time of reporting, “**unexplained death**” should be recorded on the Adverse Event eCRF. If the cause of death later becomes available (e.g., after autopsy), “unexplained death” should be replaced by the established cause of death. The term “**sudden death**” should not be used unless combined with the presumed cause of death (e.g., “sudden cardiac death”).

If the death is attributed to progression of UC, "ulcerative colitis progression" should be recorded on the Adverse Event eCRF.

Deaths that occur after the adverse event reporting period should be reported as described in Section 5.6.

5.3.5.8 Preexisting Medical Conditions

A preexisting medical condition is one that is present at the screening visit for this study. Such conditions should be recorded on the General Medical History and Baseline Conditions eCRF.

A preexisting medical condition should be recorded as an adverse event only if the frequency, severity, or character of the condition worsens during the study. When recording such events on the Adverse Event eCRF, it is important to convey the concept that the preexisting condition has changed by including applicable descriptors (e.g., "more frequent headaches").

5.3.5.9 Lack of Efficacy or Worsening of Ulcerative Colitis

Medical occurrences or symptoms of deterioration that are anticipated as part of UC should be recorded as an adverse event if judged by the investigator to have unexpectedly worsened in severity or frequency or changed in nature at any time during the study. When recording an unanticipated worsening UC on the Adverse Event eCRF, it is important to convey the concept that the condition has changed by including applicable descriptors (e.g., "accelerated ulcerative colitis" or "worsening of ulcerative colitis").

5.3.5.10 Hospitalization or Prolonged Hospitalization

Any adverse event that results in hospitalization (i.e., in-patient admission to a hospital) or prolonged hospitalization should be documented and reported as a serious adverse event (per the definition of serious adverse event in Section 5.2.2), except as outlined below. The duration of hospitalization should also be noted on the eCRF.

An event that leads to hospitalization under the following circumstances should not be reported as an adverse event or a serious adverse event:

- Hospitalization for respite care
- Planned hospitalization required by the protocol (e.g., for study drug administration or insertion of access device for study drug administration)
- Hospitalization for a preexisting condition, provided that all of the following criteria are met:

The hospitalization was planned prior to the study or was scheduled during the study when elective surgery became necessary because of the expected normal progression of the disease.

The patient has not suffered an adverse event.

An event that leads to hospitalization under the following circumstances is not considered to be a serious adverse event, but should be reported as an adverse event instead:

- Hospitalization that was necessary because of patient requirement for outpatient care outside of normal outpatient clinic operating hours

5.3.5.11 Adverse Events Associated with an Overdose or Error in Drug Administration

Study drug overdose is the accidental or intentional use of the drug in an amount higher than the dose being studied. An overdose or error in administration (e.g., dosing outside of the allowed window and injection without completion of full volume administration) of study drug is not an adverse event unless it results in untoward medical effects.

Any study drug overdose or error in administration (e.g., dosing outside of the allowed window and injection without completion of full volume administration) of study drug should be noted on the Study Drug Administration eCRF.

All adverse events associated with an overdose or error in administration (e.g., dosing outside of the allowed window and injection without completion of full volume administration) of study drug should be recorded on the Adverse Event eCRF. If the associated adverse event fulfills serious criteria, the event should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.3.5.12 Patient-Reported Outcome Data

Adverse event reports will not be derived from PRO data by the Sponsor, and safety analyses will not be performed using PRO data. Sites are not expected to review the PRO data for adverse events.

5.4 IMMEDIATE REPORTING REQUIREMENTS FROM INVESTIGATOR TO SPONSOR

Certain events require immediate reporting to allow the Sponsor to take appropriate measures to address potential new risks in a clinical trial. The investigator must report such events to the Sponsor immediately; under no circumstances should reporting take place more than 24 hours after the investigator learns of the event. The following is a list of events that the investigator must report to the Sponsor within 24 hours after learning of the event, regardless of relationship to study drug:

- Serious adverse events (See Section 5.4.2 for further details)
- Adverse events of special interest (See Section 5.4.2 for further details)
- Pregnancies (See Section 5.4.3 for further details)

The investigator must report new significant follow-up information for these events to the Sponsor immediately (i.e., no more than 24 hours after becoming aware of the information). New significant information includes the following:

- New signs or symptoms or a change in the diagnosis
- Significant new diagnostic test results
- Change in causality based on new information
- Change in the event's outcome, including recovery
- Additional narrative information on the clinical course of the event

Investigators must also comply with local requirements for reporting serious adverse events to the local health authority and IRB/EC.

5.4.1 Emergency Medical Contacts

Medical Monitor Contact Information

Primary Contact

Medical Monitor: [REDACTED], M.B., Ch.B.

Primary: +1 973 659 6677

Secondary: +1 570 819 8565

To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will access the IQVIA Medical Emergency List, escalate emergency medical calls, provide medical translation service (if necessary), connect the investigator with a Quintiles Medical Monitor, and track all calls. The Emergency Medical Call Center Help Desk will be available 24 hours per day, 7 days per week. A primary global contact number and additional back up number for the Help Desk and Medical Monitor contact information will be distributed to all investigators (see "Protocol Administrative and Contact Information & List of Investigators").

5.4.2 Reporting Requirements for Serious Adverse Events and Adverse Events of Special Interest

After informed consent has been obtained, but prior to initiation of study drug, only serious adverse events caused by a protocol-mandated intervention should be reported. The paper Clinical Trial Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators should be completed and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators.

After initiation of study drug, serious adverse events and adverse events of special interest will be reported until the patient completes his or her last study visit. Investigators should record all case details that can be gathered immediately (i.e., within 24 hours after learning of the event) on the Adverse Event eCRF and submit the report via the EDC system. A report will be generated and sent to Roche Safety Risk Management by the EDC system.

In the event that the EDC system is unavailable, the paper Clinical Trial Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to investigators should be completed and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and emailing the form with use of the fax number or email address provided to investigators. Once the EDC system is available, all information will need to be entered and submitted via the EDC system.

5.4.3 Reporting Requirements for Pregnancies

5.4.3.1 Pregnancies in Female Patients

Female patients of childbearing potential will be instructed to immediately inform the investigator if they become pregnant during the study or within 24 weeks after the last dose of study drug. A paper Clinical Trial Pregnancy Reporting Form should be completed and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the pregnancy), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators. Pregnancy should not be recorded on the Adverse Event eCRF. The investigator should discontinue study drug and counsel the patient, discussing the risks of the pregnancy and the possible effects on the fetus. Monitoring of the patient should continue until conclusion of the pregnancy. Any serious adverse events associated with the pregnancy (e.g., an event in the fetus, an event in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the Adverse Event eCRF.

In addition, the investigator will submit a paper Clinical Trial Pregnancy Reporting Form when updated information on the course and outcome of the pregnancy becomes available.

5.4.3.2 Pregnancies in Female Partners of Male Patients

Male patients will be instructed through the Informed Consent Form to immediately inform the investigator if their partner becomes pregnant during the study or within 24 weeks after the last dose of study drug. A paper Clinical Trial Pregnancy Reporting Form should be completed and submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the pregnancy), either by faxing or by scanning and emailing the form using the fax number or email address provided to investigators. Attempts should be made to collect and report details of the course and outcome of any pregnancy in the partner of a male patient exposed to study drug. When

permitted by the site, the pregnant partner would need to sign an Authorization for Use and Disclosure of Pregnancy Health Information to allow for follow-up on her pregnancy. If the authorization has been signed, the investigator should submit a paper Clinical Trial Pregnancy Reporting Form when updated information on the course and outcome of the pregnancy becomes available. An investigator who is contacted by the male patient or his pregnant partner may provide information on the risks of the pregnancy and the possible effects on the fetus, to support an informed decision in cooperation with the treating physician and/or obstetrician.

5.4.3.3 Abortions

Any abortion should be classified as a serious adverse event (as the Sponsor considers abortions to be medically significant), recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.4.3.4 Congenital Anomalies/Birth Defects

Any congenital anomaly/birth defect in a child born to a female patient or female partner of a male patient exposed to study drug should be classified as a serious adverse event, recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2).

5.4.4 Reporting Requirements for Medical Device Complaints

See Section 4.3.6 for reporting requirements for medical devices.

5.5 FOLLOW-UP OF PATIENTS AFTER ADVERSE EVENTS

5.5.1 Investigator Follow-Up

The investigator should follow each adverse event until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, the patient is lost to follow-up, or the patient withdraws consent. Every effort should be made to follow all serious adverse events considered to be related to study drug or trial-related procedures until a final outcome can be reported.

During the study period, resolution of adverse events (with dates) should be documented on the Adverse Event eCRF and in the patient's medical record to facilitate source data verification.

All pregnancies reported during the study should be followed until pregnancy outcome.

5.5.2 Sponsor Follow-Up

For serious adverse events, adverse events of special interest, and pregnancies, the Sponsor or a designee may follow up by telephone, fax, email, and/or a monitoring visit to obtain additional case details and outcome information (e.g., from hospital discharge summaries, consultant reports, autopsy reports) in order to perform an independent medical assessment of the reported case.

5.6 POST-STUDY ADVERSE EVENTS

Patients who enter Study GA28951 should follow the adverse event reporting requirements for that study.

Post-study, if the patient does not enter Study GA28951, the Sponsor should be notified if the investigator becomes aware of any serious adverse event, occurring after the end of the adverse event reporting period (defined as the last study visit [see Section 5.3.1]) if the event is believed to be related to prior study drug treatment. In addition, the Sponsor should also be notified if the investigator becomes aware of any post-study events of confirmed or suspected PML, regardless of relationship to study drug, for up to 2 years after the patient's last dose of study drug.

The investigator should report these events directly to Roche or its designee either by faxing or by scanning and emailing the paper Clinical Trial Serious Adverse Event/Adverse Event of Special Interest Reporting Form with use of the fax number or email address provided to investigators.

5.7 EXPEDITED REPORTING TO HEALTH AUTHORITIES, INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, AND ETHICS COMMITTEES

The Sponsor will promptly evaluate all serious adverse events and adverse events of special interest against cumulative product experience to identify and expeditiously communicate possible new safety findings to investigators, IRBs, ECs, and applicable health authorities based on applicable legislation.

To determine reporting requirements for single adverse event cases, the Sponsor will assess the expectedness of these events for etrolizumab using the following reference document:

- Etrolizumab Investigator's Brochure:

Within the Investigator's Brochure, the reference safety information is provided in Section 6.4 (Identified Risks and Adverse Drug Reactions [Reference Safety Information]).

To determine reporting requirements for single adverse event cases for adalimumab, the Sponsor will assess the expectedness of these events using the reference safety information in the E.U. SmPC for adalimumab.

The Sponsor will compare the severity of each event and the cumulative event frequency reported for the study with the severity and frequency reported in the applicable reference document.

Reporting requirements will also be based on the investigator's assessment of causality and seriousness, with allowance for upgrading by the Sponsor as needed.

All serious related (as assessed by the investigator and/or sponsor) adverse events occurring in a patient administered etrolizumab at any time during the trial and assessed as unexpected per the reference safety information will be considered Suspected Unexpected Serious Adverse Reactions (SUSARs) for the purpose of regulatory reporting to all health authorities, with the exception of the FDA. For the FDA, SUSARs will be submitted as IND Safety Reports, in line with the FDA guidance “Safety Reporting Requirements for INDs and BA/BE Studies” dated December 2012.

The Sponsor will report all SUSARs into the EudraVigilance database in accordance with the “Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (‘CT-3’).”

To satisfy local regulatory reporting criteria while maintaining the blind, investigators will be informed of all unexpected serious adverse events, regardless of study drug assignment (i.e., they may also receive reports of patients on placebo).

6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN

The primary analysis will be performed when all data through Week 14 are in the database and data have been cleaned and verified.

Whereas Sponsor personnel will be unblinded to treatment assignment to perform the primary analyses, patients and study site personnel who were blinded during the study will remain blinded to individual treatment assignment until after the study is completed (after all patients have either completed the safety follow-up period or discontinued early from the study) and the database is locked.

Detailed specifications of the statistical methods will be described in the Statistical Analysis Plan (SAP).

6.1 DETERMINATION OF SAMPLE SIZE

A total of approximately 350 patients will be randomized in a 2:2:1 ratio: etrolizumab (n= 140), adalimumab (n= 140), and placebo (n= 70), respectively.

Under the assumption of a difference in remission rates between the etrolizumab and placebo arms of 25% (35% vs. 10%), the sample size of 140 patients receiving etrolizumab and 70 patients receiving placebo will provide > 90% power to detect a difference with use of a χ^2 test at the two-sided 5% significance level. The assumption is based on the observed Week 10 remission results in the Phase II etrolizumab study for the TNF-naive subgroup. In addition, under the assumption of a remission rate of $\leq 20\%$ in the adalimumab arm (based on the clinical remission induction results achieved in the Phase III adalimumab ULTRA2 trial [Sandborn et al. 2012]), the planned size of 140 patients/active treatment arm will provide approximately 80% power to detect a

15% absolute difference between the remission rates in the etrolizumab and adalimumab arms (35% vs. 20%), with use of a χ^2 test at the two-sided 5% significance level.

6.2 SUMMARIES OF CONDUCT OF STUDY

The number of patients randomized will be tabulated by study site and treatment arm. Patient disposition (the number of patients randomized, treated, and completing the treatment period/study period) will be tabulated by treatment arm. Reasons for premature study drug discontinuation or withdrawal from study, any eligibility criteria deviations, and other major protocol deviations will be summarized by treatment arm.

6.3 SUMMARIES OF TREATMENT GROUP COMPARABILITY

Demographic and baseline characteristics such as age, sex, race, region, use of corticosteroids and immunosuppressants, duration of disease, and MCS and its subscores will be summarized for all randomized patients by treatment group by use of descriptive statistics. Exposure to study drug (number of study treatments and duration of treatment) will be summarized by treatment arm.

6.4 EFFICACY ANALYSES

Efficacy analyses will *be performed using a modified intent-to-treat analysis set including* all patients randomized who received at least one dose of study drug with patients grouped according to the treatment assigned at randomization.

Patients who are non-evaluable for efficacy at a specific timepoint (e.g., due to missing data or enrollment in Part 1 [OLE] of the OLE-SM protocol between Week 10 and Week 14) will be considered non-responders for all response/remission type endpoints. In addition, initiation of an agent not allowed in combination with etrolizumab, an immunosuppressant, oral or topical 5-ASA, corticosteroid, or increase in dose over baseline levels will lead to non-responder classification.

For continuous outcomes (e.g., IBDQ, UC-PRO/SS), scores after the first use of rescue medication will be imputed using the worst post-baseline score from the following assessments: the last score available prior to the start date of first rescue medication and all scores available after the start date of rescue medication use.

In addition to the analyses described in Section 6.4 and Section 6.4.2, the following analyses will be performed for the primary efficacy endpoint and key secondary efficacy endpoints. Details of these analyses will be described in the SAP:

- Sensitivity analyses to evaluate the robustness of results to the primary analysis methods (e.g., handling of dropouts)
- Subgroup analyses to evaluate the consistency of results across prespecified subgroups (e.g., based on age, sex, race/ethnicity, baseline UC medications, baseline CS dose)

To manage the overall type I error, the hypotheses will be tested sequentially. The first hypothesis to be tested will compare the primary endpoint between the etrolizumab and the placebo arms (primary efficacy objective). If this test result is not statistically significant, further hypothesis tests will be considered exploratory and no claims of statistical significance will be made. The testing hierarchy for the secondary hypotheses will be described in the SAP. All endpoints will be assessed at a nominal two-sided 5% significance level.

6.4.1 Primary Efficacy Endpoint

The difference in remission rates between the etrolizumab and placebo arms at Week 10 will be compared (at the two-sided 5% significance level) with use of the Cochran-Mantel-Haenszel test statistic stratified by concomitant treatment with corticosteroids at randomization (yes/no), concomitant treatment with immunosuppressants at randomization (yes/no), and disease activity measured during screening ($MCS \leq 9$, $MCS \geq 10$). The absolute difference in remission rates and 95% CIs for the point estimate will be calculated.

6.4.2 Secondary Efficacy Endpoints

The secondary efficacy endpoints for this study are as follows:

- Proportion of patients in remission at Week 10 (compared with adalimumab only)
- Proportion of patients in clinical remission at Week 10
- Proportion of patients with clinical response at Week 10
- Proportion of patients with improvement in endoscopic appearance of the mucosa at Week 10
- Proportion of patients in endoscopic remission at Week 10
- Proportion of patients who achieve remission at Weeks 10 and 14
- Proportion of patients in histologic remission at Week 10
- Change from baseline in MCS rectal bleeding subscore at Week 6
- Change from baseline in MCS stool frequency subscore at Week 6
- Change from baseline to Week 10 in UC bowel movement signs and symptoms, as assessed by the UC-PRO/SS
- Change from baseline to Week 10 in UC abdominal symptoms, as assessed by the UC-PRO/SS
- Change from baseline to Week 10 in health-related QOL, as assessed by the overall IBDQ score

The analysis of the responder type secondary endpoints will be performed in the same fashion as for the primary endpoint. Change from baseline continuous endpoints will be analyzed using an analysis of covariance model with concomitant treatment with corticosteroids, concomitant treatment with immunosuppressants, baseline disease activity ($MCS \leq 9$, $MCS \geq 10$) as stratification variables, and the baseline value of the studied measure as a covariate.

Further details on secondary endpoint analyses and a description of additional exploratory analyses will be provided in the SAP.

6.4.3 Exploratory Efficacy Endpoints

The exploratory efficacy endpoints are as follows:

- Proportion of patients who achieved clinical remission at Week 10 and remission at Week 14
- Proportion of patients who achieved clinical remission at Weeks 10 and 14
- Proportion of patients with change in histologic disease activity from baseline to Week 10
- Proportion of patients with improvement in histologic and/or endoscopic disease activity
- Change in health utilities, as assessed by the EQ-5D, from baseline to Week 10
- Proportion of patients in *response and* remission at Week 10 in subgroups by baseline expression levels of colonic tissue and/or peripheral blood biomarkers, including, but not limited to, αE integrin
- Proportion of patients with response *and* remission, as determined by the mMCS

The derivation of the αE or other biomarker subsets used to define the subgroups will be described prior to the unblinding of the study.

6.5 SAFETY ANALYSES

The safety analyses will include all randomized patients who received at least one dose of study drug, with patients grouped according to the treatment actually received.

Safety will be assessed through descriptive summaries of adverse events, laboratory test results (serum chemistry and hematology including complete blood count with differential and platelet counts), and antibodies to etrolizumab.

Additional details will be provided in the SAP.

6.5.1 Adverse Events

Verbatim descriptions of treatment-emergent adverse events will be coded and their incidence will be summarized by treatment arm, as appropriate. A treatment-emergent adverse event is defined as any new adverse event reported or any worsening of an existing condition on or after the first dose of study drug. In addition, separate summaries will be generated for serious adverse events, deaths, and adverse events leading to discontinuation of study drug. Adverse events will be summarized by mapped term, appropriate thesaurus level, and toxicity grade.

Analyses will be performed for:

- Systemic hypersensitivity events
 Specific analyses will be performed for anaphylactic reactions using the anaphylactic reaction Sampson's criteria (see [Appendix 8](#)).
- Serious infections
 The frequency of serious infections, in particular GI infections, will be summarized for each treatment arm.
- Opportunistic infections
 The occurrence of opportunistic infections will be summarized for each treatment arm.
- Malignancies
 Events that occur in the Neoplasms, Benign, Malignant, and Unspecified (Including Cysts and Polyps) System Organ Class will also be summarized for each treatment arm.
- Injection-site reactions
 The frequency of injection-site reactions will be summarized for each treatment arm.

6.5.2 Laboratory Tests

Descriptive summaries of laboratory values at baseline and throughout the study will be tabulated by treatment arm. For selected parameters, changes from baseline and the proportion of patients experiencing clinically significant changes relative to baseline will be summarized by treatment arm.

The number and percentage of patients with positive serum antibodies to etrolizumab at baseline and during the study will be tabulated by treatment arm.

6.6 PHARMACOKINETIC, PHARMACODYNAMIC, AND BIOMARKER ANALYSES

For PK assessment, group average serum–etrolizumab concentration versus time data will be tabulated and plotted. The serum concentrations of etrolizumab will be summarized at Week 10 and Week 14. Estimates for these parameters will be tabulated and summarized (mean, standard deviation, coefficient of variation, median, minimum, and maximum).

Additional PK or exposure-response analyses may be conducted as appropriate.

PD and biomarker analyses will include examination of baseline associations with response and other biomarkers and changes over time in exploratory biomarkers post-treatment relative to baseline. Results will be summarized descriptively.

7. DATA COLLECTION AND MANAGEMENT

7.1 DATA QUALITY ASSURANCE

Sponsor, contract research organization (CRO), and Data Management vendor will be responsible for the data management of this study, including quality checking of the data. Sites will be responsible for data entry into an eCRF via the EDC system. In the event of discrepant data, data queries will be issued to the sites and resolved by the sites via the EDC system. The Sponsor will produce an EDC Study Specification document that describes the quality checking to be performed on the data. In addition, eCRF Help Text will be provided to the sites through the EDC system. eCRFs and correction documentation will be maintained in the EDC system's audit trail.

Central laboratory data will be transferred directly to the Sponsor, with use of the Sponsor's standard procedures to handle and process the electronic transfer of these data.

7.2 ELECTRONIC CASE REPORT FORMS

eCRFs are to be completed using a Sponsor-designated EDC system. Sites will receive training and have access to the Help Text in the Medidata RAVE for appropriate eCRF completion. eCRFs will be submitted electronically to the Sponsor and should be handled in accordance with instructions from the Sponsor.

All eCRFs should be completed by designated, trained site staff. eCRFs should be reviewed and electronically signed and dated by the investigator or a designee.

At the end of the study, the investigator will receive patient data for his or her site in a readable format on a compact disc that must be kept with the study records. Acknowledgement of receipt of the compact disc is required.

7.3 ELECTRONIC PATIENT-REPORTED OUTCOME DATA

Patient-reported data will be collected electronically through use of electronic devices provided by an ePRO vendor. The electronic devices are designed for entry of data in a way that is attributable, secure, and accurate, in compliance with U.S. Food and Drug Administration (FDA) regulations for electronic records (21 Code of Federal Regulations, Part 11). The data will be transmitted to a centralized database at the ePRO vendor. The data from the ePRO devices are available for view access only via secure access to a Web portal provided by the ePRO vendor. Only identified and trained users may view the data, and their actions become part of the audit trail. The Sponsor will have view access only. Regular data transfers will occur from the centralized database at the vendor to the database at the Sponsor.

Once the study is complete, the ePRO data, audit trail, and trial and system documentation will be archived. The Sponsor will receive all data entered by patient on the e-diary and tablet device and all the study documentation.

Details regarding patient-reported data and the electronic devices are available in the Study Reference Manual. System backups for data stored by the Sponsor and records retention for the study data will be consistent with the Sponsor's standard procedures.

7.4 SOURCE DATA DOCUMENTATION

Study monitors will perform ongoing source data verification to confirm that critical protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate, complete, and verifiable from source documents.

Source documents (paper or electronic) are those in which patient data are recorded and documented for the first time. They include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, PRO questionnaires, evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies of transcriptions that are certified after verification as being accurate and complete, microfiche, photographic negatives, microfilm or magnetic media, X-rays, MRIs, ECGs, patient files, and records kept at pharmacies, laboratories, and medico-technical departments involved in a clinical trial.

Before study initiation, the types of source documents that are to be generated will be clearly defined in the Trial Monitoring Plan. This includes any protocol data to be entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and considered source data.

Source documents that are required to verify the validity and completeness of data entered into the eCRFs must not be obliterated or destroyed and must be retained per the policy for retention of records described in Section 7.6.

To facilitate source data verification, the investigators and institutions must provide the Sponsor direct access to applicable source documents and reports for trial-related monitoring, Sponsor audits, and IRB/EC review. The investigational site must also allow inspection by applicable health authorities.

7.5 USE OF COMPUTERIZED SYSTEMS

When clinical observations are entered directly into an investigational site's computerized medical record system (i.e., in lieu of original hardcopy records), the electronic record can serve as the source document if the system has been validated in accordance with health authority requirements pertaining to computerized systems used in clinical research. An acceptable computerized data collection system allows preservation of the original entry of data. If original data are modified, the system should maintain a viewable audit trail that shows the original data as well as the reason for the change, name of the person making the change, and date of the change.

7.6 RETENTION OF RECORDS

Records and documents pertaining to the conduct of this study and the distribution of IMP, including eCRFs, patient data (including PRO), Informed Consent Forms, laboratory test results, and medication inventory records, must be retained by the Principal Investigator for at least 15 years after completion or discontinuation of the study or for the length of time required by relevant national or local health authorities, whichever is longer. After that period of time, the documents may be destroyed, subject to local regulations.

No records may be disposed of without the written approval of the Sponsor. Written notification should be provided to the Sponsor prior to transferring any records to another party or moving them to another location.

8. ETHICAL CONSIDERATIONS

8.1 COMPLIANCE WITH LAWS AND REGULATIONS

This study will be conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki or the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the individual. The study will comply with the requirements of the ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). Studies conducted in the United States or under a U.S. Investigational New Drug (IND) application will comply with U.S. FDA regulations and applicable local, state, and federal laws. Studies conducted in the EU/EEA will comply with the EU Clinical Trial Directive (2001/20/EC).

8.2 INFORMED CONSENT

The Sponsor's sample Informed Consent Form (and ancillary sample Informed Consent Forms such as a Child's Assent or Caregiver's Informed Consent Form, if applicable) will be provided to each site. If applicable, it will be provided in a certified translation of the local language. The Sponsor or its designee must review and approve any proposed deviations from the Sponsor's sample Informed Consent Forms or any alternate consent forms proposed by the site (collectively, the "Consent Forms") before IRB/EC submission. The final IRB/EC-approved Consent Forms must be provided to the Sponsor for health authority submission purposes according to local requirements.

The Informed Consent Form will contain a separate section that addresses the use of remaining mandatory samples for optional exploratory research. The investigator or authorized designee will explain to each patient the objectives of the exploratory research. Patients will be told that they are free to refuse to participate and may withdraw their specimens at any time and for any reason during the storage period. A separate, specific signature will be required to document a patient's agreement to allow any remaining specimens to be used for exploratory research. Patients who decline to participate will not provide a separate signature.

The Consent Forms must be signed and dated by the patient or the patient's legally authorized representative before his or her participation in the study. The case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained prior to participation in the study.

The Consent Forms should be revised whenever there are changes to study procedures or when new information becomes available that may affect the willingness of the patient to participate. The final revised IRB/EC-approved Consent Forms must be provided to the Sponsor for health authority submission purposes.

Patients must be re-consented to the most current version of the Consent Forms (or to a significant new information/findings addendum in accordance with applicable laws and IRB/EC policy) during their participation in the study. For any updated or revised Consent Forms, the case history or clinical records for each patient shall document the informed consent process and that written informed consent was obtained using the updated/revised Consent Forms for continued participation in the study.

A copy of each signed Consent Form must be provided to the patient or the patient's legally authorized representative. All signed and dated Consent Forms must remain in each patient's study file or in the site file and must be available for verification by study monitors at any time.

For sites in the United States, each Consent Form may also include patient authorization to allow use and disclosure of personal health information in compliance with the U.S. Health Insurance Portability and Accountability Act of 1996 (HIPAA). If the site

utilizes a separate Authorization Form for patient authorization for use and disclosure of personal health information under the HIPAA regulations, the review, approval, and other processes outlined above apply except that IRB review and approval may not be required per study site policies.

8.3 INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE

This protocol, the Informed Consent Forms, any information to be given to the patient, and relevant supporting information must be submitted to the IRB/EC by the Principal Investigator and reviewed and approved by the IRB/EC before the study is initiated. In addition, any patient recruitment materials must be approved by the IRB/EC.

The Principal Investigator is responsible for providing written summaries of the status of the study to the IRB/EC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/EC. Investigators are also responsible for promptly informing the IRB/EC of any protocol amendments (see Section 9.6).

In addition to the requirements for reporting all adverse events to the Sponsor, investigators must comply with requirements for reporting serious adverse events to the local health authority and IRB/EC. Investigators may receive written IND safety reports or other safety-related communications from the Sponsor. Investigators are responsible for ensuring that such reports are reviewed and processed in accordance with health authority requirements and the policies and procedures established by their IRB/EC, and archived in the site's study file.

8.4 CONFIDENTIALITY

The Sponsor maintains confidentiality standards by coding each patient enrolled in the study through assignment of a unique patient identification number. This means that patient names are not included in data sets that are transmitted to any Sponsor location.

Patient medical information obtained by this study is confidential and may be disclosed to third parties only as permitted by the Informed Consent Form (or separate authorization for use and disclosure of personal health information) signed by the patient, unless permitted or required by law.

Medical information may be given to a patient's personal physician or other appropriate medical personnel responsible for the patient's welfare, for treatment purposes.

Data generated by this study must be available for inspection upon request by representatives of the U.S. FDA and other national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRB/EC for each study site, as appropriate.

8.5 FINANCIAL DISCLOSURE

Investigators will provide the Sponsor with sufficient, accurate financial information in accordance with local regulations to allow the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate health authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study (i.e., last patient last visit).

9. STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION

9.1 STUDY DOCUMENTATION

The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented including, but not limited to, the protocol, protocol amendments, Informed Consent Forms, and documentation of IRB/EC and governmental approval. In addition, at the end of the study, the investigator will receive the patient data, which include an audit trail containing a complete record of all changes to data.

9.2 PROTOCOL DEVIATIONS

The investigator should document and explain any protocol deviations. The investigator should promptly report any deviations that might have an impact on patient safety and data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC policies and procedures. The Sponsor will review all protocol deviations and assess whether any represent a serious breach of Good Clinical Practice guidelines and require reporting to health authorities. As per the Sponsor's standard operating procedures, prospective requests to deviate from the protocol, including requests to waive protocol eligibility criteria, are not allowed.

9.3 SITE INSPECTIONS

Site visits will be conducted by the Sponsor or an authorized representative for inspection of study data, patients' medical records, and eCRFs. The investigator will permit national and local health authorities, Sponsor monitors, representatives, and collaborators, and the IRBs/ECs to inspect facilities and records relevant to this study.

9.4 ADMINISTRATIVE STRUCTURE

This study is sponsored by F. Hoffmann–La Roche Ltd. Approximately 350 patients will participate in this global study.

A CRO will be contracted to manage the study and perform monitoring activities.

Centralized facilities (vendors) will be used to collect QOL data and endoscopy reading and interpretation; however, the investigator or a designee will also read the endoscopy if required for clinically indicated safety reasons.

A central laboratory (i.e., Roche or a vendor) will be used for most laboratory assessments, including histologic grading of colonic biopsy samples as per the laboratory manual. A selected group of assessments will be performed on site or by a local laboratory.

The eCRF data will be recorded via a Sponsor-designated EDC system. An IxRS will be used for study drug inventory management and to randomize patients to study drug.

An iDMC will be established to perform regular review of the safety data to ensure the ongoing safety of participating patients. Its composition and a description of its responsibilities will be provided in an iDMC charter.

9.5 PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS

Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing information on the trial to healthcare professionals and to the public, both at scientific congresses and in peer-reviewed journals. The Sponsor will comply with all requirements for publication of study results. For more information, refer to the Roche Global Policy on Sharing of Clinical Trials Data at the following website:

http://www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf

The results of this study may be published or presented at congresses. For all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to submit a journal manuscript reporting primary clinical trial results within 6 months after the availability of the respective clinical study report. In addition, for all clinical trials in patients involving an IMP for which a marketing authorization application has been filed or approved in any country, the Sponsor aims to publish results from analyses of additional endpoints and exploratory data that are clinically meaningful and statistically sound.

The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior to submission for publication or presentation. This allows the Sponsor to protect proprietary information and to provide comments based on information from other studies that may not yet be available to the investigator.

In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter trials only in their entirety and not as individual center data. In this case, a coordinating investigator will be designated by mutual agreement.

Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements. Any formal publication of the study in which contribution of Sponsor personnel exceeded that of conventional monitoring will be considered as a joint publication by the investigator and the appropriate Sponsor personnel.

Any inventions and resulting patents, improvements, and/or know-how originating from the use of data from this study will become and remain the exclusive and unburdened property of the Sponsor, except where agreed otherwise.

9.6 PROTOCOL AMENDMENTS

Any protocol amendments will be prepared by the Sponsor. Protocol amendments will be submitted to the IRB/EC and to regulatory authorities in accordance with local regulatory requirements.

Approval must be obtained from the IRB/EC and regulatory authorities (as locally required) before implementation of any changes, except for changes necessary to eliminate an immediate hazard to patients or changes that involve logistical or administrative aspects only (e.g., change in Medical Monitor or contact information).

10. REFERENCES

- Bradley GM, Oliva-Hemker M. Infliximab for the treatment of pediatric ulcerative colitis. *Expert Rev Gastroenterol Hepatol* 2012;6:659–65.
- Cepek KL, Parker CM, Madara JL, et al. Integrin $\alpha^E\beta_7$ mediates adhesion of T lymphocytes to epithelial cells. *J Immunol* 1993;150:3459–70.
- Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor-necrosis factor- α in the treatment of inflammatory bowel disease. *Nat Clin Pract Gastroenterol Hepatology* 2006;3:220.
- Chebli LA, Chaves LD, Pimentel FF, et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. *Inflamm Bowel Dis* 2010;4:613–9.
- Dotan, I. Early use of gut-selective therapy in Crohn's disease for long-term remission. Presented at Takeda-organized symposium during the 12th Congress of European Crohn's and Colitis Organization, 17 February 2017 (unpublished).
- Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. *Gastroenterology* 2001;121:255–60.
- Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. *Clin Gastroenterol Hepatol* 2008;6:1370–7.
- Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the $\alpha_4\beta_7$ integrin. *N Engl J Med* 2005;352:2499–507.
- Feagan BG, Rutgeerts PG, Sand BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2013;369:699–710.
- Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. *Gastroenterology* 1989;96:804–10.
- Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet* 2002;359:1541–49.
- Holzmann B, McIntyre BW, Weissman IL. Identification of a murine Peyer's patch-specific lymphocyte homing receptor as an integrin molecule with an α -chain homologous to human VLA-4- α . *Cell* 1989;56:37–46.
- Hu M, Crowe DT, Weissman IL, et al. Cloning and expression of mouse integrin $\beta_p(\beta_7)$: a functional role in Peyer's patch-specific lymphocyte homing. *Proc Natl Acad Sci USA* 1992;89:8254–8.
- Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 1999;28:S23–7.

- Khan N, Abbas AM, Moehlen M, et al. Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Health Care System. *Inflamm Bowel Dis.* 2013; 19:7.
- Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. *Lancet* 2012; 380:1909–15.
- Lobel EZ, Korelitz BI, Xuereb MA, et al. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. *Am J Gastroenterol* 2004; 3:462–5.
- Mañosa M, García V, Castro L, et al. Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. *J Crohns Colitis* 2011;5:397–40.
- Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the Nancy histological index for UC. *Gut* 2017;66:43–9.
- Marchal-Bressenot A, Scherl A, Salleron J, et al. A practical guide to assess the Nancy histological index for UC. *Gut* 2016;65:1919–20.
- Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012;142:46–54.
- Rabin, R, deCharro, F. EQ-5D: a measure of health status from the EuroQol Group. *Ann Med* 2001;33:337–43.
- Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. *GUT* 2011;60:780–7.
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2005;353:2462–76.
- Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. *J Allergy Clin Immunol* 2006;117:391–7.
- Sandborn WJ, Colombel JF, D'Haens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. *Aliment Pharmacol Ther* 2013;37:204–13.
- Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. *N Engl J Med* 2005;353:1912–25.
- Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2017;376:1723–36.

Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. *J Gastro* 2012;142:257–65.

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. *N Engl J Med* 1987;317:1625–9).

Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. *Neurology* 2011;77:1061–77.

Appendix 1 Schedule of Assessments

Assessment	Screening Day ^a -35 to -1	Study Week (± 3 days)									Early Withdrawal from Treatment Phase ^{ee}	
		0 ^b	2	4	6	8	10	12 ^c	14 ^c	Unscheduled Visit ^d		
Informed consent	x											
Review eligibility criteria ^e	x	x ^b										
Demographic data	x											
Pregnancy test ^f	x	x ^b		x		x			x			x
Vital signs (BP and pulse)	x	x ^b		x		x			x			x
ECG	x											x
Chest X-ray ^g	x											
Height		x										
Weight		x										
Medical history	x											
Physical examination ^h	x	x						x				x
PML neurologic examination ⁱ	x			x				x			x ^d	x
Hematology	x	x ^b						x			x ^d	x ^j
Chemistry	x	x ^b						x			x ^d	x ^j
Urinalysis	x	x ^b									x ^d	
TB screen ^k	x											
HIV test	x											
Hepatitis B and C serology ^l	x											
Hepatitis B DNA ^m	x							x				

Appendix 1 Schedule of Assessments (cont.)

Assessment	Screening Day ^a -35 to -1	Study Week (± 3 days)									Early Withdrawal from Treatment Phase ^{ee}	
		0 ^b	2	4	6	8	10	12 ^c	14 ^c	Unscheduled Visit ^d		
Hepatitis C RNA (Amplicor) ⁿ	x											
PK sampling (serum)		x ^o					x		x	x ^d	x ^j	
Anti-therapeutic antibody sample (serum) ^{o,p}		x ^o		x ^o			x		x ^q	x ^d	x ^{j,q}	
Plasma sample (storage for JCV antibody testing) ^r	x											
MCS (includes endoscopy) ^s	x						x		x	x ^d	x ^{j,ff}	
Partial MCS (pMCS, excludes endoscopy) ^{t,u}		x		x	x					x ^d	x ^j	
Stool sample collection	x ^v	x ^w					x ^w			x ^d	x ^w	
Colonic biopsy (CMV, if required)	x ^x									x ^d		
Colonic biopsy (histopathological confirmation of UC if required)	x ^y											
Colonic biopsy (formalin)	x ^z						x ^{aa}		x ^{aa}	x ^{d,x}	x ^{j,x,ff}	
Colonic biopsy (RNAlater)	x ^z						x ^{aa}		x ^{aa}	x ^{d,y}	x ^{j,aa,ff}	
Serum sample (CRP)		x ^o					x			x ^d	x ^j	
Serum sample (future exploratory PD) ^m		x					x		x		x	
Blood sample (RNA Paxgene) ^{bb}		x ^o					x					
Blood sample for genetic analysis (DNA) optional		x										
UC-PRO/SS ^{cc}		x		x		x	x					
IBDQ ^{dd}		x					x					

Appendix 1 Schedule of Assessments (cont.)

Assessment	Screening Day ^a -35 to -1	Study Week (± 3 days)									Early Withdrawal from Treatment Phase ^{ee}
		0 ^b	2	4	6	8	10	12 ^c	14 ^c	Unscheduled Visit ^d	
EQ-5D ^{dd}		x					x				
Concomitant medications		x	x	x	x	x	x	x	x	x	x
Adverse events	x	x	x	x	x	x	x	x	x	x	x
Adalimumab/adalimumab placebo administration		x	x	x	x	x					
Etrolizumab/etrolizumab placebo administration		x		x		x			x		

BP= blood pressure; CMV= cytomegalovirus; ECG= electrocardiogram; EQ-5D= EuroQoL Five-Dimension Questionnaire; HBV= hepatitis B virus; CRP= C-reactive protein; IBDQ= Inflammatory Bowel Disease Questionnaire.; JCV= John Cunningham virus; MCS= Mayo Clinic Score; PD= pharmacodynamics; PGA= physician's global assessment; PK= pharmacokinetic; pMCS= partial Mayo Clinic Score; PML= progressive multifocal leukoencephalopathy; qPCR= quantitative polymerase chain reactions; TB= tuberculosis, UC-PRO/SS= Ulcerative Colitis Patient-Reported Outcome Signs and Symptoms.

Notes: All study assessments and blood draws are to be conducted prior to study drug administration.

All colonic biopsy samples will be taken during flexible sigmoidoscopy/colonoscopy procedure.

^a All assessments must be performed after obtaining informed consent. Endoscopy should be performed 4–16 days prior to randomization (Day 1) (i.e., Day -16 to Day -4). The total screening period is 35 days. Under no circumstances will either window be extended.

^b Day 1 of Week 0.

^c Only patients who achieve clinical remission, as assessed at Week 10, will attend Week 12 and Week 14 visits

Appendix 1 Schedule of Assessments (cont.)

- ^d Unscheduled visit represents a visit that is not as per Schedule of Assessments and is required for an adverse event or for potential relapse assessment. All indicated assessments are NOT performed at each unscheduled visit. Assessments would be symptom-driven (e.g., only perform PML neurologic examination if patient reports symptoms suspected of PML; for disease worsening, infectious etiologies may be investigated if clinically indicated; and confirmation of clinical relapse is performed by the MCS). Assessments corresponding to items noted in this column should be recorded on the eCRF.
- ^e Perform prior to first administration of study drug.
- ^f Serum test at screening for all female patients except those who are more than 1-year postmenopausal or are surgically sterile. Urine test at all visits other than screening; if urine test result is positive, perform a confirmatory serum test. Do not administer etrolizumab unless the serum pregnancy test result is negative.
- ^g Not required if normal chest X-ray result within 3 months prior to screening.
- ^h Full physical examination required at screening; symptom-driven physical examination at all other timepoints indicated.
- ⁱ PML neurologic examination consists of the PML Subjective Checklist and the PML Objective Checklist. Administer before other assessments as per [Appendix 5](#).
- ^j Not required if unscheduled visit leads to withdrawal and assessment previously conducted at unscheduled visit.
- ^k The following tests are acceptable screening assays for latent TB in this study: purified protein derivative (a tuberculin skin test reaction; e.g., Mantoux test), INF- γ based test (e.g., QuantiFERON-TB Gold).
- ^l Patients must undergo screening for HBV and hepatitis C. This includes testing for HBsAG (HBV surface antigen), anti-HBc total (HBV core antibody total), and hepatitis C antibody.
- ^m Enrolled patients who are hepatitis B core antibody positive should have hepatitis B DNA measured at these timepoints.
- ⁿ Measurement of HCV RNA with use of the Amplicor assay is required when the patient has a known history of HCV antibody positivity with past documentation of undetectable HCV RNA, either with or without history of anti-viral treatment. Patients with newly diagnosed HCV antibody positivity are not eligible for this study, and, therefore, do not require measurement of HCV.
- ^o All samples to be collected prior to administration of study drug. The PK, ATA, and exploratory PD sample collections will be from all patients.
- ^p If serum sickness or a clinically significant allergic drug reaction is suspected, Sponsor should be notified, and serum for the analysis of study drug level and ATAs should be drawn and sent to the central laboratory. ATA samples may also be utilized for exploratory PD assessments or assessment of drug concentrations.
- ^q Collection of sample for ATA is required at final or early withdrawal visit, unless it coincides with first visit in Part 1 of Study GA28951 (where a sample for ATA must be collected).

Appendix 1 Schedule of Assessments (cont.)

- ^r A blood sample to test for antibodies to JCV will be taken and stored for possible later assessment of how widespread the JCV infection is in the study population. Sample testing for the presence of JCV antibodies is not helpful in predicting risk for PML or for evaluating neurologic symptoms. The sample may be tested if there is a strong belief that this information will be helpful in managing a patient's condition.
- ^s Endoscopy + rectal bleeding assessment + stool frequency assessment + PGA. Patients who have not undergone full colonoscopy with documented results within 1 year prior to screening should undergo colonoscopy in lieu of sigmoidoscopy at the screening visit to allow for screening for cancer/dysplasia (yes/no).
- ^t Partial MCS during screening is defined as the MCS score excluding the endoscopy score. Physician's Global Assessment component of MCS/partial MCS will be conducted prior to randomization on Day 1.
- ^u Rectal bleeding assessment + stool frequency assessment + PGA.
- ^v For culture and sensitivity testing; ova, parasites, and *Clostridium difficile* toxin testing.
- ^w Sample analyses may include, but not limited to, analysis of fecal calprotectin and other exploratory PD biomarkers (such as analyses of the microbiota and bacterial cultures).
- ^x If required: If there is suspicion for clinically significant CMV colitis, one biopsy sample should be obtained from the base of the ulcer to evaluate for histological presence of CMV. Analysis should be performed locally if possible, or can be sent to a central laboratory, if necessary. Result must be negative for CMV prior to dosing on Day 1.
- ^y If required: If patient does not have previously documented histopathologic confirmation of UC as defined in the inclusion criteria, one biopsy sample can be obtained from the base of the ulcer and read locally for histopathologic confirmation of UC.
- ^z In addition to the optional biopsy samples noted in footnote "x" and "y" above, 5 pairs (10 samples) will also be obtained at screening. All will be sent to the central laboratory for further storage or distribution. Two pairs (taken from the most inflamed area of colon within 20–40 cm of anal verge [sigmoid]) will be placed in a stabilization buffer (such as RNAlater or a similar buffer) and stored at –80°C (1 pair for diagnostic qPCR and 1 pair for PD biomarkers qPCR). Two pairs from the most inflamed area of colon within 20–40 cm of anal verge (sigmoid) will be placed in formalin and then paraffin embedded (1 pair will be used for exploratory PD biomarkers and the other pair will be used for diagnostic). The last pair will be taken from the most inflamed area of the worst affected segment and will be placed in formalin and then paraffin embedded (this sample will be used for histopathology and exploratory PD biomarkers). Original biopsy location and endoscopic depth should be clearly indicated.

Appendix 1 Schedule of Assessments (cont.)

- ^{aa} A total of 4 pairs (8 samples) will be obtained. All will be sent to the central laboratory for further storage or distribution. One pair will be placed in stabilization buffer (such as RNAlater or a similar buffer) and stored at –80°C for exploratory PD or diagnostic biomarker qPCR. The other 3 pairs, representing 3 different segments (rectum, sigmoid, descending colon), will be placed in formalin and then paraffin embedded; these biopsies will be used for histopathology, exploratory PD biomarkers and/or diagnostic biomarker. Original biopsy location and endoscopic depth should be clearly indicated.
- ^{bb} PAXgene blood RNA samples must be collected after all other blood and serum samples.
- ^{cc} During screening, patients must be trained on the use of the e-diary. Patients are to complete the e-diary on a daily basis for at least 9–12 consecutive days around the time of each scheduled visit for the UC–PRO/SS.
- ^{dd} With the exception of Week 0, the IBDQ and the EQ-5D will be completed in the clinic by the patient after the PML neurological examination but before any other non-PRO assessments and before the patient receives any disease status information or study drug during that visit.
- ^{ee} If clinical remission is not achieved at Week 10, the patient will be given the option to participate in Part 1 (OLE) of Study GA28951, if eligible, to receive open-label etrolizumab at Week 12 (which will correspond to Day 1 in Study GA28951). In this case, an early withdrawal from treatment visit is not required (i.e., the Week 10 visit will be the patient's last visit in this study). An early withdrawal from treatment visit is to be conducted if the patient withdraws at any other timepoint in the study.
- ^{ff} For patients exiting the treatment period early for any reason, an endoscopy to document disease activity may be performed at the discretion of the investigator.

Appendix 2 12-Week Safety Follow-Up

Assessment	Week (+3 days)		Unscheduled Visit ^c
	6 ^a	12/Early Termination ^b	
ECG		x	
PML neurologic examination ^d		x	
PD sampling (serum)		x	
PK sampling (serum)		x	
Anti-therapeutic antibody sample (serum) ^e		x	
Medication changes	x	x	x
Adverse events	x	x	x

ATA=anti-therapeutic antibody sample; ECG=electrocardiogram;
PK=pharmacokinetic; PD=pharmacodynamic; PML=progressive multifocal
leukoencephalopathy.

- ^a Week 6 study assessments are to be made by telephone call and not by clinic visit.
- ^b Denotes early termination visit from Safety Follow-Up period.
- ^c Unscheduled visit for safety monitoring.
- ^d PML neurologic examination consists of the PML Subjective Checklist and the PML Objective Checklist. Administer before other assessments as per [Appendix 5](#).
- ^e At all timepoints indicated and whenever serum sickness is suspected. ATA samples may be used for determination of drug concentrations or exploratory PD assessments.

Appendix 3

Childbearing Potential, Pregnancy Testing, and Contraception

All women of childbearing potential (including those who have had a tubal ligation) will have a serum pregnancy test at screening and a urine pregnancy test prior to administration of study drug at subsequent visits. If a urine pregnancy test result is positive, study drug will not be administered until pregnancy is ruled out. The result must be confirmed by a serum pregnancy test (conducted by the central laboratory). Refer to Section 5.4.3 of the protocol for management of a patient with a confirmed pregnancy.

All female patients are considered to be of childbearing potential unless they meet one of the following criteria:

- The patient has been postmenopausal (non–therapy-induced amenorrhea) for at least 12 months
- The patient had a surgical bilateral oophorectomy (with or without hysterectomy) more than 6 weeks prior to enrollment
- The patient had a hysterectomy

Female patients of reproductive or childbearing potential who are unwilling to use a highly effective method of contraception or remain abstinent during the treatment period and for at least 24 weeks after the last dose of study drug will be excluded from study participation.

Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

Examples of highly effective contraception include the following:

- Combined oral contraceptive pill
- Contraceptive transdermal patch
- Intrauterine device
- Implants for contraception
- Injections for contraception (with prolonged release)
- Hormonal vaginal device
- Sterilization, surgical tubal ligation

Appendix 3 Childbearing Potential, Pregnancy Testing, and Contraception (cont.)

- Sole sexual partner consisting of surgically sterilized male partner with appropriate postsurgical verification of the absence of spermatozoa in the ejaculate
- Double-barrier methods: condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository (Note: a female condom and male condom should not be used together because friction between the two can result in either product failing)

Patients may provide verbal confirmation that the partner completed appropriate follow-up after vasectomy. Sites are not required to obtain partner medical records.

For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm, as defined below:

With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 24 weeks after the last dose of study drug. Men must refrain from donating sperm during this same period.

For men and women: The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, and postovulation methods) and withdrawal are not acceptable methods of contraception.

Appendix 4

Mayo Clinic Score Measurement

Mayo Clinic Score is a composite endpoint with four components. The score ranges from 0 to 12 with higher scores indicating more severe disease.

The Mayo Clinic components are as follows:

1. STOOL FREQUENCY

0= Normal number of stools for this patient

1= 1 to 2 stools more than normal

2= 3 to 4 more stools than normal

3= 5 or more stools than normal

Subscore 0–3

2. RECTAL BLEEDING

0= No blood in stool

1= Streaks of blood with stool less than half the time

2= Obvious blood with stool most of the time

3= Blood alone passed

Subscore 0–3

3. ENDOSCOPY

0= Normal or inactive disease

1= Mild disease (erythema, decreased vascular pattern, mild friability)

2= Moderate disease (marked erythema, lack of vascular pattern, friability, erosions)

3= Severe disease (spontaneous bleeding, ulceration)

Subscore 0–3

4. PHYSICIAN'S GLOBAL ASSESSMENT

0= Normal (Subscores are 0)

1= Mild disease (Subscores are mostly 1s)

2= Moderate disease (Subscores are 1 to 2)

3= Severe disease (Subscores are 2 to 3)

Subscore 0–3

Appendix 4 Mayo Clinic Score Measurement (cont.)

DATA COLLECTION REQUIREMENTS

Data will be collected on e-diary and other electronic media; during conversion to these media the format of the questions may change.

- A CRITICAL DATA POINT TAKEN AT BASELINE IS THE PATIENT'S NORMAL NUMBER OF STOOLS. This is defined as the number of stool passed when a patient is in remission/ not in flare. This is to be taken from the most recent available data in the patient's medical notes or taken during patient interview at screening. This value will remain stable throughout the study.
- Normal number of stools is to be rounded up (e.g., normal number of stools=1-2 would be rounded to 2).
- The NORMAL number of stools is to be recorded on the e-diary and made visible to the patient to assist with their scoring relative to this number.

NOTE: Data recorded during bowel preparation procedures and day of endoscopy is to be ignored (bowel preparation and endoscopy procedure days are to be loaded onto the e-diary by the patient and excluded from the MCS calculation)

1. Stool frequency

- Stool frequency is to be recorded daily from start of screening to the end of the study in the e-diary.
- The stool frequency is to be compared to the patient's normal stool frequency and entered as a score between 0 and 3 (see 1 above) (e.g., a patient normally has 1 stool per day and today has 4 stools. Therefore the patient has 3 stools more than "normal," which yields a value of 2 for that day.)
- The stool frequency will be defined as the passage of solid or liquid fecal material. Episodes of incontinence count. A non-productive trip to the bathroom or the simple passage of gas DOES NOT COUNT as stool.
- The baseline stool frequency value will be taken from patient e-diary recordings that are entered between Day -22 (inclusive) and bowel preparation for the screening endoscopy and will be calculated as the average (rounded to the nearest integer) from the three most recent stool frequency scores that were entered just prior to the day of bowel preparation. However, up to three post-endoscopy scores, starting with the score recorded 2 days after the endoscopy, may be used to calculate baseline stool frequency, but ONLY when fewer than three scores are available between Day -22 and bowel preparation. The days selected for this calculation are intended to prevent the use of stool frequency recordings during the screening period that are impacted by bowel preparation and endoscopy, including the day immediately following the endoscopy.

Appendix 4

Mayo Clinic Score Measurement (cont.)

- For patients undergoing re-screening who meet the criteria to waive the endoscopy (see Section 4.5.2.1.2), the stool frequency subscore will be derived from the 3 consecutive days prior to the new enrollment day (i.e., Days -1, -2, and -3). Any missing day or days will be supplemented with the immediate next day or days recorded up to 22 days prior to the new enrollment day (e.g., if Day -2 is missing, Days -1, -3, and -4 will be used).
- The post-baseline stool frequency value for endpoint assessment will be calculated as the average (rounded to the nearest integer) from the three most recent stool frequency scores that were entered in the e-diary within the 7 days prior to the clinic visit and prior to the days devoted to bowel preparation and endoscopy.

2. Rectal bleeding

- Rectal bleeding is to be recorded daily from screening to the end of the study in the e-diary.
- The rectal bleeding score is to be categorized from 0–3 according to the definition given in 2 above.
- Patients are to be instructed to ignore any blood which is caused by menstruation or hemorrhoids.
- The baseline value for the rectal bleeding score will be taken from patient e-diary recordings that are entered between Day –22 (inclusive and bowel preparation for the screening endoscopy, and will be determined by the worst recording from the three most recent scores that were entered just prior to the day of bowel preparation. However, up to three post-endoscopy scores, starting with the score recorded 2 days after the endoscopy, may be used to calculate baseline rectal bleeding, but ONLY when fewer than three scores are available between Day –22 and bowel preparation (see Figure 1 below). The days selected for this calculation are intended to prevent the use of rectal bleeding recordings during the screening period that are impacted by bowel preparation and endoscopy, including the day immediately following the endoscopy.
- For patients undergoing re-screening who meet the criteria to waive the endoscopy (see Section 4.5.2.1.2), the rectal bleeding subscore will be derived from the 3 consecutive days prior to the new enrollment day (i.e., Days -1, -2, and -3). Any missing day or days will be supplemented with the immediate next day or days recorded up to 22 days prior to the new enrollment day (e.g., if Day -2 is missing, Days -1, -3, and -4 will be used).
- The post-baseline rectal bleeding value for endpoint assessment will be determined by the worst of the three most recent rectal bleeding scores that were entered in the e-diary within the 7 days prior to the clinic visit and prior to the days devoted to bowel preparation and endoscopy.

Appendix 4 Mayo Clinic Score Measurement (cont.)

3. Endoscopy Subscore

This score is provided by the endoscopy reading vendor as a subscore of 0 to 3.

- Findings on endoscopy will be documented by photographic evidence (central reading of endoscopy videos)
- The score will be based upon the worst affected segment (if mucosal appearance varies) for study conduct, except at post-baseline time points, when the sigmoid colon MCS endoscopic subscore will be used if the baseline sigmoid colon MCS endoscopic subscore is 2–3.

Note: The time window for performing endoscopy during the screening is 4–16 days prior to randomization (Day 1) (i.e., Day –16 to Day –4).

4. Physician's Global Assessment

The physician's global assessment WILL:

- Be based on the patient's overall status
- Reflect how the patient is doing at present. Assessment SHOULD NOT reflect past disease severity or complexity or the number/kinds of medicines the patient is receiving
- Be based on the:
 - Rectal bleeding score, stool frequency score, and endoscopic evaluation
 - Patient's recollection of abdominal discomfort and general sense of well-being
 - Patient's performance status, fecal incontinence and mood
 - Physician's observations and physical examination findings
- Reflect disease activity NOT disease severity (e.g., do not automatically give a high PGA to patients with pancolitis or severe/complicated disease or patients requiring multiple medications)

The physician's global assessment will be provided by the Investigator as a score of 0 to 3 and entered into the tablet.

CALCULATION OF THE MAYO CLINIC SCORE

Timepoints for MCS assessments can be found in the protocol Schedule of Assessments.

1. Eligibility for enrollment

Moderately to severely active ulcerative colitis as determined by a Mayo Clinic Score of 6–12 with an endoscopic subscore ≥ 2 , a rectal bleeding subscore ≥ 1 , and a stool frequency subscore ≥ 1

Appendix 4

Mayo Clinic Score Measurement (cont.)

2. Achievement of clinical response at Week 10

MCS with ≥ 3 -point decrease and 30% reduction from baseline as well as ≥ 1 -point decrease in rectal bleeding subscore or an absolute score of 0 or 1

3. Identification of Clinical Relapse


Clinical relapse is defined as an increase in pMCS ≥ 3 points compared to induction timepoint (Week 10) AND absolute pMCS of ≥ 5 AND an endoscopy subscore of ≥ 2

Appendix 4 Mayo Clinic Score Measurement (cont.)

Figure 1 Derivation of Stool Frequency and Rectal Bleeding Subscores at Screening


Scenario 1: Sufficient e-Diary Data Available prior to Endoscopy at Day -16

The e-diary data from the 3 consecutive days immediately preceding the bowel preparation day (Day -17 in this scenario) are used to derive RB and SF data for MCS calculation (Day -20 to Day -18, highlighted with red dashed lines in the figure). If e-diary data from these days are missing, RB/SF data from the preceding days (Day -21 or Day -22) will be used. No RB/SF data can be obtained prior to Day -22.




Scenario 2: Sufficient e-Diary Data Available prior to Endoscopy at Day -4

The e-diary data from the 3 consecutive days immediately preceding the bowel preparation day (Day -5 in this scenario) are used to derive RB and SF data for MCS calculation (Day -6 to Day -8, highlighted with red dashed lines in the figure). If e-diary data from these days are missing, RB/SF data from the preceding days (Days -9 to Day -22) will be used. No RB/SF data can be obtained prior to Day -22.



Scenario 3: Insufficient e-Diary Data Available prior to Endoscopy at Day -16


Only in cases where < 3 days of e-diary data are available prior to the bowel preparation day (Day -18 to Day -22 in this scenario), supplement with e-diary data starting 2 days after the endoscopy (e.g., January 28 if the endoscopy was performed on January 26). In the figure, the days highlighted with red dashed lines can be used for MCS calculation.



✓ Day with RB/SF data recorded in e-diary.
✗ Day with RB/SF data not recorded in e-diary.

Scenario 4: Shorter Screening Period: Insufficient e-Diary Data Available prior to and after Endoscopy at Day -4

With a shorter screening period, there may be insufficient e-diary data (< 3 days total) available prior to the bowel preparation day (Day -6 to Day -10 in this scenario) and between the endoscopy and randomization (Day -2 and Day -1). Only in such cases, the randomization visit must be delayed by at least 1 day by extending the screening period after the endoscopy (screening period must remain ≤ 35 days) so sufficient data can be recorded in the e-diary (on Day -1 in the extended screening period in Figure B). In the schema, the days highlighted with red dashed lines can be used for MCS calculation.



MCS=Mayo Clinic Score; RND=randomization; RB=rectal bleeding; SF=stool frequency.

Appendix 4 Mayo Clinic Score Measurement (cont.)

Figure 1 Derivation of Stool Frequency and Rectal Bleeding Subscores at Screening (cont.)

Notes:

- If 3 days of e-diary data are available between Day –22 (inclusive) and bowel preparation, use e-diary data from the 3 most recent days prior to the bowel preparation day.
- Up to 3 days of post-endoscopy e-diary data, starting 2 days after the endoscopy, may be used, but ONLY when < 3 days of e-diary data are available between Day –22 and bowel preparation.
- If 2 days of e-diary data are available between Day –22 and bowel preparation, use those data and supplement with data from the first available e-diary entry after the endoscopy, starting 2 days after the endoscopy.
- If 1 day of e-diary data is available between Day –22 and bowel preparation, use those data and supplement with data from the first two available e-diary entries after the endoscopy, starting 2 days after the endoscopy.
- If 0 days of e-diary data are available between Day –22 and bowel preparation, use data from the first three available e-diary entries after the endoscopy, starting 2 days after the endoscopy.

Derivation of stool frequency and rectal bleeding subscores at re-screening in circumstances where a second endoscopy is not required:

- For patients undergoing re-screening who meet the criteria to waive the endoscopy (see Section [4.5.2.1.2](#)), the stool frequency and rectal bleeding subscores will be derived from the 3 consecutive days prior to the new enrollment day (i.e., Days -1, -2, and -3). Any missing day or days will be supplemented with the immediate next day or days recorded up to 22 days prior to the new enrollment day (e.g., if Day -2 is missing, Days -1, -3, and -4 will be used).

Appendix 4 Mayo Clinic Score Measurement (cont.)

PARTIAL MAYO CLINIC SCORE

The partial Mayo Clinic Score is identical to the Mayo Clinic Score BUT EXCLUDES THE ENDOSCOPY SUBSCORE

- Timepoints for partial Mayo Clinic Score can be found in the protocol schedule of assessments

Partial MCS is also required at time of suspected clinical relapse. If partial MCS ≥ 3 points compared to induction timepoint AND absolute partial MCS ≥ 5 an endoscopy would be conducted and endoscopy subscore and full MCS calculated

E-DIARY MALFUNCTION OR LOSS

The help desk for the e-diary vendor (CRF Health) should be contacted in the event of e-diary malfunction or loss. Until a working e-diary can be provided to the patient, site staff should, after the e-diary malfunction or loss, retrospectively collect the previous day's stool frequency and rectal bleeding subscores from the patient via telephone interview within the next working day following the e-diary failure or loss. These data will then be transcribed into a data clarification form within CRF Health's TrialManager system for approval.

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987;317:1625–9)

Appendix 5 Worksheet for the PML Neurologic Examination

PML SUBJECTIVE AND OBJECTIVE CHECKLISTS OF NEUROLOGIC ASSESSMENTS TO MONITOR FOR PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) IN THE ETROLIZUMAB PHASE III STUDIES

PML usually manifests with subacute, progressive neurologic deficits including:

Neurologic Domain	Signs/Symptoms	Relevant PML Subjective/Objective Checklist Question
Altered mental status	Can encompass a variety of presenting signs and symptoms including cognitive changes (confusion, difficulty concentrating, memory loss) and altered behavior (including personality changes)	Q2, Q5, Q6
Higher cortical dysfunction	Impaired comprehension and/or formulation of language (aphasia), loss of ability to recognize objects, persons, sounds, shapes, or smells (agnosia)	Q2, Q5, Q6
Visual changes	Loss of visual fields (homonymous hemianopsia), double vision (diplopia)	Q1
Motor deficits	Weakness (hemiparesis or monoparesis), seizures (generalized or partial), difficulties with speech (dysarthria) or swallowing (dysphagia)	Q2, Q3
Sensory deficits	Sensory loss (i.e. paresthesia)	Q7
Coordination	Difficulty walking and maintaining balance (ataxia), lack of voluntary coordination of limb movement (limb ataxia)	Q4

To monitor patients for PML, a neurologic exam (including evaluation of cranial nerves, motor and sensory function, coordination, and mental status) will be performed as per the schedule of assessments (see [Appendix 1](#)). This neurologic exam will consist of administration of the PML Subjective Checklist and the PML Objective Checklist.

At screening, the PML Subjective Checklist and the PML Objective Checklist (including the components listed as optional, e.g. muscle group strength testing, recall of 3 objects in 1 minute, and sensory testing) should be performed.

At all other visits, the PML Subjective Checklist and the PML Objective Checklist (bolded items) should be performed, and the optional items should only be performed when there is an abnormal finding on the corresponding PML Subjective Checklist (i.e. complaints of focal weakness or focal sensory change would prompt a more detailed objective neurologic evaluation).

Appendix 5 Worksheet for the PML Neurologic Examination (cont.)

PML Subjective Checklist

Symptoms	“Compared to how you usually feel, have you had a significant change in any of the following?”		If the answer is “Yes”, obtain a description of the symptom(s) with examples	Applicable Objective Test(s): Document result on PML Objective Checklist Worksheet
	YES	NO		
1. Have you been experiencing any persistent difficulty with your vision such as loss of vision or double vision? Have you been having trouble with reading?				<ul style="list-style-type: none"> • Test visual fields and ocular motility
2. Have you been experiencing any persistent difficulty speaking or having your speech understood by others?				<ul style="list-style-type: none"> • Casual observation of speech output for dysarthria or aphasia.
3. Have you been experiencing any persistent weakness in an arm or a leg?				<ul style="list-style-type: none"> • Test for pronator drift (Barre maneuver). • Assess gait. • Test muscle strength (<i>only if indicated</i>).
4. Have you noticed yourself regularly bumping into things or having difficulty writing?				<ul style="list-style-type: none"> • Observe tandem gait and finger to nose.
5. Have you regularly been experiencing difficulty understanding others?				<ul style="list-style-type: none"> • Test ability to follow serial commands.
6. Have you had persistent problems with your memory or thinking?				<ul style="list-style-type: none"> • Recall of 3 objects over 1 minute with distraction (<i>only if indicated</i>).
7. Have you been experiencing any persistent numbness or other loss of sensation?				<ul style="list-style-type: none"> • Test sensation side to side with either pinprick or cold (<i>only if indicated</i>).

Appendix 5 Worksheet for the PML Neurologic Examination (cont.)

PML Objective Checklist

Neurologic function being assessed	Instructions (bold text indicates parts of exam required at each visit, as specified in Schedule of Assessments)	Abnormal exam?		If the answer is "Yes", describe the abnormal objective exam finding
		YES	NO	
1. Visual fields and ocular motility	<ul style="list-style-type: none"> • Visual Field Testing • Ocular Motility Testing 			
2. Speech	<ul style="list-style-type: none"> • Observe the patient's speech output for dysarthria or aphasia. 			
3. Strength	<ul style="list-style-type: none"> • Pronator drift test (Barre maneuver) • Gait testing (normal, heel and toe walk) • <i>ONLY</i> if the patient has any subjective complaints of weakness, test muscle strength of the relevant 			
4. Coordination	<ul style="list-style-type: none"> • Observe tandem gait and finger to nose 			
5. Comprehension	<ul style="list-style-type: none"> • Test ability to follow serial commands • "Take a piece of paper in your hand, fold it in half, and put it on the floor." 			
6. Memory and thinking	<ul style="list-style-type: none"> • <i>ONLY</i> if the patient has subjective complaints about their memory or thinking, test the ability of the patient to recall 3 objects over 1 minute with distraction 			
7. Sensation	<ul style="list-style-type: none"> • <i>ONLY</i> if the patient has subjective sensory complaints, evaluate relevant areas based on patient's subjective complaints by comparing left vs. right side sensation to cold (e.g. alcohol swab or cold stethoscope) or pinprick (e.g. broken Q-tip) 			

Appendix 5

Worksheet for the PML Neurologic Examination (cont.)

Please refer to the PML Algorithm in the Protocol Appendix for details.

- If there is an abnormal finding on the PML Subjective Checklist, this should be appropriately documented on the worksheet and in the eCRF.
- If there is an abnormal finding on the PML Objective Checklist, this should be appropriately documented on the worksheet and in the eCRF.
- If there are any abnormalities found on the PML Subjective Checklist that are accompanied by the corresponding abnormality on the PML Objective Checklist, or if there is high clinical suspicion for PML (in the opinion of the investigator):
 - This must be reported as an adverse event of special interest (AESI) within 24 hours
 - An urgent referral to a neurologist should be made.
 - Dosing with study drug will be suspended until PML can be ruled out.
 - Further evaluation will proceed according to the PML Algorithm in the Protocol Appendix.
 - Any confirmed diagnosis of PML should be reported as a serious adverse event (SAE).

Please complete the PML eCRF.

Was the PML Subjective Checklist administered? (Yes/No)

If yes, date of administration of PML Subjective Checklist (Date)

If yes, were there any abnormalities on the PML Subjective Checklist? (Yes/No)

Was the PML Objective Checklist administered? (Yes/No)

If yes, were there any abnormalities on the PML Objective Checklist? (Yes/No)

Is PML suspected? (Yes/No)

More detailed instructions for the PML Objective Checklist Neurologic Evaluations (please refer to the PML Neurologic Exam Video for more information):

1. Visual fields and ocular motility

Visual Field Testing:

- Position yourself approximately 3 feet away from the patient, with eyes at the same level.
- Keeping both eyes open, ask the patient to cover one eye and ask if all parts of your face and head are clear to them. Ask them to repeat, covering the other eye.

Appendix 5

Worksheet for the PML Neurologic Examination (cont.)

- Have the patient cover one eye and stare at your nose, and then ask them how many fingers you are holding up, testing each of the 4 visual quadrants. Repeat with the other eye covered.

Ocular Motility Testing:

- Evaluate the patient for conjugate eye movement.
- Starting about 3 feet from center, move in a big “H”, pausing at the center and at lateral gaze, and finishing with convergence (finger to their nose). Watch for nystagmus in lateral gaze, smooth pursuits, and pupillary constriction with convergence. Note: a couple of beats of nystagmus upon extreme lateral gaze is considered normal.

2. Speech

- Observe the patient’s speech output for dysarthria or aphasia.
- *Dysarthria* is a motor speech disorder. Findings can include “slurred” speech, decreased volume, slow rate of speech, limited tongue, lip, and jaw movement, abnormal rhythm when speaking, changes in vocal quality, and drooling or poor control of saliva.
- *Aphasia* is a disorder that results from damage to parts of the brain that control language, and can lead to problems with any or all of the following: speaking, listening, reading or writing.

3. Strength

Pronator drift test (Barre maneuver):

- Ask the patient to stand with their feet together and extend their arms out in front of them at 90 degrees (parallel to floor) with palms facing upwards toward the ceiling.
- Ask the patient to close their eyes and keep their arms extended for 15 seconds.
- If either arm drifts downward, upward, or starts to pronate (i.e. thumb turns up), this is considered an abnormal exam.

Gait testing:

- Ask the patient to walk across the room (~10 feet). The patient should have a normal gait, with their left arm swinging forward when the right foot leads, and vice versa. Be certain to note whether there is symmetric arm swinging, because a slight decrease in arm swinging may be an indicator of upper extremity weakness.
- Ask the patient to walk on their heels across the room (~10 feet). Carefully observe whether they have any difficulty maintaining their toes off the ground or loss of balance.
- Ask the patient to walk on their toes across the room (~10 feet). Carefully observe if they have any difficulty maintaining their heels off the ground or loss of balance.

Appendix 5

Worksheet for the PML Neurologic Examination (cont.)

Additional strength testing (*ONLY* if the patient has any subjective complaints of weakness):

- Test muscle strength of the relevant muscle groups based on the patient's subjective complaints.
- General guidelines for a basic muscle strength exam:
 - Upper extremity:
 - Finger grip strength
 - Flexion at elbow
 - Extension at elbow
 - Deltoid strength: Maintain bent arms up (perpendicular to floor) and resist while investigator pushes down
 - Shoulder shrug against resistance
 - Lower extremity: (examine while patient is sitting down)
 - Raise thigh (while bent)
 - Straighten leg
 - Flex leg
 - Flex foot
 - Extend foot

4. Coordination

Tandem gait:

- As the patient is looking at his feet, ask them to walk 8 steps with one foot touching in front of the other (demonstrate for them).

Finger to nose:

- Hold your finger out so they need to reach out and lean. Start near the center, and move your finger slowly so that they reach across their body. Make sure they alternate touching your finger and their nose at a good speed. Inability to perform this accurately is considered an abnormal test.

5. Comprehension

- Test ability to follow serial commands
- “Take a piece of paper in your hand, fold it in half, and put it on the floor.”

Appendix 5

Worksheet for the PML Neurologic Examination (cont.)

6. Memory and Thinking


- (*ONLY* if the patient has subjective complaints about their memory or thinking) test the ability of the patient to recall 3 objects over 1 minute with distraction.

7. Sensation

- (*ONLY* if the patient has subjective sensory complaints) evaluate relevant areas based on the patient's subjective complaints by comparing left vs. right side sensation to cold (e.g. alcohol swab or cold stethoscope) or pinprick (e.g. broken Q-tip). Confirm that the patient is able to feel the sensation symmetrically.

Appendix 6 Algorithm for the Evaluation of Progressive Multifocal Leukoencephalopathy

- If there is a positive finding on the PML Subjective or Objective Checklist, this should be appropriately documented.
- If there are any abnormalities found on the PML Subjective Checklist that are accompanied by the corresponding abnormality on the PML Objective Checklist, or if there is high clinical suspicion for PML (in the opinion of the investigator):
 - **Report as an AESI within 24 hours**
 - **Urgently refer the patient to a neurologist**
 - **Suspend dosing of drug until PML can be ruled out**



Appendix 7 Patient Daily Diary

**PATIENT DIARY CARD
FORMAT MAY CHANGE DURING THE SWITCH TO ELECTRONIC FORMAT**

PATIENT NUMBER

Monthly Record of Study Medication Injections
--

Week	Date/Time of Injection dd-mmm-yyyy e.g. 30/Sep/2013 (24 h clock) e.g. 14:00	Location of Injection	Information About Your Injection
0 Day 1	INJECTION 1 Date: ___/___/_____ Time: ___:___ <input type="checkbox"/> Injection done at clinic <input type="checkbox"/> Injection administered by caregiver	<input type="checkbox"/> thigh <input type="checkbox"/> arm <input type="checkbox"/> abdomen	<input type="checkbox"/> Injection not done <input type="checkbox"/> Less than full amount of pre-filled syringe injected <input type="checkbox"/> Incorrectly injected medication* <input type="checkbox"/> OTHER COMMENTS:
4	INJECTION 2 Date: ___/___/_____ Time: ___:___ <input type="checkbox"/> Injection done at clinic <input type="checkbox"/> Injection administered by caregiver	<input type="checkbox"/> thigh <input type="checkbox"/> arm <input type="checkbox"/> abdomen	<input type="checkbox"/> Injection not done <input type="checkbox"/> Less than full amount of pre-filled syringe injected <input type="checkbox"/> Incorrectly injected medication* <input type="checkbox"/> OTHER COMMENTS:

An incorrectly administered injection is defined as

- an SC injection which was given intramuscularly
- an SC injection was given to a body site that is not allowed per protocol (namely a site other than thigh, arm or abdomen)

If you experience any side effects following your injection please remember to describe these to the study staff the next time you speak with them

RESULT OF PREGNANCY TEST
 DATE PREGNANCY TEST CONDUCTED --/--/----
 PREGNANCY TEST RESULT: POSITIVE NEGATIVE NOT DONE

Appendix 8

Clinical Criteria for Diagnosing Anaphylaxis

These criteria are taken from a summary report from the second symposium on the definition and management of anaphylaxis, conducted by the National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network.¹ Anaphylaxis is highly likely when any one of the following three criteria is fulfilled:


1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula)

AND AT LEAST ONE OF THE FOLLOWING:

- Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia)
 - Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia, syncope, incontinence)
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes to several hours):
 - Involvement of the skin-mucosal tissue (e.g., generalized hives, itch-flush, swollen lips-tongue-uvula)
 - Respiratory compromise (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia)
 - Reduced blood pressure or associated symptoms (e.g., hypotonia, syncope, incontinence)
 - Persistent gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting)
 3. Reduced blood pressure after exposure to known allergen for that patient (minutes to several hours):
 - Infants and children: low systolic blood pressure (age specific)² or greater than 30% decrease in systolic blood pressure
 - Adults: systolic blood pressure of less than 90 mmHg or greater than 30% decrease from that person's baseline

¹ Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. *J Allergy Clin Immunol* 2006;117:391–7.

² Low systolic blood pressure for children is defined as less than 70 mmHg from 1 month to 1 year, less than (70 mmHg + [2 x age]) from 1 to 10 years, and less than 90 mmHg from 11 to 17 years.



Appendix 10
Quality of Life in Inflammatory Bowel Disease Questionnaire
(IBDQ)

QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ)

This questionnaire is designed to find out how you have been feeling during the last 2 weeks. You will be asked about symptoms you have been having as a result of your inflammatory bowel disease, the way you have been feeling in general, and how your mood has been.

1. How frequent have your bowel movements been during the last two weeks? Please indicate how frequent your bowel movements have been during the last two weeks by picking one of the options from

- 1 BOWEL MOVEMENTS AS OR MORE FREQUENT THAN THEY HAVE EVER BEEN
- 2 EXTREMELY FREQUENT
- 3 VERY FREQUENT
- 4 MODERATE INCREASE IN FREQUENCY OF BOWEL MOVEMENTS
- 5 SOME INCREASE IN FREQUENCY OF BOWEL MOVEMENTS
- 6 SLIGHT INCREASE IN FREQUENCY OF BOWEL MOVEMENTS
- 7 NORMAL, NO INCREASE IN FREQUENCY OF BOWEL MOVEMENTS

2. How often has the feeling of fatigue or of being tired and worn out been a problem for you during the last 2 weeks? Please indicate how often the feeling of fatigue or tiredness has been a problem for you during the last 2 weeks by picking one of the options from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

3. How often during the last 2 weeks have you felt frustrated, impatient, or restless? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

Copyright © 1989 McMaster University, Hamilton, Ontario, Canada

The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright ©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed or used in any way without the prior written consent of McMaster University.
Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details

** NOT FOR USE – EXAMPLE ONLY**

This Questionnaire is protected by copyright. To obtain a License to use this Questionnaire, contact the McMaster Industry Liaison Office, McMaster University, email: milo@mcmaster.ca

4. How often during the last 2 weeks have you been unable to attend school or do your work because of your bowel problem? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

5. How much of the time during the last 2 weeks have your bowel movements been loose? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

6. How much energy have you had during the last 2 weeks? Please choose an option from

- 1 NO ENERGY AT ALL
- 2 VERY LITTLE ENERGY
- 3 A LITTLE ENERGY
- 4 SOME ENERGY
- 5 A MODERATE AMOUNT OF ENERGY
- 6 A LOT OF ENERGY
- 7 FULL OF ENERGY

Copyright © 1989 McMaster University, Hamilton, Ontario, Canada

The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright ©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed or used in any way without the prior written consent of McMaster University.
Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details

** NOT FOR USE – EXAMPLE ONLY**

This Questionnaire is protected by copyright. To obtain a License to use this Questionnaire, contact the McMaster Industry Liaison Office, McMaster University, email: milo@mcmaster.ca

7. How often during the last 2 weeks did you feel worried about the possibility of needing to have surgery because of your bowel problem. Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

8. How often during the last 2 weeks have you had to delay or cancel a social engagement because of your bowel problem? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

9. How often during the last 2 weeks have you been troubled by cramps in your abdomen? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

Copyright © 1989 McMaster University, Hamilton, Ontario, Canada

The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright ©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed or used in any way without the prior written consent of McMaster University.
Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details

** NOT FOR USE – EXAMPLE ONLY**

This Questionnaire is protected by copyright. To obtain a License to use this Questionnaire, contact the McMaster Industry Liaison Office, McMaster University, email: milo@mcmaster.ca

10. How often during the last 2 weeks have you felt generally Unwell? Please choose an option from
- 1 ALL OF THE TIME
 - 2 MOST OF THE TIME
 - 3 A GOOD BIT OF THE TIME
 - 4 SOME OF THE TIME
 - 5 A LITTLE OF THE TIME
 - 6 HARDLY ANY OF THE TIME
 - 7 NONE OF THE TIME
11. How often during the last 2 weeks have you been troubled because of fear of not finding a washroom? Please choose an option from
- 1 ALL OF THE TIME
 - 2 MOST OF THE TIME
 - 3 A GOOD BIT OF THE TIME
 - 4 SOME OF THE TIME
 - 5 A LITTLE OF THE TIME
 - 6 HARDLY ANY OF THE TIME
 - 7 NONE OF THE TIME
12. How much difficulty have you had, as a result of your bowel problems, doing leisure or sports activities you would have liked to have done during the last 2 weeks? Please choose an option from
- 1 A GREAT DEAL OF DIFFICULTY; ACTIVITIES MADE IMPOSSIBLE
 - 2 A LOT OF DIFFICULTY
 - 3 A FAIR BIT OF DIFFICULTY
 - 4 SOME DIFFICULTY
 - 5 A LITTLE DIFFICULTY
 - 6 HARDLY ANY DIFFICULTY
 - 7 NO DIFFICULTY; THE BOWEL PROBLEMS DID NOT LIMIT SPORTS OR LEISURE ACTIVITIES

Copyright © 1989 McMaster University, Hamilton, Ontario, Canada

The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright ©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed or used in any way without the prior written consent of McMaster University.

Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details

** NOT FOR USE – EXAMPLE ONLY**

This Questionnaire is protected by copyright. To obtain a License to use this Questionnaire, contact the McMaster Industry Liaison Office, McMaster University, email: milo@mcmaster.ca

13. How often during the last 2 weeks have you been troubled by pain in the abdomen? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

14. How often during the last 2 weeks have you had problems getting a good night's sleep, or been troubled by waking up during the night? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

15. How often during the last 2 weeks have you felt depressed or discouraged? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

Copyright © 1989 McMaster University, Hamilton, Ontario, Canada

The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright ©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed or used in any way without the prior written consent of McMaster University.

Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details

** NOT FOR USE – EXAMPLE ONLY**

This Questionnaire is protected by copyright. To obtain a License to use this Questionnaire, contact the McMaster Industry Liaison Office, McMaster University, email: milo@mcmaster.ca

16. How often during the last 2 weeks have you had to avoid attending events where there was no washroom close at hand? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

17. Overall, in the last 2 weeks, how much of a problem have you had with passing large amounts of gas? Please choose an option from

- 1 A MAJOR PROBLEM
- 2 A BIG PROBLEM
- 3 A SIGNIFICANT PROBLEM
- 4 SOME TROUBLE
- 5 A LITTLE TROUBLE
- 6 HARDLY ANY TROUBLE
- 7 NO TROUBLE

18. Overall, in the last 2 weeks, how much of a problem have you had maintaining or getting to, the weight you would like to be at. Please choose an option from

- 1 A MAJOR PROBLEM
- 2 A BIG PROBLEM
- 3 A SIGNIFICANT PROBLEM
- 4 SOME TROUBLE
- 5 A LITTLE TROUBLE
- 6 HARDLY ANY TROUBLE
- 7 NO TROUBLE

Copyright © 1989 McMaster University, Hamilton, Ontario, Canada

The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright ©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed or used in any way without the prior written consent of McMaster University.

Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details

** NOT FOR USE – EXAMPLE ONLY**

This Questionnaire is protected by copyright. To obtain a License to use this Questionnaire, contact the McMaster Industry Liaison Office, McMaster University, email: milo@mcmaster.ca

19. Many patients with bowel problems often have worries and anxieties related to their illness. These include worries about getting cancer, worries about never feeling any better, and worries about having a relapse. In general, how often during the last 2 weeks have you felt worried or anxious? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

20. How much of the time during the last 2 weeks have you been troubled by a feeling of abdominal bloating? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

21. How often during the last 2 weeks have you felt relaxed and free of tension? Please choose an option from

- 1 NONE OF THE TIME
- 2 A LITTLE OF THE TIME
- 3 SOME OF THE TIME
- 4 A GOOD BIT OF THE TIME
- 5 MOST OF THE TIME
- 6 ALMOST ALL OF THE TIME
- 7 ALL OF THE TIME

Copyright © 1989 McMaster University, Hamilton, Ontario, Canada

The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright ©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed or used in any way without the prior written consent of McMaster University.
Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details

** NOT FOR USE – EXAMPLE ONLY**

This Questionnaire is protected by copyright. To obtain a License to use this Questionnaire, contact the McMaster Industry Liaison Office, McMaster University, email: milo@mcmaster.ca

22. How much of the time during the last 2 weeks have you had a problem with rectal bleeding with your bowel movements? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

23. How much of the time during the last 2 weeks have you felt embarrassed as a result of your bowel problem? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

24. How much of the time during the last 2 weeks have you been troubled by a feeling of having to go to the bathroom even though your bowels were empty? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

Copyright © 1989 McMaster University, Hamilton, Ontario, Canada

The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright ©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed or used in any way without the prior written consent of McMaster University.
Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details

** NOT FOR USE – EXAMPLE ONLY**

This Questionnaire is protected by copyright. To obtain a License to use this Questionnaire, contact the McMaster Industry Liaison Office, McMaster University, email: milo@mcmaster.ca

25. How much of the time during the last 2 weeks have you felt tearful or upset? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

26. How much of the time during the last 2 weeks have you been troubled by accidental soiling of your underpants? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

27. How much of the time during the last 2 weeks have you felt angry as a result of your bowel problem? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

Copyright © 1989 McMaster University, Hamilton, Ontario, Canada

The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright ©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed or used in any way without the prior written consent of McMaster University.
Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details

** NOT FOR USE – EXAMPLE ONLY**

This Questionnaire is protected by copyright. To obtain a License to use this Questionnaire, contact the McMaster Industry Liaison Office, McMaster University, email: milo@mcmaster.ca

28. To what extent has your bowel problem limited sexual activity during the last 2 weeks? Please choose an option from

- 1 NO SEX AS A RESULT OF BOWEL DISEASE
- 2 MAJOR LIMITATION AS A RESULT OF BOWEL DISEASE
- 3 MODERATE LIMITATION AS A RESULT OF BOWEL DISEASE
- 4 SOME LIMITATION AS A RESULT OF BOWEL DISEASE
- 5 A LITTLE LIMITATION AS A RESULT OF BOWEL DISEASE
- 6 HARDLY ANY LIMITATION AS A RESULT OF BOWEL DISEASE
- 7 NO LIMITATION AS A RESULT OF BOWEL DISEASE

29. How much of the time during the last 2 weeks have you been troubled by nausea or feeling sick to your stomach? Please choose an option. from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

30. How much of the time during the last 2 weeks have you felt irritable? Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

Copyright © 1989 McMaster University, Hamilton, Ontario, Canada

The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright ©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed or used in any way without the prior written consent of McMaster University.
Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details

** NOT FOR USE – EXAMPLE ONLY**

This Questionnaire is protected by copyright. To obtain a License to use this Questionnaire, contact the McMaster Industry Liaison Office, McMaster University, email: milo@mcmaster.ca

31. How often during the past 2 weeks have you felt a lack of understanding from others?
Please choose an option from

- 1 ALL OF THE TIME
- 2 MOST OF THE TIME
- 3 A GOOD BIT OF THE TIME
- 4 SOME OF THE TIME
- 5 A LITTLE OF THE TIME
- 6 HARDLY ANY OF THE TIME
- 7 NONE OF THE TIME

32. How satisfied, happy, or pleased have you been with your personal life during the past 2 weeks? Please choose one of the following options from

- 1 VERY DISSATISFIED, UNHAPPY MOST OF THE TIME
- 2 GENERALLY DISSATISFIED, UNHAPPY
- 3 SOMEWHAT DISSATISFIED, UNHAPPY
- 4 GENERALLY SATISFIED, PLEASED
- 5 SATISFIED MOST OF THE TIME, HAPPY
- 6 VERY SATISFIED MOST OF THE TIME, HAPPY
- 7 EXTREMELY SATISFIED, COULD NOT HAVE BEEN MORE HAPPY OR PLEASED

Copyright © 1989 McMaster University, Hamilton, Ontario, Canada

The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by Dr. Jan Irvine et al, is the copyright of McMaster University (Copyright ©1989, McMaster University). The IBDQ has been provided under license from McMaster University and must not be copied, distributed or used in any way without the prior written consent of McMaster University.
Contact the McMaster Industry Liaison Office at McMaster University, email: milo@mcmaster.ca for licensing details

** NOT FOR USE – EXAMPLE ONLY**

This Questionnaire is protected by copyright. To obtain a License to use this Questionnaire, contact the McMaster Industry Liaison Office, McMaster University, email: milo@mcmaster.ca

Appendix 11
EuroQoL Five-Dimension (EQ-5D) Questionnaire



Health Questionnaire
(English version for the US)

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group

Etrolizumab—F. Hoffmann-La Roche Ltd
174/Protocol GA28948, Version 8

By placing a checkmark in one box in each group below, please indicate which statements best describe your own health state today.

Mobility

- I have no problems in walking about
- I have some problems in walking about
- I am confined to bed

Self-Care

- I have no problems with self-care
- I have some problems washing or dressing myself
- I am unable to wash or dress myself

Usual Activities (e.g. work, study, housework, family or leisure activities)

- I have no problems with performing my usual activities
- I have some problems with performing my usual activities
- I am unable to perform my usual activities

Pain/Discomfort

- I have no pain or discomfort
- I have moderate pain or discomfort
- I have extreme pain or discomfort

Anxiety/Depression

- I am not anxious or depressed
- I am moderately anxious or depressed
- I am extremely anxious or depressed

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group

To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

**Your own
health state
today**

Best
imaginable
health state

100

90

80

70

60

50

40

30

20

10

0

90

80

70

60

50

40

30

20

10

0

90

80

70

60

50

40

30

20

10

0

90

80

70

60

50

40

30

20

10

0

Worst
imaginable
health state

© 1998 EuroQol Group. EQ-5D™ is a trade mark of the EuroQol Group

Appendix 12

Nancy Histological Index

Histologic activity on colon biopsies will be measured using the Nancy histological index (below). Histologic remission is defined as a Nancy histological index of 0–1 based on consensus guidelines recommending that histologic remission should be defined by the absence of neutrophils in the crypts and lamina propria.

Nancy Histological Index (NHI)

Marker	Assessment	NHI Grade
Erosion or ulceration	Present	4: Severely active disease
Acute inflammatory infiltrate	Moderate to severe	3: Moderately active disease
	Mild	2: Mildly active disease
Chronic inflammatory infiltrate	Moderate or marked increase	1: Chronic inflammatory infiltrate with no acute inflammatory infiltrate
	No or mild increase	0: No histologically significant disease

Histologic remission: $NHI \leq 1$

References

Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the Nancy histological index for UC. *Gut* 2017;66:43–9.

Marchal-Bressenot A, Scherl A, Salleron J, et al. A practical guide to assess the Nancy histological index for UC. *Gut* 2016;65:1919–20.